false2022Q20001058290--12-3100010582902022-01-012022-06-3000010582902022-07-22xbrli:shares00010582902022-06-30iso4217:USD00010582902021-12-31iso4217:USDxbrli:shares00010582902022-04-012022-06-3000010582902021-04-012021-06-3000010582902021-01-012021-06-300001058290us-gaap:CommonStockMember2021-12-310001058290us-gaap:AdditionalPaidInCapitalMember2021-12-310001058290us-gaap:RetainedEarningsMember2021-12-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001058290us-gaap:RetainedEarningsMember2022-01-012022-03-3100010582902022-01-012022-03-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001058290us-gaap:CommonStockMember2022-01-012022-03-310001058290us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001058290us-gaap:CommonStockMember2022-03-310001058290us-gaap:AdditionalPaidInCapitalMember2022-03-310001058290us-gaap:RetainedEarningsMember2022-03-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100010582902022-03-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001058290us-gaap:CommonStockMember2022-04-012022-06-300001058290us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001058290us-gaap:RetainedEarningsMember2022-04-012022-06-300001058290us-gaap:CommonStockMember2022-06-300001058290us-gaap:AdditionalPaidInCapitalMember2022-06-300001058290us-gaap:RetainedEarningsMember2022-06-300001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001058290us-gaap:CommonStockMember2020-12-310001058290us-gaap:AdditionalPaidInCapitalMember2020-12-310001058290us-gaap:RetainedEarningsMember2020-12-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100010582902020-12-310001058290us-gaap:RetainedEarningsMember2021-01-012021-03-3100010582902021-01-012021-03-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001058290us-gaap:CommonStockMember2021-01-012021-03-310001058290us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001058290us-gaap:CommonStockMember2021-03-310001058290us-gaap:AdditionalPaidInCapitalMember2021-03-310001058290us-gaap:RetainedEarningsMember2021-03-310001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100010582902021-03-310001058290us-gaap:RetainedEarningsMember2021-04-012021-06-300001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001058290us-gaap:CommonStockMember2021-04-012021-06-300001058290us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001058290us-gaap:CommonStockMember2021-06-300001058290us-gaap:AdditionalPaidInCapitalMember2021-06-300001058290us-gaap:RetainedEarningsMember2021-06-300001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000010582902021-06-300001058290srt:NorthAmericaMemberctsh:FinancialServicesMember2022-04-012022-06-300001058290srt:NorthAmericaMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290srt:NorthAmericaMemberctsh:ProductsandResourcesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:NorthAmericaMember2022-04-012022-06-300001058290srt:NorthAmericaMember2022-04-012022-06-300001058290srt:NorthAmericaMemberctsh:FinancialServicesMember2022-01-012022-06-300001058290srt:NorthAmericaMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290srt:NorthAmericaMemberctsh:ProductsandResourcesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:NorthAmericaMember2022-01-012022-06-300001058290srt:NorthAmericaMember2022-01-012022-06-300001058290country:GBctsh:FinancialServicesMember2022-04-012022-06-300001058290country:GBctsh:HealthSciencesMember2022-04-012022-06-300001058290country:GBctsh:ProductsandResourcesMember2022-04-012022-06-300001058290country:GBctsh:CommunicationMediaandTechnologyMember2022-04-012022-06-300001058290country:GB2022-04-012022-06-300001058290country:GBctsh:FinancialServicesMember2022-01-012022-06-300001058290country:GBctsh:HealthSciencesMember2022-01-012022-06-300001058290country:GBctsh:ProductsandResourcesMember2022-01-012022-06-300001058290country:GBctsh:CommunicationMediaandTechnologyMember2022-01-012022-06-300001058290country:GB2022-01-012022-06-300001058290ctsh:FinancialServicesMemberctsh:EuropeexcludingUnitedKingdomMember2022-04-012022-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:ProductsandResourcesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:EuropeexcludingUnitedKingdomMember2022-04-012022-06-300001058290ctsh:EuropeexcludingUnitedKingdomMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberctsh:EuropeexcludingUnitedKingdomMember2022-01-012022-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:ProductsandResourcesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:EuropeexcludingUnitedKingdomMember2022-01-012022-06-300001058290ctsh:EuropeexcludingUnitedKingdomMember2022-01-012022-06-300001058290ctsh:FinancialServicesMembersrt:EuropeMember2022-04-012022-06-300001058290ctsh:HealthSciencesMembersrt:EuropeMember2022-04-012022-06-300001058290ctsh:ProductsandResourcesMembersrt:EuropeMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:EuropeMember2022-04-012022-06-300001058290srt:EuropeMember2022-04-012022-06-300001058290ctsh:FinancialServicesMembersrt:EuropeMember2022-01-012022-06-300001058290ctsh:HealthSciencesMembersrt:EuropeMember2022-01-012022-06-300001058290ctsh:ProductsandResourcesMembersrt:EuropeMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:EuropeMember2022-01-012022-06-300001058290srt:EuropeMember2022-01-012022-06-300001058290ctsh:FinancialServicesMemberctsh:RestofWorldMember2022-04-012022-06-300001058290ctsh:HealthSciencesMemberctsh:RestofWorldMember2022-04-012022-06-300001058290ctsh:ProductsandResourcesMemberctsh:RestofWorldMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:RestofWorldMember2022-04-012022-06-300001058290ctsh:RestofWorldMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberctsh:RestofWorldMember2022-01-012022-06-300001058290ctsh:HealthSciencesMemberctsh:RestofWorldMember2022-01-012022-06-300001058290ctsh:ProductsandResourcesMemberctsh:RestofWorldMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:RestofWorldMember2022-01-012022-06-300001058290ctsh:RestofWorldMember2022-01-012022-06-300001058290ctsh:FinancialServicesMember2022-04-012022-06-300001058290ctsh:HealthSciencesMember2022-04-012022-06-300001058290ctsh:ProductsandResourcesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMember2022-04-012022-06-300001058290ctsh:FinancialServicesMember2022-01-012022-06-300001058290ctsh:HealthSciencesMember2022-01-012022-06-300001058290ctsh:ProductsandResourcesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMember2022-01-012022-06-300001058290ctsh:FinancialServicesMemberctsh:ConsultingAndTechnologyServicesMember2022-04-012022-06-300001058290ctsh:ConsultingAndTechnologyServicesMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290ctsh:ProductsandResourcesMemberctsh:ConsultingAndTechnologyServicesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:ConsultingAndTechnologyServicesMember2022-04-012022-06-300001058290ctsh:ConsultingAndTechnologyServicesMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberctsh:ConsultingAndTechnologyServicesMember2022-01-012022-06-300001058290ctsh:ConsultingAndTechnologyServicesMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290ctsh:ProductsandResourcesMemberctsh:ConsultingAndTechnologyServicesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:ConsultingAndTechnologyServicesMember2022-01-012022-06-300001058290ctsh:ConsultingAndTechnologyServicesMember2022-01-012022-06-300001058290ctsh:OutsourcingServicesMemberctsh:FinancialServicesMember2022-04-012022-06-300001058290ctsh:OutsourcingServicesMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290ctsh:OutsourcingServicesMemberctsh:ProductsandResourcesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:OutsourcingServicesMember2022-04-012022-06-300001058290ctsh:OutsourcingServicesMember2022-04-012022-06-300001058290ctsh:OutsourcingServicesMemberctsh:FinancialServicesMember2022-01-012022-06-300001058290ctsh:OutsourcingServicesMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290ctsh:OutsourcingServicesMemberctsh:ProductsandResourcesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:OutsourcingServicesMember2022-01-012022-06-300001058290ctsh:OutsourcingServicesMember2022-01-012022-06-300001058290ctsh:FinancialServicesMemberus-gaap:TimeAndMaterialsContractMember2022-04-012022-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:ProductsandResourcesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:TimeAndMaterialsContractMember2022-04-012022-06-300001058290us-gaap:TimeAndMaterialsContractMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberus-gaap:TimeAndMaterialsContractMember2022-01-012022-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:ProductsandResourcesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:TimeAndMaterialsContractMember2022-01-012022-06-300001058290us-gaap:TimeAndMaterialsContractMember2022-01-012022-06-300001058290ctsh:FinancialServicesMemberus-gaap:FixedPriceContractMember2022-04-012022-06-300001058290ctsh:HealthSciencesMemberus-gaap:FixedPriceContractMember2022-04-012022-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:FixedPriceContractMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:FixedPriceContractMember2022-04-012022-06-300001058290us-gaap:FixedPriceContractMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberus-gaap:FixedPriceContractMember2022-01-012022-06-300001058290ctsh:HealthSciencesMemberus-gaap:FixedPriceContractMember2022-01-012022-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:FixedPriceContractMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:FixedPriceContractMember2022-01-012022-06-300001058290us-gaap:FixedPriceContractMember2022-01-012022-06-300001058290ctsh:FinancialServicesMemberctsh:TransactionOrVolumeBasedMember2022-04-012022-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:ProductsandResourcesMember2022-04-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:TransactionOrVolumeBasedMember2022-04-012022-06-300001058290ctsh:TransactionOrVolumeBasedMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberctsh:TransactionOrVolumeBasedMember2022-01-012022-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:ProductsandResourcesMember2022-01-012022-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:TransactionOrVolumeBasedMember2022-01-012022-06-300001058290ctsh:TransactionOrVolumeBasedMember2022-01-012022-06-300001058290srt:NorthAmericaMemberctsh:FinancialServicesMember2021-04-012021-06-300001058290srt:NorthAmericaMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290srt:NorthAmericaMemberctsh:ProductsandResourcesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:NorthAmericaMember2021-04-012021-06-300001058290srt:NorthAmericaMember2021-04-012021-06-300001058290srt:NorthAmericaMemberctsh:FinancialServicesMember2021-01-012021-06-300001058290srt:NorthAmericaMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290srt:NorthAmericaMemberctsh:ProductsandResourcesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:NorthAmericaMember2021-01-012021-06-300001058290srt:NorthAmericaMember2021-01-012021-06-300001058290country:GBctsh:FinancialServicesMember2021-04-012021-06-300001058290country:GBctsh:HealthSciencesMember2021-04-012021-06-300001058290country:GBctsh:ProductsandResourcesMember2021-04-012021-06-300001058290country:GBctsh:CommunicationMediaandTechnologyMember2021-04-012021-06-300001058290country:GB2021-04-012021-06-300001058290country:GBctsh:FinancialServicesMember2021-01-012021-06-300001058290country:GBctsh:HealthSciencesMember2021-01-012021-06-300001058290country:GBctsh:ProductsandResourcesMember2021-01-012021-06-300001058290country:GBctsh:CommunicationMediaandTechnologyMember2021-01-012021-06-300001058290country:GB2021-01-012021-06-300001058290ctsh:FinancialServicesMemberctsh:EuropeexcludingUnitedKingdomMember2021-04-012021-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:ProductsandResourcesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:EuropeexcludingUnitedKingdomMember2021-04-012021-06-300001058290ctsh:EuropeexcludingUnitedKingdomMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberctsh:EuropeexcludingUnitedKingdomMember2021-01-012021-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290ctsh:EuropeexcludingUnitedKingdomMemberctsh:ProductsandResourcesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:EuropeexcludingUnitedKingdomMember2021-01-012021-06-300001058290ctsh:EuropeexcludingUnitedKingdomMember2021-01-012021-06-300001058290ctsh:FinancialServicesMembersrt:EuropeMember2021-04-012021-06-300001058290ctsh:HealthSciencesMembersrt:EuropeMember2021-04-012021-06-300001058290ctsh:ProductsandResourcesMembersrt:EuropeMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:EuropeMember2021-04-012021-06-300001058290srt:EuropeMember2021-04-012021-06-300001058290ctsh:FinancialServicesMembersrt:EuropeMember2021-01-012021-06-300001058290ctsh:HealthSciencesMembersrt:EuropeMember2021-01-012021-06-300001058290ctsh:ProductsandResourcesMembersrt:EuropeMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMembersrt:EuropeMember2021-01-012021-06-300001058290srt:EuropeMember2021-01-012021-06-300001058290ctsh:FinancialServicesMemberctsh:RestofWorldMember2021-04-012021-06-300001058290ctsh:HealthSciencesMemberctsh:RestofWorldMember2021-04-012021-06-300001058290ctsh:ProductsandResourcesMemberctsh:RestofWorldMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:RestofWorldMember2021-04-012021-06-300001058290ctsh:RestofWorldMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberctsh:RestofWorldMember2021-01-012021-06-300001058290ctsh:HealthSciencesMemberctsh:RestofWorldMember2021-01-012021-06-300001058290ctsh:ProductsandResourcesMemberctsh:RestofWorldMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:RestofWorldMember2021-01-012021-06-300001058290ctsh:RestofWorldMember2021-01-012021-06-300001058290ctsh:FinancialServicesMember2021-04-012021-06-300001058290ctsh:HealthSciencesMember2021-04-012021-06-300001058290ctsh:ProductsandResourcesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMember2021-04-012021-06-300001058290ctsh:FinancialServicesMember2021-01-012021-06-300001058290ctsh:HealthSciencesMember2021-01-012021-06-300001058290ctsh:ProductsandResourcesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMember2021-01-012021-06-300001058290ctsh:FinancialServicesMemberctsh:ConsultingAndTechnologyServicesMember2021-04-012021-06-300001058290ctsh:ConsultingAndTechnologyServicesMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290ctsh:ProductsandResourcesMemberctsh:ConsultingAndTechnologyServicesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:ConsultingAndTechnologyServicesMember2021-04-012021-06-300001058290ctsh:ConsultingAndTechnologyServicesMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberctsh:ConsultingAndTechnologyServicesMember2021-01-012021-06-300001058290ctsh:ConsultingAndTechnologyServicesMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290ctsh:ProductsandResourcesMemberctsh:ConsultingAndTechnologyServicesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:ConsultingAndTechnologyServicesMember2021-01-012021-06-300001058290ctsh:ConsultingAndTechnologyServicesMember2021-01-012021-06-300001058290ctsh:OutsourcingServicesMemberctsh:FinancialServicesMember2021-04-012021-06-300001058290ctsh:OutsourcingServicesMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290ctsh:OutsourcingServicesMemberctsh:ProductsandResourcesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:OutsourcingServicesMember2021-04-012021-06-300001058290ctsh:OutsourcingServicesMember2021-04-012021-06-300001058290ctsh:OutsourcingServicesMemberctsh:FinancialServicesMember2021-01-012021-06-300001058290ctsh:OutsourcingServicesMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290ctsh:OutsourcingServicesMemberctsh:ProductsandResourcesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:OutsourcingServicesMember2021-01-012021-06-300001058290ctsh:OutsourcingServicesMember2021-01-012021-06-300001058290ctsh:FinancialServicesMemberus-gaap:TimeAndMaterialsContractMember2021-04-012021-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:ProductsandResourcesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:TimeAndMaterialsContractMember2021-04-012021-06-300001058290us-gaap:TimeAndMaterialsContractMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberus-gaap:TimeAndMaterialsContractMember2021-01-012021-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290us-gaap:TimeAndMaterialsContractMemberctsh:ProductsandResourcesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:TimeAndMaterialsContractMember2021-01-012021-06-300001058290us-gaap:TimeAndMaterialsContractMember2021-01-012021-06-300001058290ctsh:FinancialServicesMemberus-gaap:FixedPriceContractMember2021-04-012021-06-300001058290ctsh:HealthSciencesMemberus-gaap:FixedPriceContractMember2021-04-012021-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:FixedPriceContractMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:FixedPriceContractMember2021-04-012021-06-300001058290us-gaap:FixedPriceContractMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberus-gaap:FixedPriceContractMember2021-01-012021-06-300001058290ctsh:HealthSciencesMemberus-gaap:FixedPriceContractMember2021-01-012021-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:FixedPriceContractMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberus-gaap:FixedPriceContractMember2021-01-012021-06-300001058290us-gaap:FixedPriceContractMember2021-01-012021-06-300001058290ctsh:FinancialServicesMemberctsh:TransactionOrVolumeBasedMember2021-04-012021-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:ProductsandResourcesMember2021-04-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:TransactionOrVolumeBasedMember2021-04-012021-06-300001058290ctsh:TransactionOrVolumeBasedMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberctsh:TransactionOrVolumeBasedMember2021-01-012021-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290ctsh:TransactionOrVolumeBasedMemberctsh:ProductsandResourcesMember2021-01-012021-06-300001058290ctsh:CommunicationMediaandTechnologyMemberctsh:TransactionOrVolumeBasedMember2021-01-012021-06-300001058290ctsh:TransactionOrVolumeBasedMember2021-01-012021-06-3000010582902022-07-012022-06-30xbrli:pure0001058290us-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:ShortTermInvestmentsMember2021-12-310001058290ctsh:LongterminvestmentsMember2022-06-300001058290ctsh:LongterminvestmentsMember2021-12-310001058290ctsh:CertificatesOfDepositAndCommercialPaperMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:CorporateDebtSecuritiesMember2022-06-300001058290us-gaap:CommercialPaperMember2022-06-300001058290srt:MaximumMember2022-06-300001058290us-gaap:CorporateDebtSecuritiesMember2021-12-310001058290us-gaap:CommercialPaperMember2021-12-310001058290srt:MaximumMember2021-12-310001058290us-gaap:LoansPayableMemberctsh:CreditAgreementMember2018-11-300001058290us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMemberctsh:CreditAgreementMember2018-11-300001058290us-gaap:EurodollarMemberctsh:CreditAgreementMember2022-01-012022-06-300001058290us-gaap:BaseRateMemberctsh:CreditAgreementMember2022-01-012022-06-300001058290srt:MinimumMemberus-gaap:EurodollarMemberctsh:CreditAgreementMember2022-01-012022-06-300001058290srt:MaximumMemberus-gaap:EurodollarMemberctsh:CreditAgreementMember2022-01-012022-06-300001058290srt:MinimumMemberctsh:EurocurrencyWithoutDebtRatingsMemberctsh:CreditAgreementMember2022-01-012022-06-300001058290srt:MaximumMemberctsh:EurocurrencyWithoutDebtRatingsMemberctsh:CreditAgreementMember2022-01-012022-06-300001058290ctsh:WorkingCapitalFacilityMember2022-03-01iso4217:INR0001058290ctsh:WorkingCapitalFacilityMember2022-06-300001058290us-gaap:LoansPayableMemberctsh:CreditAgreementMember2022-06-300001058290us-gaap:LoansPayableMemberctsh:CreditAgreementMember2021-12-310001058290ctsh:CreditAgreementMember2022-06-300001058290ctsh:CreditAgreementMember2021-12-310001058290us-gaap:ForeignCountryMemberctsh:A2013IndiaShareRepurchaseMemberus-gaap:MinistryOfFinanceIndiaMember2013-01-012013-12-310001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:MinistryOfFinanceIndiaMember2016-01-012016-12-310001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:MinistryOfFinanceIndiaMember2018-03-310001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:MinistryOfFinanceIndiaMember2022-06-300001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:MinistryOfFinanceIndiaMember2018-04-300001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:OtherCurrentAssetsMemberus-gaap:MinistryOfFinanceIndiaMember2022-06-300001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:OtherCurrentAssetsMemberus-gaap:MinistryOfFinanceIndiaMember2021-12-310001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:MinistryOfFinanceIndiaMemberctsh:LongterminvestmentsMember2022-06-300001058290us-gaap:ForeignCountryMemberctsh:A2016IndiaCashRemittanceMemberus-gaap:MinistryOfFinanceIndiaMemberctsh:LongterminvestmentsMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001058290us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMember2022-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMember2021-12-310001058290us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2021-12-310001058290us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberctsh:ForeignExchangeContractMaturity2022Member2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberctsh:ForeignExchangeContractMaturity2022Member2021-12-310001058290us-gaap:CashFlowHedgingMemberctsh:ForeignExchangeContractMaturity2023Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-06-300001058290us-gaap:CashFlowHedgingMemberctsh:ForeignExchangeContractMaturity2023Memberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberctsh:ForeignExchangeContractMaturity2024Member2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberctsh:ForeignExchangeContractMaturity2024Member2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeOptionMember2022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeOptionMember2021-12-310001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-04-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-06-300001058290us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2022-04-012022-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2021-04-012021-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2022-01-012022-06-300001058290us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMemberus-gaap:NondesignatedMember2021-01-012021-06-300001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-06-300001058290us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2022-06-300001058290us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2022-06-300001058290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290ctsh:CertificatesOfDepositAndCommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberctsh:CertificatesOfDepositAndCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290ctsh:CertificatesOfDepositAndCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ShortTermInvestmentsMember2022-06-300001058290ctsh:CertificatesOfDepositAndCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-06-300001058290us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001058290us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberctsh:LongterminvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290ctsh:LongterminvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-06-300001058290us-gaap:FairValueMeasurementsRecurringMemberctsh:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-06-300001058290us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001058290us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2021-12-310001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001058290us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2021-12-310001058290us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2021-12-310001058290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-12-310001058290us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001058290us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberctsh:LongterminvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290ctsh:LongterminvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001058290us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001058290us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001058290us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001058290ctsh:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-12-310001058290ctsh:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2020-12-310001058290ctsh:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300001058290ctsh:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-06-300001058290ctsh:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2022-06-300001058290ctsh:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-06-300001058290us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001058290us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001058290us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300001058290us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-06-300001058290us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-03-310001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-12-310001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-04-012022-06-300001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-06-300001058290us-gaap:CostOfSalesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-04-012022-06-300001058290us-gaap:CostOfSalesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-06-300001058290us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-04-012022-06-300001058290us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-06-300001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-06-300001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001058290us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001058290us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001058290us-gaap:AccumulatedTranslationAdjustmentMember2021-04-012021-06-300001058290us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-06-300001058290us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-03-310001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-04-012021-06-300001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-06-300001058290us-gaap:CostOfSalesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-04-012021-06-300001058290us-gaap:CostOfSalesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-06-300001058290us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-04-012021-06-300001058290us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-06-300001058290us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-06-300001058290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001058290ctsh:SyntelSterlingBestShoresMauritiusLtdMember2020-10-272020-10-270001058290ctsh:SyntelSterlingBestShoresMauritiusLtdMember2021-04-202021-04-200001058290ctsh:IndiaDefinedContributionObligationMember2019-03-310001058290ctsh:FinancialServicesMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001058290ctsh:FinancialServicesMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001058290ctsh:FinancialServicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001058290ctsh:FinancialServicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001058290us-gaap:OperatingSegmentsMemberctsh:HealthSciencesMember2022-04-012022-06-300001058290us-gaap:OperatingSegmentsMemberctsh:HealthSciencesMember2021-04-012021-06-300001058290us-gaap:OperatingSegmentsMemberctsh:HealthSciencesMember2022-01-012022-06-300001058290us-gaap:OperatingSegmentsMemberctsh:HealthSciencesMember2021-01-012021-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001058290ctsh:ProductsandResourcesMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001058290ctsh:CommunicationsMediaandTechnologyMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001058290ctsh:CommunicationsMediaandTechnologyMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001058290ctsh:CommunicationsMediaandTechnologyMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001058290ctsh:CommunicationsMediaandTechnologyMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001058290us-gaap:OperatingSegmentsMember2022-04-012022-06-300001058290us-gaap:OperatingSegmentsMember2021-04-012021-06-300001058290us-gaap:OperatingSegmentsMember2022-01-012022-06-300001058290us-gaap:OperatingSegmentsMember2021-01-012021-06-300001058290us-gaap:CorporateNonSegmentMember2022-04-012022-06-300001058290us-gaap:CorporateNonSegmentMember2021-04-012021-06-300001058290us-gaap:CorporateNonSegmentMember2022-01-012022-06-300001058290us-gaap:CorporateNonSegmentMember2021-01-012021-06-300001058290srt:NorthAmericaMember2022-06-300001058290srt:NorthAmericaMember2021-12-310001058290srt:EuropeMember2022-06-300001058290srt:EuropeMember2021-12-310001058290ctsh:RestofWorldMember2022-06-300001058290ctsh:RestofWorldMember2021-12-310001058290us-gaap:SubsequentEventMember2022-07-262022-07-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
| | | | | | | | |
☒ | Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| For the quarterly period ended | June 30, 2022 |
☐ | Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| For the transition period from to |
Commission File Number 0-24429 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
(Exact Name of Registrant as Specified in Its Charter) | | | | | | | | | | | |
Delaware | | 13-3728359 |
(State or Other Jurisdiction of Incorporation or Organization) | | (I.R.S. Employer Identification No.) |
| | |
300 Frank W. Burr Blvd.
Teaneck, New Jersey 07666
(Address of Principal Executive Offices including Zip Code)
Registrant’s telephone number, including area code: (201) 801-0233
N/A
(Former Name, Former Address and Former Fiscal Year,
if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: | | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Class A Common Stock, $0.01 par value per share | CTSH | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No: ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No: ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. | | | | | | | | | | | |
Large Accelerated Filer | ☒ | Accelerated filer | ☐ |
| | | |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | |
| | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of July 22, 2022:
| | | | | | | | |
Class | | Number of Shares |
Class A Common Stock, par value $0.01 per share | | 517,784,927 |
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
TABLE OF CONTENTS
| | | | | | | | |
| | Page |
| |
| | |
PART I. | | |
| | |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
| | |
Item 3. | | |
| | |
Item 4. | | |
| | |
PART II. | | |
| | |
Item 1. | | |
| | |
Item 1A. | | |
| | |
Item 2. | | |
| | |
Item 6. | | |
| |
| |
GLOSSARY | | | | | | |
Defined Term | Definition | |
10b5-1 Plan | Trading plan adopted pursuant to Rule 10b5-1 of the Exchange Act | |
Adjusted Diluted EPS | Adjusted Diluted Earnings Per Share | |
ASC | Accounting Standards Codification | |
ASR | Accelerated Stock Repurchase | |
CC | Constant Currency | |
CITA | Commissioner of Income Tax (Appeals) | |
| | |
CMT | Communications, Media and Technology | |
COVID-19 | The novel coronavirus disease | |
Credit Agreement | Credit agreement with a commercial bank syndicate, as amended | |
CTS India | Our principal operating subsidiary in India | |
DOJ | United States Department of Justice | |
DSO | Days Sales Outstanding | |
EPS | Earnings Per Share | |
ESG | Environmental, Social and Governance | |
EU | European Union | |
Exchange Act | Securities Exchange Act of 1934, as amended | |
GAAP | Generally Accepted Accounting Principles in the United States of America | |
High Court | Madras High Court | |
India Defined Contribution Obligation | Certain statutory defined contribution obligations of employees and employers in India | |
IoT | Internet of Things | |
ITD | Indian Income Tax Department | |
SCI | Supreme Court of India | |
SEC | United States Securities and Exchange Commission | |
Second Circuit | United States Court of Appeals for the Second Circuit | |
SG&A | Selling, general and administrative | |
Syntel | Syntel Sterling Best Shores Mauritius Ltd. | |
Tax Reform Act | Tax Cuts and Jobs Act | |
Term Loan | Unsecured term loan under the Credit Agreement | |
TriZetto | The TriZetto Group, Inc., now known as Cognizant Technology Software Group, Inc. | |
USDC-NJ | United States District Court for the District of New Jersey | |
USDC-SDNY | United States District Court for the Southern District of New York | |
| | | | | | | | |
Cognizant Technology Solutions | 1 | June 30, 2022 Form 10-Q |
PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements (Unaudited).
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Unaudited)
| | | | | | | | | | | |
(in millions, except par values) | June 30, 2022 | | December 31, 2021 |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 1,768 | | | $ | 1,792 | |
Short-term investments | 552 | | | 927 | |
Trade accounts receivable, net | 3,785 | | | 3,557 | |
Other current assets | 918 | | | 1,066 | |
Total current assets | 7,023 | | | 7,342 | |
Property and equipment, net | 1,121 | | | 1,171 | |
Operating lease assets, net | 907 | | | 933 | |
Goodwill | 5,517 | | | 5,620 | |
Intangible assets, net | 1,101 | | | 1,218 | |
Deferred income tax assets, net | 473 | | | 404 | |
Long-term investments | 443 | | | 463 | |
Other noncurrent assets | 673 | | | 701 | |
Total assets | $ | 17,258 | | | $ | 17,852 | |
Liabilities and Stockholders’ Equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 357 | | | $ | 361 | |
Deferred revenue | 408 | | | 403 | |
Short-term debt | 38 | | | 38 | |
Operating lease liabilities | 178 | | | 195 | |
Accrued expenses and other current liabilities | 2,172 | | | 2,532 | |
Total current liabilities | 3,153 | | | 3,529 | |
Deferred revenue, noncurrent | 24 | | | 40 | |
Operating lease liabilities, noncurrent | 747 | | | 783 | |
Deferred income tax liabilities, net | 207 | | | 218 | |
Long-term debt | 608 | | | 626 | |
Long-term income taxes payable | 283 | | | 378 | |
Other noncurrent liabilities | 286 | | | 287 | |
Total liabilities | 5,308 | | | 5,861 | |
Commitments and contingencies (See Note 10) | | | |
Stockholders’ equity: | | | |
Preferred stock, $0.10 par value, 15 shares authorized, none issued | — | | | — | |
Class A common stock, $0.01 par value, 1,000 shares authorized, 518 and 525 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 5 | | | 5 | |
Additional paid-in capital | 21 | | | 27 | |
Retained earnings | 12,193 | | | 11,922 | |
Accumulated other comprehensive income (loss) | (269) | | | 37 | |
Total stockholders’ equity | 11,950 | | | 11,991 | |
Total liabilities and stockholders’ equity | $ | 17,258 | | | $ | 17,852 | |
The accompanying notes are an integral part of the unaudited consolidated financial statements.
| | | | | | | | |
Cognizant Technology Solutions | 2 | June 30, 2022 Form 10-Q |
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
(in millions, except per share data) | Three Months Ended June 30, | | Six Months Ended June 30, |
| 2022 | | 2021 | | 2022 | | 2021 |
Revenues | $ | 4,906 | | | $ | 4,585 | | | $ | 9,732 | | | $ | 8,986 | |
Operating expenses: | | | | | | | |
Cost of revenues (exclusive of depreciation and amortization expense shown separately below) | 3,119 | | | 2,863 | | | 6,216 | | | 5,627 | |
Selling, general and administrative expenses | 883 | | | 881 | | | 1,745 | | | 1,708 | |
| | | | | | | |
Depreciation and amortization expense | 144 | | | 145 | | | 287 | | | 286 | |
Income from operations | 760 | | | 696 | | | 1,484 | | | 1,365 | |
Other income (expense), net: | | | | | | | |
Interest income | 9 | | | 7 | | | 15 | | | 16 | |
Interest expense | (3) | | | (2) | | | (5) | | | (4) | |
Foreign currency exchange gains (losses), net | (4) | | | (7) | | | (4) | | | (16) | |
Other, net | (1) | | | — | | | — | | | (2) | |
Total other income (expense), net | 1 | | | (2) | | | 6 | | | (6) | |
Income before provision for income taxes | 761 | | | 694 | | | 1,490 | | | 1,359 | |
Provision for income taxes | (184) | | | (184) | | | (354) | | | (344) | |
Income (loss) from equity method investments | — | | | 2 | | | 4 | | | 2 | |
Net income | $ | 577 | | | $ | 512 | | | $ | 1,140 | | | $ | 1,017 | |
Basic earnings per share | $ | 1.11 | | | $ | 0.97 | | | $ | 2.18 | | | $ | 1.93 | |
Diluted earnings per share | $ | 1.11 | | | $ | 0.97 | | | $ | 2.18 | | | $ | 1.92 | |
Weighted average number of common shares outstanding - Basic | 520 | | | 527 | | | 522 | | | 528 | |
Dilutive effect of shares issuable under stock-based compensation plans | 1 | | | 1 | | | 1 | | | 1 | |
Weighted average number of common shares outstanding - Diluted | 521 | | | 528 | | | 523 | | | 529 | |
The accompanying notes are an integral part of the unaudited consolidated financial statements.
| | | | | | | | |
Cognizant Technology Solutions | 3 | June 30, 2022 Form 10-Q |
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | Three Months Ended June 30, | | Six Months Ended June 30, |
| 2022 | | 2021 | | 2022 | | 2021 |
Net income | $ | 577 | | | $ | 512 | | | $ | 1,140 | | | $ | 1,017 | |
Change in Accumulated other comprehensive income (loss), net of tax: | | | | | | | |
Foreign currency translation adjustments | (193) | | | 14 | | | (230) | | | (11) | |
Unrealized gains and losses on cash flow hedges | (57) | | | (13) | | | (76) | | | (17) | |
| | | | | | | |
Other comprehensive income (loss) | (250) | | | 1 | | | (306) | | | (28) | |
Comprehensive income | $ | 327 | | | $ | 513 | | | $ | 834 | | | $ | 989 | |
The accompanying notes are an integral part of the unaudited consolidated financial statements.
| | | | | | | | |
Cognizant Technology Solutions | 4 | June 30, 2022 Form 10-Q |
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | | Class A Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Total |
| Shares | | Amount | |
Balance, December 31, 2021 | | 525 | | | $ | 5 | | | $ | 27 | | | $ | 11,922 | | | $ | 37 | | | $ | 11,991 | |
Net income | | — | | | — | | | — | | | 563 | | | — | | | 563 | |
Other comprehensive income (loss) | | — | | | — | | | — | | | — | | | (56) | | | (56) | |
Common stock issued, stock-based compensation plans | | 1 | | | — | | | 31 | | | — | | | — | | | 31 | |
Stock-based compensation expense | | — | | | — | | | 56 | | | — | | | — | | | 56 | |
Repurchases of common stock | | (5) | | | — | | | (83) | | | (387) | | | — | | | (470) | |
Dividends declared, $0.27 per share | | — | | | — | | | — | | | (142) | | | — | | | (142) | |
Balance, March 31, 2022 | | 521 | | | 5 | | | 31 | | | 11,956 | | | (19) | | | 11,973 | |
Net income | | — | | | — | | | — | | | 577 | | | — | | | 577 | |
Other comprehensive income (loss) | | — | | | — | | | — | | | — | | | (250) | | | (250) | |
Common stock issued, stock-based compensation plans | | 1 | | | — | | | 21 | | | — | | | — | | | 21 | |
Stock-based compensation expense | | — | | | — | | | 89 | | | — | | | — | | | 89 | |
Repurchases of common stock | | (4) | | | — | | | (120) | | | (198) | | | — | | | (318) | |
Dividends declared, $0.27 per share | | — | | | — | | | — | | | (142) | | | — | | | (142) | |
Balance, June 30, 2022 | | 518 | | | $ | 5 | | | $ | 21 | | | $ | 12,193 | | | $ | (269) | | | $ | 11,950 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | | Class A Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Income (Loss) | | Total |
| Shares | | Amount | |
Balance, December 31, 2020 | | 530 | | | $ | 5 | | | $ | 32 | | | $ | 10,689 | | | $ | 110 | | | $ | 10,836 | |
Net income | | — | | | — | | | — | | | 505 | | | — | | | 505 | |
Other comprehensive income (loss) | | — | | | — | | | — | | | — | | | (29) | | | (29) | |
Common stock issued, stock-based compensation plans | | 1 | | | — | | | 43 | | | — | | | — | | | 43 | |
Stock-based compensation expense | | — | | | — | | | 62 | | | — | | | — | | | 62 | |
Repurchases of common stock | | (3) | | | — | | | (93) | | | (159) | | | — | | | (252) | |
Dividends declared, $0.24 per share | | — | | | — | | | — | | | (128) | | | — | | | (128) | |
Balance, March 31, 2021 | | 528 | | | 5 | | | 44 | | | 10,907 | | | 81 | | | 11,037 | |
Net income | | — | | | — | | | — | | | 512 | | | — | | | 512 | |
Other comprehensive income (loss) | | — | | | — | | | — | | | — | | | 1 | | | 1 | |
Common stock issued, stock-based compensation plans | | 1 | | | — | | | 32 | | | — | | | — | | | 32 | |
Stock-based compensation expense | | — | | | — | | | 67 | | | — | | | — | | | 67 | |
Repurchases of common stock | | (4) | | | — | | | (111) | | | (205) | | | — | | | (316) | |
Dividends declared, $0.24 per share | | — | | | — | | | — | | | (128) | | | — | | | (128) | |
Balance, June 30, 2021 | | 525 | | | $ | 5 | | | $ | 32 | | | $ | 11,086 | | | $ | 82 | | | $ | 11,205 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
The accompanying notes are an integral part of the unaudited consolidated financial statements.
| | | | | | | | |
Cognizant Technology Solutions | 5 | June 30, 2022 Form 10-Q |
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| | | | | | | | | | | |
(in millions) | For the Six Months Ended June 30, |
| 2022 | | 2021 |
Cash flows from operating activities: | | | |
Net income | $ | 1,140 | | | $ | 1,017 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
Depreciation and amortization | 287 | | | 286 | |
| | | |
Deferred income taxes | (74) | | | 119 | |
Stock-based compensation expense | 145 | | | 129 | |
| | | |
Other | 51 | | | (2) | |
Changes in assets and liabilities: | | | |
Trade accounts receivable | (251) | | | (279) | |
Other current and noncurrent assets | 131 | | | 60 | |
Accounts payable | (9) | | | 17 | |
Deferred revenues, current and noncurrent | (8) | | | (34) | |
Other current and noncurrent liabilities | (578) | | | (591) | |
Net cash provided by operating activities | 834 | | | 722 | |
Cash flows from investing activities: | | | |
Purchases of property and equipment | (163) | | | (163) | |
Purchases of available-for-sale investment securities | (513) | | | (105) | |
Proceeds from maturity or sale of available-for-sale investment securities | 375 | | | — | |
Purchases of held-to-maturity investment securities | (32) | | | (89) | |
Proceeds from maturity of held-to-maturity investment securities | 30 | | | 76 | |
Purchases of other investments | (256) | | | (642) | |
Proceeds from maturity or sale of other investments | 769 | | | 322 | |
Proceeds from sales of businesses | 19 | | | — | |
Payments for business combinations, net of cash acquired | — | | | (658) | |
Net cash provided by (used in) investing activities | 229 | | | (1,259) | |
Cash flows from financing activities: | | | |
Issuance of common stock under stock-based compensation plans | 52 | | | 75 | |
| | | |
| | | |
Repurchases of common stock | (792) | | | (560) | |
Repayment of Term Loan borrowings and finance lease and earnout obligations | (26) | | | (28) | |
| | | |
Dividends paid | (284) | | | (255) | |
Net cash (used in) financing activities | (1,050) | | | (768) | |
Effect of exchange rate changes on cash and cash equivalents | (37) | | | (7) | |
(Decrease) in cash and cash equivalents | (24) | | | (1,312) | |
Cash and cash equivalents, beginning of year | 1,792 | | | 2,680 | |
Cash and cash equivalents, end of period | $ | 1,768 | | | $ | 1,368 | |
The accompanying notes are an integral part of the unaudited consolidated financial statements.
| | | | | | | | |
Cognizant Technology Solutions | 6 | June 30, 2022 Form 10-Q |
COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
| | | | | | | | | | | | | | |
Note 1 — Interim Consolidated Financial Statements |
The terms “Cognizant,” “we,” “our,” “us” and “the Company” refer to Cognizant Technology Solutions Corporation and its subsidiaries unless the context indicates otherwise. We have prepared the accompanying unaudited consolidated financial statements included herein in accordance with GAAP and the Exchange Act. The accompanying unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements (and notes thereto) included in our Annual Report on Form 10-K for the year ended December 31, 2021. In our opinion, all adjustments considered necessary for a fair statement of the accompanying unaudited consolidated financial statements have been included and all adjustments are of a normal and recurring nature. Operating results for the interim periods are not necessarily indicative of results that may be expected to occur for the entire year.
| | | | | | | | | | | | | | |
Note 2 — Revenues and Trade Accounts Receivable |
Disaggregation of Revenues
The tables below present disaggregated revenues from contracts with clients by client location, service line and contract type for each of the business segments. We believe this disaggregation best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by industry, market and other economic factors. Our consulting and technology services include consulting, application development, systems integration, and application testing services as well as software solutions and related services while our outsourcing services include application maintenance, infrastructure and business process services. Revenues are attributed to geographic regions based upon client location, which is the client's billing address. Substantially all revenues in the North America region relate to clients in the United States.
We have defined our Financial Services, Health Sciences (previously referred to as Healthcare), Products and Resources and Communications, Media and Technology segments as ("FS"), ("HS"), ("P&R"), and ("CMT"), respectively, in our disaggregation of revenues tables.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, 2022 | | Six Months Ended June 30, 2022 |
| | |
(in millions) | | FS | | HS | | P&R | | CMT | | Total | | FS | | HS | | P&R | | CMT | | Total |
Revenues | | | | | | | | | | | | | | | | | | | | |
Geography: | | | | | | | | | | | | | | | | | | | | |
North America | | $ | 1,104 | | | $ | 1,210 | | | $ | 770 | | | $ | 572 | | | $ | 3,656 | | | $ | 2,184 | | | $ | 2,405 | | | $ | 1,531 | | | $ | 1,105 | | | $ | 7,225 | |
United Kingdom | | 147 | | | 44 | | | 134 | | | 133 | | | 458 | | | 298 | | | 88 | | | 266 | | | 259 | | | 911 | |
Continental Europe | | 143 | | | 126 | | | 143 | | | 33 | | | 445 | | | 300 | | | 246 | | | 288 | | | 70 | | | 904 | |
Europe - Total | | 290 | | | 170 | | | 277 | | | 166 | | | 903 | | | 598 | | | 334 | | | 554 | | | 329 | | | 1,815 | |
Rest of World | | 148 | | | 28 | | | 93 | | | 78 | | | 347 | | | 288 | | | 61 | | | 185 | | | 158 | | | 692 | |
Total | | $ | 1,542 | | | $ | 1,408 | | | $ | 1,140 | | | $ | 816 | | | $ | 4,906 | | | $ | 3,070 | | | $ | 2,800 | | | $ | 2,270 | | | $ | 1,592 | | | $ | 9,732 | |
| | | | | | | | | | | | | | | | | | | | |
Service line: | | | | | | | | | | | | | | | | | | | | |
Consulting and technology services | | $ | 1,078 | | | $ | 805 | | | $ | 753 | | | $ | 465 | | | $ | 3,101 | | | $ | 2,135 | | | $ | 1,609 | | | $ | 1,507 | | | $ | 913 | | | $ | 6,164 | |
Outsourcing services | | 464 | | | 603 | | | 387 | | | 351 | | | 1,805 | | | 935 | | | 1,191 | | | 763 | | | 679 | | | 3,568 | |
Total | | $ | 1,542 | | | $ | 1,408 | | | $ | 1,140 | | | $ | 816 | | | $ | 4,906 | | | $ | 3,070 | | | $ | 2,800 | | | $ | 2,270 | | | $ | 1,592 | | | $ | 9,732 | |
| | | | | | | | | | | | | | | | | | | | |
Type of contract: | | | | | | | | | | | | | | | | | | | | |
Time and materials | | $ | 894 | | | $ | 505 | | | $ | 471 | | | $ | 471 | | | $ | 2,341 | | | $ | 1,784 | | | $ | 999 | | | $ | 938 | | | $ | 919 | | | $ | 4,640 | |
Fixed-price | | 578 | | | 617 | | | 581 | | | 309 | | | 2,085 | | | 1,135 | | | 1,235 | | | 1,153 | | | 601 | | | 4,124 | |
Transaction or volume-based | | 70 | | | 286 | | | 88 | | | 36 | | | 480 | | | 151 | | | 566 | | | 179 | | | 72 | | | 968 | |
Total | | $ | 1,542 | | | $ | 1,408 | | | $ | 1,140 | | | $ | 816 | | | $ | 4,906 | | | $ | 3,070 | | | $ | 2,800 | | | $ | 2,270 | | | $ | 1,592 | | | $ | 9,732 | |
| | | | | | | | |
Cognizant Technology Solutions | 7 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, 2021 | | Six Months Ended June 30, 2021 |
| | |
(in millions) | | FS | | HS | | P&R | | CMT | | Total | | FS | | HS | | P&R | | CMT | | Total |
Revenues | | | | | | | | | | | | | | | | | | | | |
Geography: | | | | | | | | | | | | | | | | | | | | |
North America | | $ | 1,049 | | | $ | 1,131 | | | $ | 723 | | | $ | 469 | | | $ | 3,372 | | | $ | 2,062 | | | $ | 2,232 | | | $ | 1,441 | | | $ | 920 | | | $ | 6,655 | |
United Kingdom | | 130 | | | 45 | | | 116 | | | 112 | | | 403 | | | 255 | | | 85 | | | 222 | | | 211 | | | 773 | |
Continental Europe | | 186 | | | 120 | | | 132 | | | 44 | | | 482 | | | 378 | | | 238 | | | 235 | | | 87 | | | 938 | |
Europe - Total | | 316 | | | 165 | | | 248 | | | 156 | | | 885 | | | 633 | | | 323 | | | 457 | | | 298 | | | 1,711 | |
Rest of World | | 137 | | | 29 | | | 84 | | | 78 | | | 328 | | | 265 | | | 58 | | | 155 | | | 142 | | | 620 | |
Total | | $ | 1,502 | | | $ | 1,325 | | | $ | 1,055 | | | $ | 703 | | | $ | 4,585 | | | $ | 2,960 | | | $ | 2,613 | | | $ | 2,053 | | | $ | 1,360 | | | $ | 8,986 | |
| | | | | | | | | | | | | | | | | | | | |
Service line: | | | | | | | | | | | | | | | | | | | | |
Consulting and technology services | | $ | 1,012 | | | $ | 769 | | | $ | 668 | | | $ | 422 | | | $ | 2,871 | | | $ | 1,979 | | | $ | 1,514 | | | $ | 1,284 | | | $ | 818 | | | $ | 5,595 | |
Outsourcing services | | 490 | | | 556 | | | 387 | | | 281 | | | 1,714 | | | 981 | | | 1,099 | | | 769 | | | 542 | | | 3,391 | |
Total | | $ | 1,502 | | | $ | 1,325 | | | $ | 1,055 | | | $ | 703 | | | $ | 4,585 | | | $ | 2,960 | | | $ | 2,613 | | | $ | 2,053 | | | $ | 1,360 | | | $ | 8,986 | |
| | | | | | | | | | | | | | | | | | | | |
Type of contract: | | | | | | | | | | | | | | | | | | | | |
Time and materials | | $ | 908 | | | $ | 514 | | | $ | 446 | | | $ | 422 | | | $ | 2,290 | | | $ | 1,807 | | | $ | 1,033 | | | $ | 864 | | | $ | 819 | | | $ | 4,523 | |
Fixed-price | | 500 | | | 529 | | | 506 | | | 249 | | | 1,784 | | | 971 | | | 1,028 | | | 987 | | | 479 | | | 3,465 | |
Transaction or volume-based | | 94 | | | 282 | | | 103 | | | 32 | | | 511 | | | 182 | | | 552 | | | 202 | | | 62 | | | 998 | |
Total | | $ | 1,502 | | | $ | 1,325 | | | $ | 1,055 | | | $ | 703 | | | $ | 4,585 | | | $ | 2,960 | | | $ | 2,613 | | | $ | 2,053 | | | $ | 1,360 | | | $ | 8,986 | |
| | | | | | | | | | | | | | | | | | | | |
Costs to Fulfill
Costs to fulfill, such as setup or transition activities, are recorded in "Other noncurrent assets" in our unaudited consolidated statements of financial position and the amortization expense of costs to fulfill is included in "Cost of revenues" in our unaudited consolidated statements of operations. Costs to obtain contracts were immaterial for the periods disclosed. The following table presents information related to the capitalized costs to fulfill for the six months ended June 30:
| | | | | | | | | | | | | | |
(in millions) | | 2022 | | 2021 |
Beginning balance | | $ | 394 | | | $ | 467 | |
Costs capitalized | | 19 | | | 25 | |
Amortization expense | | (55) | | | (58) | |
Impairment charge | | — | | | (9) | |
Ending balance | | $ | 358 | | | $ | 425 | |
Contract Balances
A contract asset is a right to consideration that is conditional upon factors other than the passage of time. Contract assets are presented in "Other current assets" in our unaudited consolidated statements of financial position and primarily relate to unbilled amounts on fixed-price contracts utilizing the cost-to-cost method of revenue recognition. The table below shows movements in contract assets for the six months ended June 30:
| | | | | | | | | | | | | | |
(in millions) | | 2022 | | 2021 |
Beginning balance | | $ | 310 | | | $ | 315 | |
Revenues recognized during the period but not billed | | 318 | | | 266 | |
Amounts reclassified to trade accounts receivable | | (243) | | | (229) | |
Effect of foreign currency exchange movements | | (7) | | | — | |
Ending balance | | $ | 378 | | | $ | 352 | |
| | | | | | | | |
Cognizant Technology Solutions | 8 | June 30, 2022 Form 10-Q |
Contract liabilities, or deferred revenue, consist of advance payments and billings in excess of revenues recognized. The table below shows movements in the deferred revenue balances (current and noncurrent) for the six months ended June 30:
| | | | | | | | | | | | | | |
(in millions) | | 2022 | | 2021 |
Beginning balance | | $ | 443 | | | $ | 419 | |
Amounts billed but not recognized as revenues | | 385 | | | 327 | |
Revenues recognized related to the beginning balance of deferred revenue | | (388) | | | (357) | |
Effect of foreign currency exchange movements | | (8) | | | — | |
Ending balance | | $ | 432 | | | $ | 389 | |
Revenues recognized during the six months ended June 30, 2022 for performance obligations satisfied or partially satisfied in previous periods were immaterial.
Remaining Performance Obligations
As of June 30, 2022, the aggregate amount of transaction price allocated to remaining performance obligations was $1,605 million, of which approximately 85% is expected to be recognized as revenues within 2 years. Disclosure is not required for performance obligations that meet any of the following criteria:
(1)contracts with a duration of one year or less as determined under ASC Topic 606: "Revenue from Contracts with Customers",
(2)contracts for which we recognize revenues based on the right to invoice for services performed,
(3)variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation in accordance with ASC 606-10-25-14(b), for which the criteria in ASC 606-10-32-40 have been met, or
(4)variable consideration in the form of a sales-based or usage-based royalty promised in exchange for a license of intellectual property.
Many of our performance obligations meet one or more of these exemptions and therefore are not included in the remaining performance obligation amount disclosed above.
Trade Accounts Receivable and Allowance for Credit Losses
We calculate expected credit losses for trade accounts receivable based on historical credit loss rates for each aging category as adjusted for the current market conditions and forecasts about future economic conditions. The following table presents the activity in the allowance for credit losses for trade accounts receivable for the six months ended June 30:
| | | | | | | | | | | | | | |
(in millions) | | 2022 | | 2021 |
Beginning balance | | $ | 50 | | | $ | 57 | |
Credit loss expense (income) | | — | | | 1 | |
Write-offs charged against the allowance | | (7) | | | (9) | |
| | | | |
Ending balance | | $ | 43 | | | $ | 49 | |
| | | | | | | | |
Cognizant Technology Solutions | 9 | June 30, 2022 Form 10-Q |
Our investments were as follows:
| | | | | | | | | | | |
(in millions) | June 30, 2022 | | December 31, 2021 |
Short-term investments: | | | |
Equity investment security | $ | 26 | | | $ | 26 | |
Available-for-sale investment securities | 448 | | | 310 | |
Held-to-maturity investment securities | 38 | | | 37 | |
Time deposits | 40 | | | 554 | |
Total short-term investments | $ | 552 | | | $ | 927 | |
| | | | | | | | | | | |
Long-term investments: | | | |
Other investments | $ | 68 | | | $ | 66 | |
Restricted time deposits(1) | 375 | | | 397 | |
Total long-term investments | $ | 443 | | | $ | 463 | |
Equity Investment Security
Our equity investment security is a U.S. dollar denominated investment in a fixed income mutual fund. Realized and unrealized gains and losses were immaterial for the three and six months ended June 30, 2022 and 2021.
Available-for-Sale Investment Securities
Our available-for-sale investment securities consist of highly rated U.S. dollar denominated investments in certificates of deposit and commercial paper maturing within one year. As of June 30, 2022, the amortized cost and fair value of the available-for-sale investments were $448 million. As of December 31, 2021, the amortized cost and fair value of the available-for-sale investments were $310 million. Unrealized losses were immaterial as of June 30, 2022 and December 31, 2021. There were no realized gains or losses related to the available-for-sale investment securities during the six months ended June 30, 2022 and 2021. There were no sales of available-for sale investment securities during the six months ended June 30, 2022 and 2021.
Held-to-Maturity Investment Securities
Our held-to-maturity investment securities consist of Indian rupee denominated investments in commercial paper and international corporate bonds. The basis for the measurement of fair value of the held-to-maturity investment securities is Level 2 in the fair value hierarchy.
The amortized cost and fair value of held-to-maturity investment securities were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 30, 2022 | | December 31, 2021 |
(in millions) | Amortized Cost | | | | | | Fair Value | | Amortized Cost | | Fair Value |
Short-term investments, maturing within one year: | | | | | | | | | | | |
Corporate debt securities | $ | 19 | | | | | | | $ | 19 | | | $ | 17 | | | $ | 17 | |
Commercial paper | 19 | | | | | | | 19 | | | 20 | | | 20 | |
Total held-to-maturity investments | $ | 38 | | | | | | | $ | 38 | | | $ | 37 | | | $ | 37 | |
As of June 30, 2022, $12 million of corporate debt securities and $16 million of commercial paper were in an unrealized loss position. The total unrealized loss was less than $1 million and none of the securities had been in an unrealized loss position for longer than 12 months. As of December 31, 2021, $17 million of corporate debt securities and $10 million of commercial paper were in an unrealized loss position. The total unrealized loss was less than $1 million and none of the securities had been in an unrealized loss position for longer than 12 months.
The securities in our portfolio are highly rated and short-term in nature. As of June 30, 2022, the corporate debt securities were rated AA+ or better and the commercial paper securities were rated A-1+ by CRISIL, an Indian subsidiary of S&P Global.
| | | | | | | | |
Cognizant Technology Solutions | 10 | June 30, 2022 Form 10-Q |
Other Investments
As of June 30, 2022 and December 31, 2021, we had equity method investments of $66 million and $63 million, respectively, primarily related to an investment in the technology sector. As of June 30, 2022 and December 31, 2021, we had equity securities without a readily determinable fair value of $2 million and $3 million, respectively.
| | | | | | | | | | | | | | |
Note 4 — Accrued Expenses and Other Current Liabilities |
Accrued expenses and other current liabilities were as follows: | | | | | | | | | | | |
(in millions) | June 30, 2022 | | December 31, 2021 |
Compensation and benefits | $ | 1,277 | | | $ | 1,601 | |
Customer volume and other incentives | 279 | | | 242 | |
| | | |
Income taxes | 126 | | | 74 | |
Professional fees | 175 | | | 220 | |
Other | 315 | | | 395 | |
Total accrued expenses and other current liabilities | $ | 2,172 | | | $ | 2,532 | |
In 2018, we entered into the Credit Agreement providing for the $750 million Term Loan and a $1,750 million unsecured revolving credit facility, which are due to mature in November 2023. We are required under the Credit Agreement to make scheduled quarterly principal payments on the Term Loan.
The Credit Agreement requires interest to be paid, at our option, at either the ABR, the Eurocurrency Rate or the Daily Simple RFR (each as defined in the Credit Agreement), plus, in each case, an Applicable Margin (as defined in the Credit Agreement). Initially, the Applicable Margin is 0.875% with respect to Eurocurrency Rate and Daily Simple RFR and 0.00% with respect to ABR loans. Subsequently, the Applicable Margin with respect to Eurocurrency Rate and Daily Simple RFR may range from 0.75% to 1.125%, depending on our public debt ratings (or, if we have not received public debt ratings, from 0.875% to 1.125%, depending on our Leverage Ratio, which is the ratio of indebtedness for borrowed money to Consolidated EBITDA, as defined in the Credit Agreement). The Term Loan is a Eurocurrency Rate Loan.
The Credit Agreement contains customary affirmative and negative covenants as well as a financial covenant. We were in compliance with all debt covenants and representations of the Credit Agreement as of June 30, 2022.
In March 2022, our India subsidiary renewed its 13 billion Indian rupee ($165 million at the June 30, 2022 exchange rate) working capital facility, which requires us to repay any balances within 90 days from the date of disbursement. There is a 1.0% prepayment penalty applicable to payments made within 30 days of disbursement. This working capital facility contains affirmative and negative covenants and may be renewed annually. As of June 30, 2022, we have not borrowed funds under this facility.
Short-term Debt
As of both June 30, 2022 and December 31, 2021, we had $38 million of short-term debt related to current maturities of the Term Loan.
Long-term Debt
The following table summarizes the long-term debt balances as of:
| | | | | | | | | | | |
(in millions) | June 30, 2022 | | December 31, 2021 |
| | | |
Term Loan | $ | 647 | | | $ | 666 | |
Less: | | | |
Current maturities | (38) | | | (38) | |
Deferred financing costs | (1) | | | (2) | |
Long-term debt, net of current maturities | $ | 608 | | | $ | 626 | |
The carrying value of our debt approximated its fair value as of June 30, 2022 and December 31, 2021.
| | | | | | | | |
Cognizant Technology Solutions | 11 | June 30, 2022 Form 10-Q |
Our effective income tax rates were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2022 | | 2021 | | 2022 | | 2021 |
Effective income tax rate | 24.2 | % | | 26.5 | % | | 23.8 | % | | 25.3 | % |
We are involved in two separate ongoing disputes with the ITD in connection with previously disclosed share repurchase transactions undertaken by CTS India in 2013 and 2016 to repurchase shares from its shareholders (non-Indian Cognizant entities) valued at $523 million and $2.8 billion, respectively.
The 2016 transaction was undertaken pursuant to a plan approved by the High Court in Chennai, India, and resulted in the payment of $135 million in Indian income taxes - an amount we believe includes all the applicable taxes owed for this transaction under Indian law. In March 2018, the ITD asserted that it is owed an additional 33 billion Indian rupees ($418 million at the June 30, 2022 exchange rate) on the 2016 transaction. We deposited 5 billion Indian rupees, representing 15% of the disputed tax amount related to the 2016 transaction, with the ITD. As of June 30, 2022 and December 31, 2021, the deposit with the ITD was $63 million and $67 million, respectively, presented in "Other noncurrent assets". Additionally, certain time deposits of CTS India were placed under lien in favor of the ITD, representing the remainder of the disputed tax amount. As of June 30, 2022 and December 31, 2021, the balance of deposits under lien was 30 billion Indian rupees, including previously earned interest, or $375 million and $397 million, respectively, as presented in "Long-term investments". The dispute in relation to the 2013 share repurchase transaction is also in litigation. At this time, the ITD has not made specific demands with regards to this transaction.
In April 2020, we received a formal assessment from the ITD on the 2016 transaction, which is consistent with its previous assertions. In June 2020, we filed an appeal against this assessment to the CITA. In March 2022, we received a negative decision from the CITA.
We continue to believe we have paid all applicable taxes owed on both the 2016 and the 2013 transactions and we continue to defend our positions with respect to both matters. Accordingly, we have not recorded any reserves for these matters as of June 30, 2022.
| | | | | | | | | | | | | | |
Note 7 — Derivative Financial Instruments |
In the normal course of business, we use foreign exchange forward and option contracts to manage foreign currency exchange rate risk. Derivatives may give rise to credit risk from the possible non-performance by counterparties. Credit risk is limited to the fair value of those contracts that are favorable to us. We have limited our credit risk by limiting the amount of credit exposure with any one financial institution and conducting ongoing evaluation of the creditworthiness of the financial institutions with which we do business. In addition, all the assets and liabilities related to the foreign exchange derivative contracts set forth in the below table are subject to master netting arrangements, such as the International Swaps and Derivatives Association Master Agreement, with each individual counterparty. These master netting arrangements generally provide for net settlement of all outstanding contracts with the counterparty in the case of an event of default or a termination event. We have presented all the assets and liabilities related to the foreign exchange derivative contracts, as applicable, on a gross basis, with no offsets, in our unaudited consolidated statements of financial position. There is no financial collateral (including cash collateral) posted or received by us related to the foreign exchange derivative contracts.
| | | | | | | | |
Cognizant Technology Solutions | 12 | June 30, 2022 Form 10-Q |
The following table provides information on the location and fair values of derivative financial instruments included in our unaudited consolidated statements of financial position as of:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | | | | June 30, 2022 | | December 31, 2021 |
Designation of Derivatives | | Location on Statement of Financial Position | | Assets | | Liabilities | | Assets | | Liabilities |
Foreign exchange forward and option contracts – Designated as cash flow hedging instruments | | Other current assets | | $ | 6 | | | $ | — | | | $ | 51 | | | $ | — | |
| | Other noncurrent assets | | — | | | — | | | 15 | | | — | |
| | Accrued expenses and other current liabilities | | — | | | 21 | | | — | | | — | |
| | Other noncurrent liabilities | | — | | | 10 | | | — | | | — | |
| | Total | | 6 | | | 31 | | | 66 | | | — | |
Foreign exchange forward contracts – Not designated as hedging instruments | | Other current assets | | 3 | | | — | | | 3 | | | — | |
| | Accrued expenses and other current liabilities | | — | | | — | | | — | | | 7 | |
| | Total | | 3 | | | — | | | 3 | | | 7 | |
Total | | | | $ | 9 | | | $ | 31 | | | $ | 69 | | | $ | 7 | |
Cash Flow Hedges
We have entered into a series of foreign exchange derivative contracts that are designated as cash flow hedges of Indian rupee denominated payments in India. These contracts are intended to partially offset the impact of movement of the Indian rupee against the U.S. dollar on future operating costs and are scheduled to mature each month during the remainder of 2022, 2023 and the first six months of 2024. The changes in fair value of these contracts are initially reported in "Accumulated other comprehensive income (loss)" in our unaudited consolidated statements of financial position and are subsequently reclassified to earnings within "Cost of revenues" and "Selling, general and administrative expenses" in our unaudited consolidated statements of operations in the same period that the forecasted Indian rupee denominated payments are recorded in earnings. As of June 30, 2022, we estimate that $11 million, net of tax, of net losses related to derivatives designated as cash flow hedges reported in "Accumulated other comprehensive income (loss)" in our unaudited consolidated statements of financial position is expected to be reclassified into earnings within the next 12 months.
The notional value of the outstanding contracts by year of maturity was as follows:
| | | | | | | | | | | |
(in millions) | June 30, 2022 | | December 31, 2021 |
2022 | $ | 1,038 | | | $ | 1,643 | |
2023 | 1,380 | | | 880 | |
2024 | 395 | | | — | |
Total notional value of contracts outstanding (1) | $ | 2,813 | | | $ | 2,523 | |
| | | |
(1)Includes $8 million and $78 million notional value of option contracts as of June 30, 2022 and December 31, 2021, respectively, with the remaining notional value related to forward contracts.
| | | | | | | | |
Cognizant Technology Solutions | 13 | June 30, 2022 Form 10-Q |
The following table provides information on the location and amounts of pre-tax gains and losses on our cash flow hedges for the three months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | Change in Derivative Gains and Losses Recognized in Accumulated Other Comprehensive Income (Loss) (effective portion) | | Location of Net Gains Reclassified from Accumulated Other Comprehensive Income (Loss) into Income (effective portion) | | Net Gains Reclassified from Accumulated Other Comprehensive Income (Loss) into Income (effective portion) |
| 2022 | | 2021 | | | | 2022 | | 2021 |
Foreign exchange forward and option contracts – Designated as cash flow hedging instruments | $ | (66) | | | $ | (3) | | | Cost of revenues | | $ | 5 | | | $ | 12 | |
| | | | | SG&A expenses | | 1 | | | 2 | |
| | | | | Total | | $ | 6 | | | $ | 14 | |
The following table provides information on the location and amounts of pre-tax gains and losses on our cash flow hedges for the six months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | Change in Derivative Gains and Losses Recognized in Accumulated Other Comprehensive Income (Loss) (effective portion) | | Location of Net Gains Reclassified from Accumulated Other Comprehensive Income (Loss) into Income (effective portion) | | Net Gains Reclassified from Accumulated Other Comprehensive Income (Loss) into Income (effective portion) |
| 2022 | | 2021 | | | | 2022 | | 2021 |
Foreign exchange forward and option contracts – Designated as cash flow hedging instruments | $ | (76) | | | $ | 14 | | | Cost of revenues | | $ | 17 | | | $ | 30 | |
| | | | | SG&A expenses | | 2 | | | 5 | |
| | | | | Total | | $ | 19 | | | $ | 35 | |
The activity related to the change in net unrealized gains and losses on the cash flow hedges included in "Accumulated other comprehensive income (loss)" in our unaudited consolidated statements of stockholders' equity is presented in Note 9.
Other Derivatives
We use foreign exchange forward contracts to provide an economic hedge against balance sheet exposures to certain monetary assets and liabilities denominated in currencies other than the functional currency of our foreign subsidiaries. We entered into foreign exchange forward contracts that are scheduled to mature in the third quarter of 2022. Realized gains or losses and changes in the estimated fair value of these derivative financial instruments are recorded in the caption "Foreign currency exchange gains (losses), net" in our unaudited consolidated statements of operations.
Additional information related to the outstanding foreign exchange forward contracts not designated as hedging instruments was as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | June 30, 2022 | | December 31, 2021 |
| Notional | | Fair Value | | Notional | | Fair Value |
Contracts outstanding | $ | 1,072 | | | $ | 3 | | | $ | 847 | | | $ | (4) | |
| | | | | | | | |
Cognizant Technology Solutions | 14 | June 30, 2022 Form 10-Q |
The following table provides information on the location and amounts of realized and unrealized pre-tax gains on the other derivative financial instruments for the three and six months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Location of Net Gains on Derivative Instruments | | Amount of Net Gains on Derivative Instruments |
| | | Three Months Ended June 30, | | Six Months Ended June 30, |
(in millions) | | | 2022 | | 2021 | | 2022 | | 2021 |
Foreign exchange forward contracts – Not designated as hedging instruments | Foreign currency exchange gains (losses), net | | $ | 32 | | | $ | 3 | | | $ | 45 | | | $ | 6 | |
The related cash flow impacts of all the derivative activities are reflected as cash flows from operating activities.
| | | | | | | | | | | | | | |
Note 8 — Fair Value Measurements |
We measure our cash equivalents, certain investments, contingent consideration liabilities and foreign exchange forward and option contracts at fair value. Fair value is the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions.
The fair value hierarchy consists of the following three levels:
•Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities.
•Level 2 – Inputs are quoted prices for similar assets or liabilities in an active market, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable and market-corroborated inputs which are derived principally from or corroborated by observable market data.
•Level 3 – Inputs are derived from valuation techniques in which one or more significant inputs or value drivers are unobservable.
The following table summarizes the financial assets and (liabilities) measured at fair value on a recurring basis as of June 30, 2022:
| | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | Level 1 | | Level 2 | | Level 3 | | Total |
Cash equivalents: | | | | | | | |
Money market funds | $ | 360 | | | $ | — | | | $ | — | | | $ | 360 | |
Time deposits | — | | | 229 | | | — | | | 229 | |
Commercial paper | — | | | 205 | | | — | | | 205 | |
Short-term investments: | | | | | | | |
Time deposits | — | | | 40 | | | — | | | 40 | |
Equity investment security | 26 | | | — | | | — | | | 26 | |
Available-for-sale investment securities: | | | | | | | |
Certificates of deposit and commercial paper | — | | | 448 | | | — | | | 448 | |
Other current assets: | | | | | | | |
Foreign exchange forward contracts | — | | | 9 | | | — | | | 9 | |
Long-term investments: | | | | | | | |
Restricted time deposits(1) | — | | | 375 | | | — | | | 375 | |
| | | | | | | |
| | | | | | | |
Accrued expenses and other current liabilities: | | | | | | | |
Foreign exchange forward and option contracts | — | | | (21) | | | — | | | (21) | |
Contingent consideration liabilities | — | | | — | | | (21) | | | (21) | |
Other noncurrent liabilities: | | | | | | | |
Foreign exchange forward contracts | — | | | (10) | | | — | | | (10) | |
Contingent consideration liabilities | — | | | — | | | (16) | | | (16) | |
| | | | | | | | |
Cognizant Technology Solutions | 15 | June 30, 2022 Form 10-Q |
The following table summarizes the financial assets and (liabilities) measured at fair value on a recurring basis as of December 31, 2021:
| | | | | | | | | | | | | | | | | | | | | | | |
(in millions) | Level 1 | | Level 2 | | Level 3 | | Total |
Cash equivalents: | | | | | | | |
Money market funds | $ | 507 | | | $ | — | | | $ | — | | | $ | 507 | |
Time deposits | — | | | 4 | | | — | | | 4 | |
Commercial paper | — | | | 266 | | | — | | | 266 | |
Short-term investments: | | | | | | | |
Time deposits | — | | | 554 | | | — | | | 554 | |
Equity investment security | 26 | | | — | | | — | | | 26 | |
Available-for-sale investment securities: | | | | | | | |
Commercial paper | — | | | 310 | | | — | | | 310 | |
Other current assets: | | | | | | | |
Foreign exchange forward and option contracts | — | | | 54 | | | — | | | 54 | |
Long-term investments: | | | | | | | |
Restricted time deposits(1) | — | | | 397 | | | — | | | 397 | |
Other noncurrent assets: | | | | | | | |
Foreign exchange forward and option contracts | — | | | 15 | | | — | | | 15 | |
Accrued expenses and other current liabilities: | | | | | | | |
Foreign exchange forward and option contracts | — | | | (7) | | | — | | | (7) | |
Contingent consideration liabilities | — | | | — | | | (14) | | | (14) | |
Other noncurrent liabilities: | | | | | | | |
| | | | | | | |
Contingent consideration liabilities | — | | | — | | | (21) | | | (21) | |
The following table summarizes the changes in Level 3 contingent consideration liabilities for the six months ended June 30:
| | | | | | | | | | | | | | |
(in millions) | | 2022 | | 2021 |
Beginning balance | | $ | 35 | | | $ | 54 | |
Initial measurement recognized at acquisition | | 1 | | | 8 | |
Change in fair value recognized in SG&A expenses | | 5 | | | (19) | |
Payments | | (4) | | | (3) | |
Ending balance | | $ | 37 | | | $ | 40 | |
We measure the fair value of money market funds based on quoted prices in active markets for identical assets and measure the fair value of our equity investment security based on the published daily net asset value at which investors can freely subscribe to or redeem from the fund. The fair value of certificates of deposit and commercial paper is measured based on relevant trade data, dealer quotes, or model-driven valuations using significant inputs derived from or corroborated by observable market data, such as yield curves and credit spreads. The carrying value of the time deposits approximated fair value as of June 30, 2022 and December 31, 2021.
We estimate the fair value of each foreign exchange forward contract by using a present value of expected cash flows model. This model calculates the difference between the current market forward price and the contracted forward price for each foreign exchange forward contract and applies the difference in the rates to each outstanding contract. The market forward rates include a discount and credit risk factor. We estimate the fair value of each foreign exchange option contract by using a variant of the Black-Scholes model. This model uses present value techniques and reflects the time value and intrinsic value based on observable market rates.
We estimate the fair value of contingent consideration liabilities associated with acquisitions using a variation of the income approach, which utilizes one or more significant inputs that are unobservable. This approach calculates the fair value of such liabilities based on the probability-weighted expected performance of the acquired entity against the target performance metric, discounted to present value when appropriate.
During the six months ended June 30, 2022 and the year ended December 31, 2021, there were no transfers among Level 1, Level 2 or Level 3 financial assets and liabilities.
| | | | | | | | |
Cognizant Technology Solutions | 16 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | | | | |
Note 9 — Accumulated Other Comprehensive Income (Loss) |
Changes in "Accumulated other comprehensive income (loss)" by component were as follows for the three and six months ended June 30, 2022:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months | | Six Months |
(in millions) | | Before Tax Amount | | Tax Effect | | Net of Tax Amount | | Before Tax Amount | | Tax Effect | | Net of Tax Amount |
Foreign currency translation adjustments: | | | | | | | | | | | | |
Beginning balance | | $ | (60) | | | $ | 3 | | | $ | (57) | | | $ | (22) | | | $ | 2 | | | $ | (20) | |
Change in foreign currency translation adjustments | | (197) | | | 4 | | | (193) | | | (235) | | | 5 | | | (230) | |
Ending balance | | $ | (257) | | | $ | 7 | | | $ | (250) | | | $ | (257) | | | $ | 7 | | | $ | (250) | |
Unrealized gains and losses on cash flow hedges: | | | | | | | | | | | | |
Beginning balance | | $ | 48 | | | $ | (10) | | | $ | 38 | | | $ | 71 | | | $ | (14) | | | $ | 57 | |
Unrealized (losses) arising during the period | | (66) | | | 14 | | | (52) | | | (76) | | | 16 | | | (60) | |
Reclassifications of net (gains) to: | | | | | | | | | | | | |
Cost of revenues | | (5) | | | 1 | | | (4) | | | (17) | | | 3 | | | (14) | |
SG&A expenses | | (1) | | | — | | | (1) | | | (2) | | | — | | | (2) | |
Net change | | (72) | | | 15 | | | (57) | | | (95) | | | 19 | | | (76) | |
Ending balance | | $ | (24) | | | $ | 5 | | | $ | (19) | | | $ | (24) | | | $ | 5 | | | $ | (19) | |
Accumulated other comprehensive income (loss): | | | | | | | | | | | | |
Beginning balance | | $ | (12) | | | $ | (7) | | | $ | (19) | | | $ | 49 | | | $ | (12) | | | $ | 37 | |
Other comprehensive income (loss) | | (269) | | | 19 | | | (250) | | | (330) | | | 24 | | | (306) | |
Ending balance | | $ | (281) | | | $ | 12 | | | $ | (269) | | | $ | (281) | | | $ | 12 | | | $ | (269) | |
Changes in "Accumulated other comprehensive income (loss)" by component were as follows for the three and six months ended June 30, 2021:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months | | Six Months |
(in millions) | | Before Tax Amount | | Tax Effect | | Net of Tax Amount | | Before Tax Amount | | Tax Effect | | Net of Tax Amount |
Foreign currency translation adjustments: | | | | | | | | | | | | |
Beginning balance | | $ | 29 | | | $ | 1 | | | $ | 30 | | | $ | 56 | | | $ | (1) | | | $ | 55 | |
Change in foreign currency translation adjustments | | 15 | | | (1) | | | 14 | | | (12) | | | 1 | | | (11) | |
Ending balance | | $ | 44 | | | $ | — | | | $ | 44 | | | $ | 44 | | | $ | — | | | $ | 44 | |
Unrealized gains on cash flow hedges: | | | | | | | | | | | | |
Beginning balance | | $ | 63 | | | $ | (12) | | | $ | 51 | | | $ | 67 | | | $ | (12) | | | $ | 55 | |
Unrealized (losses) gains arising during the period | | (3) | | | — | | | (3) | | | 14 | | | (3) | | | 11 | |
Reclassifications of net (gains) to: | | | | | | | | | | | | |
Cost of revenues | | (12) | | | 3 | | | (9) | | | (30) | | | 6 | | | (24) | |
SG&A expenses | | (2) | | | 1 | | | (1) | | | (5) | | | 1 | | | (4) | |
Net change | | (17) | | | 4 | | | (13) | | | (21) | | | 4 | | | (17) | |
Ending balance | | $ | 46 | | | $ | (8) | | | $ | 38 | | | $ | 46 | | | $ | (8) | | | $ | 38 | |
Accumulated other comprehensive income (loss): | | | | | | | | | | | | |
Beginning balance | | $ | 92 | | | $ | (11) | | | $ | 81 | | | $ | 123 | | | $ | (13) | | | $ | 110 | |
Other comprehensive income (loss) | | (2) | | | 3 | | | 1 | | | (33) | | | 5 | | | (28) | |
Ending balance | | $ | 90 | | | $ | (8) | | | $ | 82 | | | $ | 90 | | | $ | (8) | | | $ | 82 | |
| | | | | | | | |
Cognizant Technology Solutions | 17 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | | | | |
Note 10— Commitments and Contingencies |
We are involved in various claims and legal proceedings arising in the ordinary course of business. We accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, we do not record a liability, but instead disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. While we do not expect that the ultimate resolution of any existing claims and proceedings (other than the specific matters described below, if decided adversely), individually or in the aggregate, will have a material adverse effect on our financial position, an unfavorable outcome in some or all of these proceedings could have a material adverse impact on results of operations or cash flows for a particular period. This assessment is based on our current understanding of relevant facts and circumstances. As such, our view of these matters is subject to inherent uncertainties and may change in the future.
On January 15, 2015, Syntel sued TriZetto and Cognizant in the USDC-SDNY. Syntel’s complaint alleged breach of contract against TriZetto, and tortious interference and misappropriation of trade secrets against Cognizant and TriZetto, stemming from Cognizant’s hiring of certain former Syntel employees. Cognizant and TriZetto countersued on March 23, 2015, for breach of contract, misappropriation of trade secrets and tortious interference, based on Syntel’s misuse of TriZetto confidential information and abandonment of contractual obligations. Cognizant and TriZetto subsequently added federal Defend Trade Secrets Act and copyright infringement claims for Syntel’s misuse of TriZetto’s proprietary technology. The parties’ claims were narrowed by the court and the case was tried before a jury, which on October 27, 2020 returned a verdict in favor of Cognizant in the amount of $855 million, including $570 million in punitive damages. On April 20, 2021, the USDC-SDNY issued a post-trial order that, among other things, affirmed the jury’s award of $285 million in actual damages, but reduced the award of punitive damages from $570 million to $285 million, thereby reducing the overall damages award from $855 million to $570 million. The USDC-SDNY subsequently issued a final judgment consistent with the April 20th order. On May 26, 2021, Syntel filed a notice of appeal to the Second Circuit, and on June 3, 2021 the USDC-SDNY stayed execution of judgment pending appeal. We will not record the gain in our financial statements until it becomes realizable.
On February 28, 2019, a ruling of the SCI interpreting the India Defined Contribution Obligation altered historical understandings of the obligation, extending it to cover additional portions of the employee’s income. As a result, the ongoing contributions of our affected employees and the Company were required to be increased. In the first quarter of 2019, we accrued $117 million with respect to prior periods, assuming retroactive application of the SCI’s ruling, in "Selling, general and administrative expenses" in our unaudited consolidated statement of operations. There is significant uncertainty as to how the liability should be calculated as it is impacted by multiple variables, including the period of assessment, the application with respect to certain current and former employees and whether interest and penalties may be assessed. Since the ruling, a variety of trade associations and industry groups have advocated to the Indian government, highlighting the harm to the information technology sector, other industries and job growth in India that would result from a retroactive application of the ruling. It is possible the Indian government will review the matter and there is a substantial question as to whether the Indian government will apply the SCI’s ruling on a retroactive basis. As such, the ultimate amount of our obligation may be materially different from the amount accrued.
On October 31, 2016, November 15, 2016 and November 18, 2016, three putative shareholder derivative complaints were filed in New Jersey Superior Court, Bergen County, naming us, all of our then current directors and certain of our current and former officers at that time as defendants. These actions were consolidated in an order dated January 24, 2017. The complaints assert claims for breach of fiduciary duty, corporate waste, unjust enrichment, abuse of control, mismanagement, and/or insider selling by defendants. On April 26, 2017, the New Jersey Superior Court deferred further proceedings by dismissing the consolidated putative shareholder derivative litigation without prejudice but permitting the parties to file a motion to vacate the dismissal in the future.
On February 22, 2017, April 7, 2017 and May 10, 2017, three additional putative shareholder derivative complaints alleging similar claims were filed in the USDC-NJ, naming us and certain of our current and former directors and officers at that time as defendants. These complaints asserted claims similar to those in the previously-filed putative shareholder derivative actions. In an order dated June 20, 2017, the USDC-NJ consolidated these actions into a single action, appointed lead plaintiff and lead counsel, and stayed all further proceedings pending a final, non-appealable ruling on the motions to dismiss a consolidated putative securities class action that was resolved on December 21, 2021, when the USDC-NJ granted final approval of the settlement of the consolidated putative securities class action and entered a judgment dismissing the consolidated putative securities class action with prejudice. On October 30, 2018, lead plaintiff filed a consolidated verified derivative complaint.
On March 11, 2019, a seventh putative shareholder derivative complaint was filed in the USDC-NJ, naming us and certain of our current and former directors and officers at that time as defendants. The complaint in that action asserts claims similar to
| | | | | | | | |
Cognizant Technology Solutions | 18 | June 30, 2022 Form 10-Q |
those in the previously-filed putative shareholder derivative actions. On May 14, 2019, the USDC-NJ approved a stipulation that (i) consolidated this action with the putative shareholder derivative suits that were previously filed in the USDC-NJ; and (ii) stayed all of these suits pending an order on the motion to dismiss the second amended complaint in the above-referenced consolidated putative securities class action that was resolved on December 21, 2021. On August 3, 2020, lead plaintiffs filed an amended complaint. The USDC-NJ extended the stay through February 14, 2022. On February 14, 2022, we and certain of our current and former directors and officers moved to dismiss the amended complaint. Those motions are now fully briefed and pending before the USDC-NJ.
On June 1, 2021, an eighth putative shareholder derivative complaint was filed in the USDC-NJ, naming us and certain of our current and former directors and officers at that time as defendants. The complaint asserts claims similar to those in the previously-filed putative shareholder derivative actions. On August 2, 2021, the USDC-NJ approved a stipulation that stayed this action. The stay ended on February 14, 2022. On March 31, 2022, we and certain of our current and former directors and officers moved to dismiss the complaint. Those motions are now fully briefed and pending before the USDC-NJ.
We are presently unable to predict the duration, scope or result of the putative shareholder derivative actions. Although the Company continues to defend the putative shareholder derivative actions vigorously, these lawsuits are subject to inherent uncertainties, the actual cost of such litigation will depend upon many unknown factors and the outcome of the litigation is necessarily uncertain.
We have indemnification and expense advancement obligations pursuant to our bylaws and indemnification agreements with respect to certain current and former members of senior management and the Company’s board of directors. In connection with the matters that were the subject of our previously disclosed internal investigation, the DOJ and SEC investigations and the related litigation, we have received and expect to continue to receive requests under such indemnification agreements and our bylaws to provide funds for legal fees and other expenses. There are no amounts remaining available to us under applicable insurance policies for our ongoing indemnification and advancement obligations with respect to certain of our current and former officers and directors or incremental legal fees and other expenses related to the above matters.
See Note 6 for information relating to the ITD Dispute. Many of our engagements involve projects that are critical to the operations of our clients’ business and provide benefits that are difficult to quantify. Any failure in a client’s systems or our failure to meet our contractual obligations to our clients, including any breach involving a client’s confidential information or sensitive data, or our obligations under applicable laws or regulations could result in a claim for substantial damages against us, regardless of our responsibility for such failure. Although we attempt to contractually limit our liability for damages arising from negligent acts, errors, mistakes, or omissions in rendering our services, there can be no assurance that the limitations of liability set forth in our contracts will be enforceable in all instances or will otherwise protect us from liability for damages. Although we have general liability insurance coverage, including coverage for errors or omissions, we retain a significant portion of risk through our insurance deductibles and there can be no assurance that such coverage will cover all types of claims, continue to be available on reasonable terms or will be available in sufficient amounts to cover one or more large claims, or that the insurer will not disclaim coverage as to any future claim. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, results of operations, financial position and cash flows for a particular period.
In the normal course of business and in conjunction with certain client engagements, we have entered into contractual arrangements through which we may be obligated to indemnify clients or other parties with whom we conduct business with respect to certain matters. These arrangements can include provisions whereby we agree to hold the indemnified party and certain of their affiliated entities harmless with respect to third-party claims related to such matters as our breach of certain representations or covenants, our intellectual property infringement, our gross negligence or willful misconduct or certain other claims made against certain parties. Payments by us under any of these arrangements are generally conditioned on the client making a claim and providing us with full control over the defense and settlement of such claim. It is not possible to determine the maximum potential liability under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Historically, we have not made material payments under these indemnification agreements and therefore they have not had a material impact on our operating results, financial position, or cash flows. However, if events arise requiring us to make payment for indemnification claims under our indemnification obligations in contracts we have entered, such payments could have a material adverse effect on our business, results of operations, financial position and cash flows for a particular period.
| | | | | | | | |
Cognizant Technology Solutions | 19 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | | | | |
Note 11 — Segment Information |
Our reportable segments are:
•Financial Services, which consists of the banking and insurance operating segments;
•Health Sciences (previously referred to as Healthcare);
•Products and Resources, which consists of the retail and consumer goods; manufacturing, logistics, energy, and utilities; and travel and hospitality operating segments; and
•Communications, Media and Technology
Our segments are industry-based, and as such, we report revenue from clients in the segment with which our clients are most closely aligned. Our client partners, account executives and client relationship managers are aligned in accordance with the specific industries they serve. Our chief operating decision maker evaluates the Company's performance and allocates resources based on segment revenues and operating profit. Segment operating profit is defined as income from operations before unallocated costs. Generally, operating expenses for each operating segment have similar characteristics and are subject to the same factors, pressures and challenges. However, the economic environment and its effects on industries served by the operating segments may affect revenues and operating expenses to differing degrees.
In 2022, we made certain changes to the internal measurement of segment operating profits for the purpose of evaluating
segment performance and resource allocation. The primary reason for the change was to charge costs to the business segments that are directly managed and controlled by them. Specifically, segment operating profit now includes costs related to non-delivery personnel that support consulting services, which were previously included in "unallocated costs." We have reported 2022 segment operating profits using the new allocation methodology and have recast the 2021 results to conform to the new methodology.
Additionally, we made the following changes:
•We renamed the Healthcare reportable segment as Health Sciences. This segment, which was previously comprised of two operating segments, (i) healthcare and (ii) life sciences, is now comprised of one operating segment - health sciences.
•The Communications, Media and Technology segment, which was previously comprised of two operating segments, (i) communications and media and (ii) technology, is now comprised of one operating segment - communications, media and technology.
These changes reflect how these operating segments are currently managed and reported to the chief operating decision maker but did not affect the reportable segments' financial results.
Expenses included in segment operating profit consist principally of direct selling and delivery costs as well as a per employee charge for use of our global delivery centers and infrastructure. Certain SG&A expenses, the excess or shortfall of incentive-based compensation for commercial and delivery employees as compared to target, a portion of depreciation and amortization and the impact of the settlements of the cash flow hedges are not allocated to individual segments in internal management reports used by the chief operating decision maker. Accordingly, such expenses are excluded from segment operating profit and are included below as “unallocated costs” and adjusted against our total income from operations. Additionally, management has determined that it is not practical to allocate identifiable assets by segment, since such assets are used interchangeably among the segments.
For revenues by reportable segment and geographic area, see Note 2.
| | | | | | | | |
Cognizant Technology Solutions | 20 | June 30, 2022 Form 10-Q |
Segment operating profits by reportable segment were as follows for the three and six months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
(in millions) | 2022 | | 2021 | | 2022 | | 2021 |
Financial Services | $ | 454 | | | $ | 430 | | | $ | 875 | | | $ | 828 | |
Health Sciences | 388 | | | 382 | | | 756 | | | 787 | |
Products and Resources | 359 | | | 323 | | | 691 | | | 625 | |
Communications, Media and Technology | 271 | | | 231 | | | 516 | | | 443 | |
Total segment operating profit | 1,472 | | | 1,366 | | | 2,838 | | | 2,683 | |
Less: unallocated costs | 712 | | | 670 | | | 1,354 | | | 1,318 | |
Income from operations | $ | 760 | | | $ | 696 | | | $ | 1,484 | | | $ | 1,365 | |
Geographic Area Information
Long-lived assets by geographic area are as follows:
| | | | | | | | | | | |
| As of |
(in millions) | June 30, 2022 | | December 31, 2021 |
Long-lived Assets: (1) | | | |
North America(2) | $ | 366 | | | $ | 377 | |
Europe | 65 | | | 75 | |
Rest of World (3) | 690 | | | 719 | |
Total | $ | 1,121 | | | $ | 1,171 | |
(1)Long-lived assets include property and equipment, net of accumulated depreciation and amortization.
(2)Substantially all relates to the United States.
(3)Substantially all relates to India.
| | | | | | | | | | | | | | |
Note 12 — Subsequent Events |
Dividend
On July 26, 2022, the Board of Directors approved the Company's declaration of a $0.27 per share dividend with a record date of August 19, 2022 and a payment date of August 30, 2022.
| | | | | | | | |
Cognizant Technology Solutions | 21 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Cognizant is one of the world’s leading professional services companies, engineering modern business for the digital era. Our services include digital services and solutions, consulting, application development, systems integration, application testing, application maintenance, infrastructure services and business process services. Digital services are an important part of our portfolio, aligning with our clients' focus on becoming data-enabled, customer-centric and differentiated businesses. We are continuing to invest in digital services with a focus on four key areas: IoT, digital engineering, data and cloud. We tailor our services and solutions to specific industries with an integrated global delivery model that employs client service and delivery teams based at client locations and dedicated global and regional delivery centers. We help clients modernize technology, reimagine processes and transform experiences so they can stay ahead in a fast-changing world.
On July 6, 2022, we announced that we will be simplifying our internal operating structure around practice areas and delivery operations by merging our Digital Business & Technology and Digital Business Operations practice areas with their respective delivery organizations to create four new integrated practices: Software & Platform Engineering, Core Technologies & Insights, Enterprise Platform Services, and Intuitive Operations & Automation. This change will not impact our reportable business segments.
Q2 2022 Financial Results
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Revenue up $321 million or 7.0% from Q2 2021; 9.5% in constant currency1 | | Income from Operations up $64 million or 9.2% from Q2 2021 | | | | Operating margin up 30 bps from Q2 2021 | | | | GAAP | | Adjusted1 |
| | | | | | | Diluted EPS up $0.14 or 14.4% from Q2 2021 | | Diluted EPS up $0.15 or 15.2% from Q2 2021 |
| | | | | |
| | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
During the quarter ended June 30, 2022, revenues increased by $321 million as compared to the quarter ended June 30, 2021, representing growth of 7.0%, or 9.5% on a constant currency basis1. Our recently completed acquisitions contributed 110 basis points to revenue growth. Revenue growth also reflected our clients' continued adoption and integration of digital technologies. Revenues in the Communications, Media and Technology segment benefited from our technology clients' growing demand for services related to digital content. Products and Resources revenue growth was driven by increasing client interest in delivering cloud-based, data-driven enhanced customer experiences, the automotive industry’s shift toward electric and connected vehicles, and client investment in supply chain modernization and smart factory solutions. Revenue growth in the Health Sciences (previously referred to as Healthcare) segment was driven by increased demand for digital services among pharmaceutical companies. Financial services revenue growth reflects the growing demand for digital services, partially offset by the negative impact of the previously disclosed sale of the Samlink subsidiary, which was completed on February 1, 2022. We continue to experience pricing pressure on our non-digital services as our clients optimize the cost of supporting their legacy systems and operations.
1 Adjusted Diluted EPS and constant currency revenue growth are not measures of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information and reconciliations to the most directly comparable GAAP financial measures, as applicable.
| | | | | | | | |
Cognizant Technology Solutions | 22 | June 30, 2022 Form 10-Q |
Operating margin increased to 15.5% for the quarter ended June 30, 2022, from 15.2% for the quarter ended June 30, 2021. Our 2022 operating margin was positively impacted by delivery efficiencies, economies of scale that allowed us to leverage our cost structure over a larger organization and the depreciation of the Indian rupee against the U.S. dollar, partially offset by increased compensation costs for our delivery personnel (including employees and subcontractors).
Business Outlook
As we seek to increase our commercial momentum and accelerate growth, our four strategic priorities are:
•Accelerating digital - growing our digital business organically and inorganically;
•Globalizing Cognizant - accelerating the growth of our business in key international markets and diversifying our leadership, capabilities and delivery footprint;
•Increasing our relevance to our clients - ensuring industry-aligned thought leadership and capabilities to address clients' business needs; and
•Repositioning our brand - improving our global brand recognition and becoming better known as a global digital partner to the entire C-suite.
We continue to expect the long-term focus of our clients to be on their digital transformation into software-driven, data-enabled, customer-centric and differentiated businesses. The COVID-19 pandemic accelerated our clients' need to modernize their business, which has led to increased demand for digital capabilities.
As our clients seek to optimize the cost of supporting their legacy systems and operations, our non-digital services have been, and may continue to be, subject to pricing pressure. In addition, clients will likely continue to contend with industry-specific changes driven by evolving digital technologies, uncertainty in the regulatory environment, industry consolidation and convergence as well as international trade policies and other macroeconomic factors, which could affect their demand for our services.
As a global professional services company, we compete on the basis of the knowledge, experience, insights, skills and talent of our employees and the value they can provide to our clients. Our success is dependent, in large part, on our ability to keep our supply of skilled employees, in particular those with experience in key digital areas, in balance with client demand. Competition for skilled employees in the current labor market is intense, and we continue to experience significantly elevated voluntary attrition. For the three months ended June 30, 2022, our annualized attrition, including both voluntary and involuntary, was 35.6% as compared to 31.4% for the three months ended June 30, 2021. Challenges attracting and retaining highly qualified personnel have resulted in increased cost of delivery and have negatively impacted our ability to satisfy client demand and achieve our full revenue potential. We expect these impacts to continue for at least the remainder of 2022. Further, our ongoing and anticipated future efforts with respect to recruitment, talent management and employee engagement may not be successful and are likely to continue to result in increased compensation costs. While we strive to adjust pricing to reduce the impact of compensation increases on our operating margin, we may not be successful in fully recovering these increases, which could adversely affect our profitability.
The invasion of Ukraine by Russia and the sanctions and other measures being imposed in response to this conflict have increased the level of economic and political uncertainty worldwide. We do not have employees, facilities or significant operations in either Russia or Ukraine and revenues generated from clients in both countries were immaterial in both 2021 and the first half of 2022. However, the continuation of the hostilities or the expansion of the current conflict’s scope into surrounding geographic areas could directly impact us, our clients, vendors or subcontractors, which could impact our operations and financial performance. We continue to monitor the situation closely to ensure business continuity plans are in place for neighboring countries where we have a presence.
Our future results may be affected by potential tax law changes and other potential regulatory changes, including possible U.S. corporate income tax reform and potentially increased costs for employment and post-employment benefits in India as a result of the Code on Social Security, 2020.
| | | | | | | | |
Cognizant Technology Solutions | 23 | June 30, 2022 Form 10-Q |
Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021
The following table sets forth, for the periods indicated, certain financial data for the three months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | % of | | | | | % of | | | | | Increase |
(Dollars in millions, except per share data) | 2022 | | Revenues | | | 2021 | | Revenues | | | | | $ | | % |
Revenues | $ | 4,906 | | | 100.0 | | | | $ | 4,585 | | | 100.0 | | | | | | $ | 321 | | | 7.0 | |
Cost of revenues(a) | 3,119 | | | 63.6 | | | | 2,863 | | | 62.4 | | | | | | 256 | | | 8.9 | |
Selling, general and administrative expenses(a) | 883 | | | 18.0 | | | | 881 | | | 19.2 | | | | | | 2 | | | 0.2 | |
| | | | | | | | | | | | | | | |
Depreciation and amortization expense | 144 | | | 2.9 | | | | 145 | | | 3.2 | | | | | | (1) | | | (0.7) | |
Income from operations | 760 | | | 15.5 | | | | 696 | | | 15.2 | | | | | | 64 | | | 9.2 | |
Other income (expense), net | 1 | | | | | | (2) | | | | | | | | 3 | | | * |
Income before provision for income taxes | 761 | | | 15.5 | | | | 694 | | | 15.1 | | | | | | 67 | | | 9.7 | |
Provision for income taxes | (184) | | | | | | (184) | | | | | | | | — | | | — | |
Income (loss) from equity method investments | — | | | | | | 2 | | | | | | | | (2) | | | (100.0) | |
Net income | $ | 577 | | | 11.8 | | | | $ | 512 | | | 11.2 | | | | | | $ | 65 | | | 12.7 | |
Diluted earnings per share | $ | 1.11 | | | | | | $ | 0.97 | | | | | | | | $ | 0.14 | | | 14.4 | |
| | | | | | | | | | | | | | | |
Other Financial Information2 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
Adjusted Diluted EPS | $ | 1.14 | | | | | | $ | 0.99 | | | | | | | | $ | 0.15 | | | 15.2 | |
(a)Exclusive of depreciation and amortization expense
*Not meaningful
During the quarter ended June 30, 2022, revenues increased by $321 million as compared to the quarter ended June 30, 2021, representing growth of 7.0%, or 9.5% on a constant currency basis2. Our recently completed acquisitions contributed 110 basis points to revenue growth. Revenue growth also reflected our clients' continued adoption and integration of digital technologies. We continue to experience pricing pressure on non-digital services as clients optimize the cost of supporting their legacy systems and operations. Revenues from clients added since June 30, 2021, including those related to acquisitions, were $107 million.
2 Adjusted Diluted EPS and constant currency revenue growth are not measures of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information and reconciliations to the most directly comparable GAAP financial measures, as applicable.
| | | | | | | | |
Cognizant Technology Solutions | 24 | June 30, 2022 Form 10-Q |
| | |
Revenues - Reportable Business Segments |
The following charts set forth revenues and change in revenues by business segment and geography for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
| | |
| | Financial Services | | Health Sciences | | | | |
| | | | Increase / (Decrease) | | | | Increase / (Decrease) | | | | | | | | |
Dollars in millions | | Revenues | | $ | | % | | CC 3 | | Revenues | | $ | | % | | CC %3 | | | | | | | | |
North America | | $ | 1,104 | | | 55 | | | 5.2 | | | 5.5 | | | $ | 1,210 | | | 79 | | | 7.0 | | | 7.0 | | | | | | | | | |
United Kingdom | | 147 | | | 17 | | | 13.1 | | | 22.3 | | | 44 | | | (1) | | | (2.2) | | | 6.1 | | | | | | | | | |
Continental Europe | | 143 | | | (43) | | | (23.1) | | | (15.1) | | | 126 | | | 6 | | | 5.0 | | | 14.6 | | | | | | | | | |
Europe - Total | | 290 | | | (26) | | | (8.2) | | | 0.3 | | | 170 | | | 5 | | | 3.0 | | | 12.3 | | | | | | | | | |
Rest of World | | 148 | | | 11 | | | 8.0 | | | 13.5 | | | 28 | | | (1) | | | (3.4) | | | 4.8 | | | | | | | | | |
Total | | $ | 1,542 | | | 40 | | | 2.7 | | | 5.1 | | | $ | 1,408 | | | 83 | | | 6.3 | | | 7.6 | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Products and Resources | | Communications, Media and Technology | | | | |
| | | | Increase / (Decrease) | | | | Increase / (Decrease) | | | | | | | | |
Dollars in millions | | Revenues | | $ | | % | | CC %3 | | Revenues | | $ | | % | | CC %3 | | | | | | | | |
North America | | $ | 770 | | | 47 | | | 6.5 | | | 6.8 | | | $ | 572 | | | 103 | | | 22.0 | | | 22.1 | | | | | | | | | |
United Kingdom | | 134 | | | 18 | | | 15.5 | | | 28.0 | | | 133 | | | 21 | | | 18.8 | | | 31.4 | | | | | | | | | |
Continental Europe | | 143 | | | 11 | | | 8.3 | | | 21.7 | | | 33 | | | (11) | | | (25.0) | | | (14.0) | | | | | | | | | |
Europe - Total | | 277 | | | 29 | | | 11.7 | | | 24.6 | | | 166 | | | 10 | | | 6.4 | | | 18.6 | | | | | | | | | |
Rest of World | | 93 | | | 9 | | | 10.7 | | | 14.5 | | | 78 | | | — | | | — | | | 6.0 | | | | | | | | | |
Total | | $ | 1,140 | | | 85 | | | 8.1 | | | 11.6 | | | $ | 816 | | | 113 | | | 16.1 | | | 19.5 | | | | | | | | | |
| | |
Financial Services - revenues increased 2.7%, or 5.1% on a constant currency basis3 |
| | | | | | | | | |
| | | |
Banking | é | $8M | |
| | | |
Insurance | é | $32M | |
| | | |
| | | |
Revenue growth reflects the growing demand for digital services among U.S. regional banks, public sector clients in the United Kingdom and insurance companies. The previously disclosed sale of the Samlink subsidiary, which was completed on February 1, 2022, negatively impacted revenue growth in this segment by 190 basis points. Revenues from clients added since June 30, 2021 were $22 million.3
| | |
Health Sciences - revenues increased 6.3%, or 7.6% on a constant currency basis3 |
Effective in the second quarter of 2022, we combined the healthcare operating segment with the life sciences operating segment and renamed our Healthcare reportable segment as Health Sciences. See Note 11 to our unaudited consolidated financial statements for additional information. Revenue growth was driven by increased demand for digital services among pharmaceutical companies. Revenues from clients added since June 30, 2021 were $11 million.
3 Constant currency revenue growth is not a measure of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information.
| | | | | | | | |
Cognizant Technology Solutions | 25 | June 30, 2022 Form 10-Q |
| | |
Products and Resources - revenues increased 8.1%, or 11.6% on a constant currency basis4 |
| | | | | | | | | | | | | | | |
Manufacturing, Logistics, Energy and Utilities | é | $40M | |
| | | | | |
Retail and Consumer Goods | é | $30M | |
| | | | | |
Travel and Hospitality | é | $15M | |
| | | | | |
Revenue growth in this segment was primarily driven by increased client interest in delivering cloud-based, data-driven enhanced customer experiences, the automotive industry’s shift toward electric and connected vehicles, and client investment in supply chain modernization and smart factory solutions. Revenue growth in this segment included approximately 260 basis points related to recently completed acquisitions. Revenues from clients added since June 30, 2021 were $36 million.4
| | |
Communications, Media and Technology - revenues increased 16.1%, or 19.5% on a constant currency basis4 |
In 2022, we combined the communications and media operating segment with the technology operating segment. See Note 11 to our unaudited consolidated financial statements for additional information. Revenues in this segment reflected growing demand from our technology clients for services related to digital content, primarily driven by the largest clients in this segment, as well as demand for personalized user experiences and data modernization. Revenues from clients added since June 30, 2021 were $38 million.
| | |
Revenues - Geographic Markets |
Revenues of $4,906 million by geographic market were as follows for the three months ended June 30, 2022:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Q2 2022 as compared to Q2 2021 | | | | | | Increase |
(Dollars in millions) | | | $ | | % | | CC %4 | |
North America | | | | | | $ | 284 | | | 8.4 | | | 8.6 | | |
United Kingdom | | | | | | 55 | | | 13.6 | | | 24.7 | | |
Continental Europe | | | | | | (37) | | | (7.7) | | | 2.5 | | |
Europe - Total | | | | | | 18 | | | 2.0 | | | 12.6 | | |
Rest of World | | | | | | 19 | | | 5.8 | | | 11.2 | | |
Total revenues | | | | | | $ | 321 | | | 7.0 | | | 9.5 | | |
North America continues to be our largest market, representing 74.5% of total revenues. Outside of the North America region, revenues were negatively impacted by foreign currency exchange rate movements. Revenue growth in the United Kingdom was strong among Financial Services clients, including certain public sector clients, Products and Resources clients, and Communications, Media and Technology clients. Revenue decline in the Continental Europe region includes a negative 600 basis points impact from the previously disclosed sale of the Samlink subsidiary, which was completed on February 1, 2022, and was partially offset by growth in the German market, which benefited from recent acquisitions.
| | |
Cost of Revenues (Exclusive of Depreciation and Amortization Expense) |
| | | | | | | | | | | | |
é | $256M | | |
é | 1.2% as a % of revenues | |
¡ | % of Revenues | |
| | | | |
Our cost of revenues consists primarily of salaries, incentive-based compensation, stock-based compensation expense, employee benefits, project-related immigration and travel for technical personnel, subcontracting and equipment costs relating to revenues. The increase, as a percentage of revenues, was due to higher compensation costs for delivery personnel (including employees and subcontractors), partially offset by delivery efficiencies and the depreciation of the Indian rupee against the U.S. dollar. Challenges attracting and retaining highly qualified personnel have resulted and are likely to continue to result in higher compensation costs.
4 Constant currency revenue growth is not a measure of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information.
| | | | | | | | |
Cognizant Technology Solutions | 26 | June 30, 2022 Form 10-Q |
| | |
SG&A Expenses (Exclusive of Depreciation and Amortization Expense) |
SG&A expenses consist primarily of salaries, incentive-based compensation, stock-based compensation expense, employee benefits, immigration, travel, marketing, communications, management, finance, administrative and occupancy costs. The decrease, as a percentage of revenues, was primarily due to economies of scale that allowed us to leverage our cost structure over a larger organization, the beneficial impact of foreign currency exchange rate movements and the optimization of non-strategic SG&A expenses.
| | | | | | | | | | | | |
é | $2M | | |
ê | 1.2% as a % of revenues | |
¡ | % of Revenues | |
| | | | |
| | |
Depreciation and Amortization Expense |
Depreciation and amortization expense decreased by 0.7%, or 0.3% as a percentage of revenues, during the second quarter of 2022 as compared to the second quarter of 2021.
| | |
Operating Margin - Overall |
| | | | | | | | | | | | |
é | $64M | |
é | 0.3% as a % of revenues | |
¡ | % of Revenues | |
| | | | |
The 2022 operating margin was positively impacted by delivery efficiencies, economies of scale that allowed us to leverage our cost structure over a larger organization and the depreciation of the Indian rupee against the U.S. dollar partially offset by increased compensation costs for our delivery personnel (including employees and subcontractors).
Excluding the impact of applicable designated cash flow hedges, the depreciation of the Indian rupee against the U.S. dollar positively impacted our operating margin by approximately 80 basis points during the three months ended June 30, 2022. Each additional 1.0% change in exchange rate between the Indian rupee and the U.S. dollar will have the effect of moving our operating margin by 18 basis points.
We enter into foreign exchange derivative contracts to hedge certain Indian rupee denominated payments in India. These hedges are intended to mitigate the volatility of the changes in the exchange rate between the U.S. dollar and the Indian rupee. The settlement of our cash flow hedges positively impacted our operating margin by 12 basis points during the three months ended June 30, 2022 and by 31 basis points during the three months ended June 30, 2021.
We finished the second quarter of 2022 with approximately 341,300 employees. Annualized attrition, including both voluntary and involuntary, was approximately 35.6% for the three months ended June 30, 2022. In both 2021 and 2022, voluntary attrition constituted the vast majority of attrition for the period. Attrition in all periods presented is weighted towards our more junior employees.
In 2022, we made certain changes to the internal measurement of segment operating profits for the purpose of evaluating segment performance and resource allocation. The primary reason for the change was to charge to the business segments costs that are directly managed and controlled by them. Specifically, segment operating profit now includes costs related to non-delivery personnel that support consulting services, which were previously included in "unallocated costs." We have reported 2022 segment operating profits using the new allocation methodology and have recast the 2021 results to conform to the new methodology.
| | | | | | | | |
Cognizant Technology Solutions | 27 | June 30, 2022 Form 10-Q |
Segment operating profit and operating margin percentage were as follows:
In 2022, segment operating margins benefited from delivery efficiencies and the depreciation of the Indian rupee against the U.S. dollar partially offset by increased compensation costs for delivery personnel (including employees and subcontractors). The 2022 Health Sciences segment operating margin was additionally negatively affected by investments to support revenue growth and elevated pricing pressure on non-digital services.
Total segment operating profit and operating margin were as follows for the three months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(Dollars in millions) | 2022 | | % of Revenues | | 2021 | | % of Revenues | | Increase / (Decrease) |
Total segment operating profit | $ | 1,472 | | | 30.0 | | | $ | 1,366 | | | 29.8 | | | $ | 106 | |
Less: unallocated costs | 712 | | | | | 670 | | | | | 42 | |
Income from operations | $ | 760 | | | 15.5 | | | $ | 696 | | | 15.2 | | | $ | 64 | |
| | |
Other Income (Expense), Net |
The following table sets forth total other income (expense), net for the three months ended June 30:
| | | | | | | | | | | | | | | | | | | |
(in millions) | 2022 | | | 2021 | | Increase/ Decrease | |
Foreign currency exchange (losses) | $ | (36) | | | | $ | (10) | | | $ | (26) | | |
Gains on foreign exchange forward contracts not designated as hedging instruments | 32 | | | | 3 | | | 29 | | |
Foreign currency exchange gains (losses), net | (4) | | | | (7) | | | 3 | | |
Interest income | 9 | | | | 7 | | | 2 | | |
Interest expense | (3) | | | | (2) | | | (1) | | |
Other, net | (1) | | | | — | | | (1) | | |
Total other income (expense), net | $ | 1 | | | | $ | (2) | | | $ | 3 | | |
The foreign currency exchange losses were attributed to the remeasurement of net monetary assets and liabilities denominated in currencies other than the functional currencies of our subsidiaries. The gains on foreign exchange forward contracts not designated as hedging instruments related to the realized and unrealized gains and losses on contracts entered into to offset our foreign currency exposures. As of June 30, 2022, the notional value of our undesignated hedges was $1,072 million.
| | |
Provision for Income Taxes |
| | | | | | | | | | | | |
| | | | |
| |
¡ Effective Income Tax Rate ê 2.3% | |
| | |
| | | | |
The effective income tax rate decreased as a result of higher discrete income tax benefits, primarily related to our undistributed foreign earnings, in the second quarter of 2022 as compared to the second quarter of 2021.
The increase in net income was driven by higher income from operations and a lower effective income tax rate.
| | | | | | | | | | |
é | $65M | | | |
| | |
¡ é 0.6% of Revenues | | |
| | |
| | | | | | | | |
Cognizant Technology Solutions | 28 | June 30, 2022 Form 10-Q |
Non-GAAP Financial Measures
Portions of our disclosure include non-GAAP financial measures. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of non-GAAP financial measures to the corresponding GAAP measures, set forth below, should be carefully evaluated.
Adjusted Diluted EPS excludes unusual items, net non-operating foreign currency exchange gains or losses and the tax impact of all the applicable adjustments. The income tax impact of each item is calculated by applying the statutory rate and local tax regulations in the jurisdiction in which the item was incurred. Constant currency revenue growth is defined as revenues for a given period restated at the comparative period’s foreign currency exchange rates measured against the comparative period's reported revenues.
We believe providing investors with an operating view consistent with how we manage the Company provides enhanced transparency into our operating results. For internal management reporting and budgeting purposes, we use various GAAP and non-GAAP financial measures for financial and operational decision-making, to evaluate period-to-period comparisons, to determine portions of the compensation for executive officers and for making comparisons of our operating results to those of our competitors. We believe that the presentation of non-GAAP financial measures, which exclude certain costs, along with reconciliations to the most comparable GAAP measure, as applicable, can provide useful supplemental information to our management and investors regarding financial and business trends relating to our financial condition and results of operations.
A limitation of using non-GAAP financial measures versus financial measures calculated in accordance with GAAP is that non-GAAP financial measures may exclude costs that are recurring such as net non-operating foreign currency exchange gains or losses. In addition, other companies may calculate non-GAAP financial measures differently than us, thereby limiting the usefulness of these non-GAAP financial measures as a comparative tool. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP financial measures to allow investors to evaluate such non-GAAP financial measures.
The following table presents a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure for the three months ended June 30:
| | | | | | | | | | | | | | | |
| 2022 | | | | 2021 | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
GAAP diluted EPS | $ | 1.11 | | | | | $ | 0.97 | | | |
| | | | | | | |
Non-operating foreign currency exchange (gains) losses, pre-tax (1) | 0.01 | | | | | 0.01 | | | |
Tax effect of non-operating foreign currency exchange (gains) losses (2) | 0.02 | | | | | 0.01 | | | |
| | | | | | | |
Adjusted Diluted EPS | $ | 1.14 | | | | | $ | 0.99 | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
(1)Non-operating foreign currency exchange gains and losses, inclusive of gains and losses on related foreign exchange forward contracts not designated as hedging instruments for accounting purposes, are reported in "Foreign currency exchange gains (losses), net" in our unaudited consolidated statements of operations.
(2)Presented below are the tax impacts of each of our non-GAAP adjustments to pre-tax income:
| | | | | | | | | | | |
| Three Months Ended June 30, |
(in millions) | 2022 | | 2021 |
Non-GAAP income tax (expense) related to: | | | |
| | | |
| | | |
| | | |
| | | |
Foreign currency exchange gains and losses | $ | (14) | | | $ | (6) | |
The effective tax rate related to non-operating foreign currency exchange gains and losses varies depending on the jurisdictions in which such income and expenses are generated and the statutory rates applicable in those jurisdictions. As such, the income tax effect of non-operating foreign currency exchange gains and losses shown in the above table may not appear proportionate to the net pre-tax foreign currency exchange gains and losses reported in our unaudited consolidated statements of operations.
| | | | | | | | |
Cognizant Technology Solutions | 29 | June 30, 2022 Form 10-Q |
Six Months Ended June 30, 2022 Compared to Six Months Ended June 30, 2021
The following table sets forth, for the periods indicated, certain financial data for the six months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | % of | | | | % of | | | | Increase / Decrease |
(Dollars in millions, except per share data) | 2022 | | Revenues | | 2021 | | Revenues | | | | $ | | % |
| |
Revenues | $ | 9,732 | | | 100.0 | | | $ | 8,986 | | | 100.0 | | | | | $ | 746 | | | 8.3 | |
Cost of revenues(a) | 6,216 | | | 63.9 | | | 5,627 | | | 62.6 | | | | | 589 | | | 10.5 | |
Selling, general and administrative expenses(a) | 1,745 | | | 17.9 | | | 1,708 | | | 19.0 | | | | | 37 | | | 2.2 | |
| | | | | | | | | | | | | |
Depreciation and amortization expense | 287 | | | 2.9 | | | 286 | | | 3.2 | | | | | 1 | | | 0.3 | |
Income from operations | 1,484 | | | 15.2 | | | 1,365 | | | 15.2 | | | | | 119 | | | 8.7 | |
Other income (expense), net | 6 | | | | | (6) | | | | | | | 12 | | | * |
Income before provision for income taxes | 1,490 | | | 15.3 | | | 1,359 | | | 15.1 | | | | | 131 | | | 9.6 | |
Provision for income taxes | (354) | | | | | (344) | | | | | | | (10) | | | 2.9 | |
Income (loss) from equity method investments | 4 | | | | | 2 | | | | | | | 2 | | | 100.0 | |
Net income | $ | 1,140 | | | 11.7 | | | $ | 1,017 | | | 11.3 | | | | | $ | 123 | | | 12.1 | |
Diluted EPS | $ | 2.18 | | | | | $ | 1.92 | | | | | | | $ | 0.26 | | | 13.5 | |
Other Financial Information5 | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Adjusted Diluted EPS | $ | 2.23 | | | | | $ | 1.96 | | | | | | | $ | 0.27 | | | 13.8 | |
(a)Exclusive of depreciation and amortization expense.
*Not meaningful
During the six months ended June 30, 2022, revenues increased by $746 million as compared to the six months ended June 30, 2021, representing growth of 8.3%, or 10.2% on a constant currency basis5. Our recently completed acquisitions contributed 160 basis points to revenue growth. Revenue growth also reflected our clients' continued adoption and integration of digital technologies. We continue to experience pricing pressure on non-digital services as clients optimize the cost of supporting their legacy systems and operations. In addition, our revenues from clients added since June 30, 2021, including those related to acquisitions, were $179 million.
5 Adjusted Diluted EPS and constant currency revenue growth are not measures of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information and reconciliations to the most directly comparable GAAP financial measures.
| | | | | | | | |
Cognizant Technology Solutions | 30 | June 30, 2022 Form 10-Q |
Revenues - Reportable Business Segments
The following charts set forth revenues and change in revenues by business segment and geography for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
| | |
| | Financial Services | | Health Sciences | | | | |
| | | | Increase / (Decrease) | | | | Increase / (Decrease) | | | | | | | | |
Dollars in millions | | Revenues | | $ | | % | | CC %6 | | Revenues | | $ | | % | | CC %6 | | | | | | | | |
North America | | $ | 2,184 | | | 122 | | | 5.9 | | | 6.0 | | | $ | 2,405 | | | 173 | | | 7.8 | | | 7.8 | | | | | | | | | |
United Kingdom | | 298 | | | 43 | | | 16.9 | | | 22.9 | | | 88 | | | 3 | | | 3.5 | | | 9.8 | | | | | | | | | |
Continental Europe | | 300 | | | (78) | | | (20.6) | | | (14.2) | | | 246 | | | 8 | | | 3.4 | | | 10.8 | | | | | | | | | |
Europe - Total | | 598 | | | (35) | | | (5.5) | | | 0.7 | | | 334 | | | 11 | | | 3.4 | | | 10.6 | | | | | | | | | |
Rest of World | | 288 | | | 23 | | | 8.7 | | | 13.4 | | | 61 | | | 3 | | | 5.2 | | | 11.5 | | | | | | | | | |
Total | | $ | 3,070 | | | 110 | | | 3.7 | | | 5.5 | | | $ | 2,800 | | | 187 | | | 7.2 | | | 8.2 | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Products and Resources | | Communications, Media and Technology | | | | |
| | | | Increase / (Decrease) | | | | Increase / (Decrease) | | | | | | | | |
Dollars in millions | | Revenues | | $ | | % | | CC %6 | | Revenues | | $ | | % | | CC %6 | | | | | | | | |
North America | | $ | 1,531 | | | 90 | | | 6.2 | | | 6.4 | | | $ | 1,105 | | | 185 | | | 20.1 | | | 20.2 | | | | | | | | | |
United Kingdom | | 266 | | | 44 | | | 19.8 | | | 28.1 | | | 259 | | | 48 | | | 22.7 | | | 32.2 | | | | | | | | | |
Continental Europe | | 288 | | | 53 | | | 22.6 | | | 34.2 | | | 70 | | | (17) | | | (19.5) | | | (10.8) | | | | | | | | | |
Europe - Total | | 554 | | | 97 | | | 21.2 | | | 31.2 | | | 329 | | | 31 | | | 10.4 | | | 19.7 | | | | | | | | | |
Rest of World | | 185 | | | 30 | | | 19.4 | | | 22.8 | | | 158 | | | 16 | | | 11.3 | | | 16.7 | | | | | | | | | |
Total | | $ | 2,270 | | | 217 | | | 10.6 | | | 13.2 | | | $ | 1,592 | | | 232 | | | 17.1 | | | 19.7 | | | | | | | | | |
| | |
Financial Services - revenues increased 3.7%, or 5.5% on a constant currency basis6 |
| | | | | | | | | |
Banking | é | $27M | |
| | | |
Insurance | é | $83M | |
| | | |
| | | |
Revenue growth reflects the growing demand for digital services among U.S. regional banks, public sector clients in the United Kingdom and insurance companies. The previously disclosed sale of the Samlink subsidiary, which was completed on February 1, 2022, negatively impacted revenue growth in this segment by 160 basis points.6Revenues from clients added since June 30, 2021 were $39 million.
| | |
Health Sciences - revenues increased 7.2%, or 8.2% on a constant currency basis6 |
Effective in the second quarter of 2022, we combined the healthcare operating segment with the life sciences operating segment and renamed our Healthcare reportable segment to Health Sciences. See Note 11 to our unaudited consolidated financial statements for additional information. Revenue growth was driven by increased demand for digital services among pharmaceutical companies. Revenues from clients added since June 30, 2021 were $19 million.
6 Constant currency revenue growth is not a measure of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information.
| | | | | | | | |
Cognizant Technology Solutions | 31 | June 30, 2022 Form 10-Q |
| | |
Products and Resources - revenues increased 10.6%, or 13.2% on a constant currency basis7 |
| | | | | | | | | | | | |
Manufacturing, Logistics, Energy and Utilities | é | $113M | |
| | | | |
Retail and Consumer Goods | é | $72M | |
| | | | |
Travel and Hospitality | é | $32M | |
| | | | |
Revenue growth in this segment was primarily driven by increased client interest in delivering cloud-based, data-driven enhanced customer experiences, the automotive industry’s shift toward electric and connected vehicles, and client investment in supply chain modernization and smart factory solutions. Revenue growth in this segment included approximately 370 basis points related to recently completed acquisitions. Revenues from clients added since June 30, 2021 were $57 million.7
| | |
Communications, Media and Technology - revenues increased 17.1%, or 19.7% on a constant currency basis7 |
In 2022, we combined the communications and media operating segment with the technology operating segment. See Note 11 to our unaudited consolidated financial statements for additional information. Revenues in this segment reflected growing demand from our technology clients for services related to digital content, primarily driven by the largest clients in this segment, as well as demand for personalized user experiences and data modernization. Revenues from clients added since June 30, 2021 were $64 million.
| | |
Revenues - Geographic Markets |
Revenues of $9,732 million by geographic market were as follows for the six months ended June 30, 2022:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
YTD 2022 as compared to YTD 2021 | | | | | | Increase / (Decrease) |
(Dollars in millions) | | | $ | | % | | CC %7 | |
North America | | | | | | $ | 570 | | | 8.6 | | | 8.7 | | |
United Kingdom | | | | | | 138 | | | 17.9 | | | 25.5 | | |
Continental Europe | | | | | | (34) | | | (3.6) | | | 4.6 | | |
Europe - Total | | | | | | 104 | | | 6.1 | | | 14.0 | | |
Rest of World | | | | | | 72 | | | 11.6 | | | 16.3 | | |
Total revenues | | | | | | $ | 746 | | | 8.3 | | | 10.2 | | |
North America continues to be our largest market, representing 74.2% of total revenues for the six months ended June 30, 2022. Outside of our North America region, revenues were negatively impacted by foreign currency exchange rate movements. Revenue growth in the United Kingdom was strong among Financial Services clients, including certain public sector clients, Products and Resources clients, and Communications, Media and Technology clients. Revenue decline in the Continental Europe region includes a negative 510 basis points impact from the previously disclosed sale of the Samlink subsidiary, which was completed on February 1, 2022, and was partially offset by growth in the German market, which benefited from recent acquisitions. Revenue growth in the Rest of World region was primarily driven by the Australian market, which benefited from an acquisition that closed in the first half of 2021.
7 Constant currency revenue growth is not a measure of financial performance prepared in accordance with GAAP. See “Non-GAAP Financial Measures” for more information.
| | | | | | | | |
Cognizant Technology Solutions | 32 | June 30, 2022 Form 10-Q |
| | |
Cost of Revenues (Exclusive of Depreciation and Amortization Expense) |
| | | | | | | | | | | | |
é | $589M | | |
é | 1.3% as a % of revenues | |
¡ | % of Revenues | |
| | | | |
Our cost of revenues consists primarily of salaries, incentive-based compensation, stock-based compensation expense, employee benefits, project-related immigration and travel for technical personnel, subcontracting and equipment costs relating to revenues. The increase, as a percentage of revenues, was due to higher compensation costs for delivery personnel (including employees and subcontractors), partially offset by delivery efficiencies and the depreciation of the Indian rupee against the U.S. dollar. Challenges attracting and retaining highly qualified personnel have resulted and are likely to continue to result in higher compensation costs.
| | |
SG&A Expenses (Exclusive of Depreciation and Amortization Expense) |
SG&A expenses consist primarily of salaries, incentive-based compensation, stock-based compensation expense, employee benefits, immigration, travel, marketing, communications, management, finance, administrative and occupancy costs. The decrease, as a percentage of revenues, was primarily due to economies of scale that allowed us to leverage our cost structure over a larger organization and the optimization of non-strategic SG&A expenses.
| | | | | | | | | | | | |
é | $37M | | |
ê | 1.1% as a % of revenues | |
¡ | % of Revenues | |
| | | | |
| | |
Depreciation and Amortization Expense |
Depreciation and amortization expense increased 0.3%, or decreased 0.3% as a percentage of revenues, during the six months ended June 30, 2022 as compared to the 2021 period.
| | |
Operating Margin - Overall |
| | | | | | | | | | | | |
é | $119 million | |
| Flat as a % of revenue | |
¡ | % of Revenues | |
| | | | |
The 2022 operating margin was positively impacted by delivery efficiencies, economies of scale that allowed us to leverage our cost structure over a larger organization and the depreciation of the Indian rupee against the U.S. dollar, offset by increased compensation costs for our delivery personnel (including employees and subcontractors).
Excluding the impact of applicable designated cash flow hedges, the depreciation of the Indian rupee against the U.S. dollar positively impacted our operating margin by approximately 70 basis points during the six months ended June 30, 2022. Each additional 1.0% change in exchange rate between the Indian rupee and the U.S. dollar will have the effect of moving our operating margin by approximately 18 basis points.
We enter into foreign exchange derivative contracts to hedge certain Indian rupee denominated payments in India. These hedges are intended to mitigate the volatility of the changes in the exchange rate between the U.S. dollar and the Indian rupee. The settlement of our cash flow hedges positively impacted our operating margin by 20 basis points during the six months ended June 30, 2022 and by 39 basis points during the 2021 period.
| | | | | | | | |
Cognizant Technology Solutions | 33 | June 30, 2022 Form 10-Q |
In 2022, we made certain changes to the internal measurement of segment operating profits for the purpose of evaluating segment performance and resource allocation. The primary reason for the change was to charge to the business segments costs that are directly managed and controlled by them. Specifically, segment operating profit now includes costs related to non-delivery personnel that support consulting services, which were previously included in "unallocated costs." We have reported 2022 segment operating profits using the new allocation methodology and have recast the 2021 results to conform to the new methodology. Segment operating profit and operating margin percentage were as follows:
In 2022, segment operating margins were negatively impacted by increased compensation costs for delivery personnel (including employees and subcontractors), partially offset by delivery efficiencies and the depreciation of the Indian rupee against the U.S. dollar. The 2022 Financial Services segment operating margin reflects the gain on sale of the Samlink subsidiary while the 2022 Health Sciences segment operating margin was negatively affected by investments to support revenue growth and elevated pricing pressure on non-digital services.
Total segment operating profit and margin were as follows for the six months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
(Dollars in millions) | 2022 | | % of Revenues | | 2021 | | % of Revenues | | Increase / (Decrease) |
Total segment operating profit | $ | 2,838 | | | 29.2 | | | $ | 2,683 | | | 29.9 | | | $ | 155 | |
Less: unallocated costs | 1,354 | | | | | 1,318 | | | | | 36 | |
Income from operations | $ | 1,484 | | | 15.2 | | | $ | 1,365 | | | 15.2 | | | $ | 119 | |
| | |
Other Income (Expense), Net |
The following table sets forth total other income (expense), net for the six months ended June 30:
| | | | | | | | | | | | | | | | | | | |
(in millions) | 2022 | | | 2021 | | Increase/ Decrease | |
Foreign currency exchange (losses) | $ | (49) | | | | $ | (22) | | | $ | (27) | | |
Gains on foreign exchange forward contracts not designated as hedging instruments | 45 | | | | 6 | | | 39 | | |
Foreign currency exchange gains (losses), net | (4) | | | | (16) | | | 12 | | |
Interest income | 15 | | | | 16 | | | (1) | | |
Interest expense | (5) | | | | (4) | | | (1) | | |
Other, net | — | | | | (2) | | | 2 | | |
Total other income (expense), net | $ | 6 | | | | $ | (6) | | | $ | 12 | | |
The foreign currency exchange losses were attributed to the remeasurement of net monetary assets and liabilities denominated in currencies other than the functional currencies of our subsidiaries. The gains on foreign exchange forward contracts not designated as hedging instruments related to the realized and unrealized gains and losses on contracts entered into to offset our foreign currency exposures.
| | | | | | | | |
Cognizant Technology Solutions | 34 | June 30, 2022 Form 10-Q |
| | |
Provision for Income Taxes |
| | | | | | | | | | | | |
é | $10M | | | |
| | |
¡ Effective Income Tax Rate ê 1.5% | |
| | |
The effective income tax rate decreased as a result of higher discrete tax benefits, primarily related to our undistributed foreign earnings, in the six months ended June 30, 2022 as compared to the 2021 period.
The increase in net income was driven by higher income from operations and a lower effective income tax rate.
| | | | | | | | | | | |
é | $123M | | | |
| | | |
¡ é 0.4% of Revenues | | | |
| | | |
Non-GAAP Financial Measures
See “Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021 – Non-GAAP Financial Measures” above for additional information about our use of non-GAAP financial measures.
The following table presents a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure for the six months ended June 30:
| | | | | | | | | | | | | | | |
(Dollars in millions, except per share amounts) | 2022 | | | | 2021 | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
GAAP diluted EPS | $ | 2.18 | | | | | $ | 1.92 | | | |
| | | | | | | |
Non-operating foreign currency exchange (gains) losses, pre-tax (1) | 0.01 | | | | | 0.03 | | | |
Tax effect of non-operating foreign currency exchange (gains) losses (2) | 0.04 | | | | | 0.01 | | | |
| | | | | | | |
Adjusted Diluted EPS | $ | 2.23 | | | | | $ | 1.96 | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
(1)Non-operating foreign currency exchange gains and losses, inclusive of gains and losses on related foreign exchange forward contracts not designated as hedging instruments for accounting purposes, are reported in "Foreign currency exchange gains (losses), net" in our unaudited consolidated statements of operations.
(2)Presented below are the tax impacts of each of our non-GAAP adjustments to pre-tax income:
| | | | | | | | | | | |
(in millions) | Six Months Ended June 30, |
| 2022 | | 2021 |
Non-GAAP income tax benefit (expense) related to: | | | |
| | | |
| | | |
| | | |
| | | |
Foreign currency exchange gains and losses | (20) | | | (6) | |
The effective tax rate related to non-operating foreign currency exchange gains and losses varies depending on the jurisdictions in which such income and expenses are generated and the statutory rates applicable in those jurisdictions. As such, the income tax effect of non-operating foreign currency exchange gains and losses shown in the above table may not appear proportionate to the net pre-tax foreign currency exchange gains and losses reported in our unaudited consolidated statements of operations.
| | | | | | | | |
Cognizant Technology Solutions | 35 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | | | | |
Liquidity and Capital Resources |
Our cash generated from operations has historically been the primary source of liquidity to fund operations and investments to grow our business. As of June 30, 2022, we had cash, cash equivalents and short-term investments of $2,320 million and available capacity under our credit facilities of approximately $1,915 million.
The following table provides a summary of cash flows for the six months ended June 30:
| | | | | | | | | | | | | | | | | | | | | | |
(in millions) | | 2022 | | 2021 | | Increase / Decrease | | |
Net cash provided by (used in): | | | | | | | | |
Operating activities | | $ | 834 | | | $ | 722 | | | $ | 112 | | | |
Investing activities | | 229 | | | (1,259) | | | 1,488 | | | |
Financing activities | | (1,050) | | | (768) | | | (282) | | | |
| | | | | | | | |
| | | | | | | | |
Operating activities
The increase in cash provided by operating activities for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 was primarily driven by higher income from operations.
We monitor turnover, aging and the collection of accounts receivable by client. Our DSO calculation includes receivables, net of allowance for doubtful accounts, and contract assets, reduced by the uncollected portion of deferred revenue. Our DSO was 74 days as of June 30, 2022, 71 days as of June 30, 2021, and 69 days as of December 31, 2021, increasing as revenue growth outpaced collections.
Investing activities
The net cash provided by investing activities for the six months ended June 30, 2022 was primarily driven by net maturities of investments, partially offset by capital expenditures. Net cash used in investing activities for the six months ended June 30, 2021 was driven by cash used for acquisitions, net purchases of investments and capital expenditures.
Financing activities
The increase in cash used in financing activities for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 was primarily driven by higher repurchases of common stock.
The Credit Agreement provides for a $750 million Term Loan and a $1,750 million unsecured revolving credit facility, which are due to mature in November 2023. We are required under the Credit Agreement to make scheduled quarterly principal payments on the Term Loan. As of June 30, 2022, we had no outstanding balance on the revolving credit facility. See Note 5 to our unaudited consolidated financial statements. In March 2022, our India subsidiary renewed its one-year 13 billion Indian rupee ($165 million at the June 30, 2022 exchange rate) working capital facility, which requires us to repay any balances drawn down within 90 days from the date of disbursement. There is a 1.0% prepayment penalty applicable to payments made within 30 days after disbursement. This working capital facility contains affirmative and negative covenants and may be renewed annually. As of June 30, 2022, we have not borrowed funds under this facility.
Capital Allocation
| | | | | |
| Acquisitions |
| |
| Share Repurchases |
| |
| Dividend payments |
| |
We review our capital allocation framework on an ongoing basis, considering our financial performance and liquidity position, investments required to execute our strategic plans and initiatives, acquisition opportunities, the economic outlook, regulatory changes, the potential impacts of the COVID-19 pandemic and other relevant factors. As these factors may change over time, the actual amounts expended on stock repurchase activity, dividends, and acquisitions, if any, during any particular period cannot be predicted and may fluctuate from time to time. While we have not completed any acquisitions in 2022, our longer-term capital allocation framework is unchanged.
| | | | | | | | |
Cognizant Technology Solutions | 36 | June 30, 2022 Form 10-Q |
Other Liquidity and Capital Resources Information
We seek to ensure that our worldwide cash is available in the locations in which it is needed. As part of ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows and cash balances. We evaluate on an ongoing basis what portion of the non-U.S. cash, cash equivalents and short-term investments is needed locally to execute our strategic plans and what amount is available for repatriation back to the United States.
We expect operating cash flows, cash and short-term investment balances, together with the available capacity under our revolving credit facilities, to be sufficient to meet our operating requirements, including purchase commitments, make Tax Reform Act transition tax payments and service our debt for the next twelve months. The ability to expand and grow our business in accordance with current plans, make acquisitions, meet long-term capital requirements beyond a twelve-month period and execute our capital return plan will depend on many factors, including the rate, if any, at which cash flow increases, our ability and willingness to pay for acquisitions with capital stock and the availability of public and private debt, including the ability to extend the maturity or refinance our existing debt, and equity financing. We cannot be certain that additional financing, if required, will be available on terms and conditions acceptable to us, if at all.
| | | | | | | | | | | | | | |
Commitments and Contingencies |
See Note 10 to our unaudited consolidated financial statements. | | | | | | | | | | | | | | |
Critical Accounting Estimates |
Management’s discussion and analysis of our financial condition and results of operations is based on our unaudited consolidated financial statements that have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the amounts reported for assets and liabilities, including the recoverability of tangible and intangible assets, disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reported period. On an ongoing basis, we evaluate our estimates. The most significant estimates relate to the recognition of revenue and profits, including the application of the cost-to-cost method of measuring progress to completion for certain fixed-price contracts, income taxes, business combinations and valuation of goodwill and other long-lived assets. We base our estimates on historical experience, current trends and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual amounts may differ from the estimates used in the preparation of the accompanying unaudited consolidated financial statements. For a discussion of our critical accounting estimates, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021. Our significant accounting policies are described in Note 1 to the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.
| | | | | | | | | | | | | | |
Recently Adopted and New Accounting Pronouncements |
There have been no changes in the information provided in our Annual Report on Form 10-K for the year ended December 31, 2021.
| | | | | | | | | | | | | | |
Forward Looking Statements |
The statements contained in this Quarterly Report on Form 10-Q that are not historical facts are forward-looking statements (within the meaning of Section 21E of the Exchange Act) that involve risks and uncertainties. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believe,” “expect,” “may,” “could,” “would,” “plan,” “intend,” “estimate,” “predict,” “potential,” “continue,” “should” or “anticipate” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. From time to time, we or our representatives have made or may make forward-looking statements, orally or in writing.
Such forward-looking statements may be included in various filings made by us with the SEC, in press releases or in oral statements made by or with the approval of one of our authorized executive officers. These forward-looking statements, such as statements regarding our anticipated future revenues or operating margin, earnings, capital expenditures, impacts to our business, financial results and financial condition as a result of the COVID-19 pandemic, the competitive marketplace for talent and future attrition trends, anticipated effective income tax rate and income tax expense, liquidity, financing strategy, access to capital, capital return strategy, investment strategies, cost management, plans and objectives, including those related to our digital practice areas, investment in our business, potential acquisitions, industry trends, client behaviors and trends, the outcome of and costs associated with regulatory and litigation matters, the appropriateness of the accrual related to the India Defined Contribution Obligation and other statements regarding matters that are not historical facts, are based on our current
| | | | | | | | |
Cognizant Technology Solutions | 37 | June 30, 2022 Form 10-Q |
expectations, estimates and projections, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Actual results, performance, achievements and outcomes could differ materially from the results expressed in, or anticipated or implied by, these forward-looking statements. There are a number of important factors that could cause our results to differ materially from those indicated by such forward-looking statements, including:
•economic and political conditions globally, including the invasion of Ukraine by Russia, and in particular in the markets in which our clients and operations are concentrated;
•the continuing impact of the COVID-19 pandemic, or other future pandemics, on our business, results of operations, liquidity and financial condition;
•our ability to attract, train and retain skilled employees, including highly skilled technical personnel and personnel with experience in key digital areas and senior management to lead our business globally;
•challenges related to growing our business organically as well as inorganically through acquisitions, and our ability to achieve our targeted growth rates;
•our ability to achieve our profitability goals and maintain our capital return strategy;
•our ability to meet specified service levels or milestones required by certain of our contracts;
•intense and evolving competition and significant technological advances that our service offerings must keep pace with in the rapidly changing markets we compete in;
•legal, reputation and financial risks if we fail to protect client and/or our data from security breaches and/or cyber attacks;
•the effectiveness of our risk management, business continuity and disaster recovery plans and the potential that our global delivery capabilities could be impacted;
•restrictions on visas, in particular in the United States, United Kingdom and EU, or immigration more generally or increased costs of such visas or the wages we are required to pay employees on visas, which may affect our ability to compete for and provide services to our clients;
•risks related to anti-outsourcing legislation, if adopted, and negative perceptions associated with offshore outsourcing, both of which could impair our ability to serve our clients;
•risks and costs related to complying with numerous and evolving legal and regulatory requirements and client expectations in the many jurisdictions in which we operate, including the increased stakeholder emphasis on ESG matters;
•potential changes in tax laws, or in their interpretation or enforcement, failure by us to adapt our corporate structure and intercompany arrangements to achieve global tax efficiencies or adverse outcomes of tax audits, investigations or proceedings;
•potential exposure to litigation and legal claims in the conduct of our business; and
•the factors set forth in "Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.
You are advised to consult any further disclosures we make on related subjects in the reports we file with the SEC, including this report in the section titled “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Part I, Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2021. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
| | | | | | | | | | | |
Item 3. Quantitative and Qualitative Disclosures about Market Risk. |
There have been no material changes in our quantitative and qualitative disclosures about market risk from those disclosed in Part II, Item 7A, Quantitative and Qualitative Disclosures about Market Risk, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 16, 2022.
| | | | | | | | |
Cognizant Technology Solutions | 38 | June 30, 2022 Form 10-Q |
| | | | | | | | | | | |
Item 4. Controls and Procedures. |
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision and with the participation of our chief executive officer and our chief financial officer, evaluated the design and operating effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2022. Based on this evaluation, our chief executive officer and our chief financial officer concluded that, as of June 30, 2022, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| | | | | | | | |
Cognizant Technology Solutions | 39 | June 30, 2022 Form 10-Q |
PART II. OTHER INFORMATION
| | | | | | | | | | | | | | |
Item 1. Legal Proceedings |
See Note 10 to our unaudited consolidated financial statements. There have been no material changes in our risk factors from those disclosed in Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on February 16, 2022.
| | | | | | | | | | | | | | |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
Issuer Purchases of Equity Securities
Our stock repurchase program allows for the repurchase of up to $9.5 billion, excluding fees and expenses, of our Class A common stock through open market purchases, including under a 10b5-1 Plan or in private transactions, including through ASR agreements entered into with financial institutions, in accordance with applicable federal securities laws. The repurchase program does not have an expiration date and has a remaining authorized balance of $1,375 million as of June 30, 2022. The timing of repurchases and the exact number of shares to be purchased are determined by management, in its discretion, or pursuant to a 10b5-1 Plan, and will depend upon market conditions and other factors.
During the three months ended June 30, 2022, we repurchased $300 million of our Class A common stock under our stock repurchase program. The stock repurchase activity under our stock repurchase program during the three months ended June 30, 2022 was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Month | | Total Number of Shares Purchased | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | | Approximate Dollar Value of Shares that May Yet Be Purchased under the Plans or Programs (in millions) |
April 1, 2022 - April 30, 2022 | | — | | | $ | — | | | — | | | $ | 1,675 | |
May 1, 2022 - May 31, 2022 | | 2,157,300 | | | 72.97 | | | 2,157,300 | | | 1,518 | |
June 1, 2022 - June 30, 2022 | | 2,053,758 | | | 69.42 | | | 2,053,758 | | | 1,375 | |
Total | | 4,211,058 | | | $ | 71.24 | | | 4,211,058 | | | |
During the three months ended June 30, 2022, we also purchased shares in connection with our stock-based compensation plans, whereby shares of our common stock were tendered by employees for payment of applicable statutory tax withholdings. For the three months ended June 30, 2022, such repurchases totaled 0.2 million shares at an aggregate cost of $18 million.
| | | | | | | | |
Cognizant Technology Solutions | 40 | June 30, 2022 Form 10-Q |
EXHIBIT INDEX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Incorporated by Reference | | |
Number | | Exhibit Description | | Form | | File No. | | Exhibit | | Date | | Filed or Furnished Herewith |
3.1 | | | | 8-K | | 000-24429 | | 3.1 | | | 6/7/2018 | | |
3.2 | | | | 8-K | | 000-24429 | | 3.1 | | | 9/20/2018 | | |
10.1 | | | | | | | | | | | | Filed |
10.2 | | | | | | | | | | | | Filed |
10.3 | | | | | | | | | | | | Filed |
31.1 | | | | | | | | | | | | Filed |
31.2 | | | | | | | | | | | | Filed |
32.1 | | | | | | | | | | | | Furnished |
32.2 | | | | | | | | | | | | Furnished |
101.INS | | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | | | | | | | | | | Filed |
101.SCH | | Inline XBRL Taxonomy Extension Schema Document | | | | | | | | | | Filed |
101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | | | | | | Filed |
101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | | | | | | | Filed |
101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document | | | | | | | | | | Filed |
101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | | | | | | | Filed |
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | | | | | | | | | | Filed |
| | | | | | | | |
Cognizant Technology Solutions | 41 | June 30, 2022 Form 10-Q |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. | | | | | | | | | | | | | | | | | | | | |
| | | Cognizant Technology Solutions Corporation |
| | | | |
Date: | July 27, 2022 | | | By: | | /s/ BRIAN HUMPHRIES |
| | | | | | Brian Humphries, |
| | | | | | Chief Executive Officer |
| | | | | | (Principal Executive Officer) |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | |
Date: | July 27, 2022 | | | By: | | /s/ JAN SIEGMUND |
| | | | | | Jan Siegmund, |
| | | | | | Chief Financial Officer |
| | | | | | (Principal Financial Officer) |
| | | | | | | | |
Cognizant Technology Solutions | 42 | June 30, 2022 Form 10-Q |
[AMENDED AND RESTATED] EXECUTIVE EMPLOYMENT AND NON-DISCLOSURE, NON-COMPETITION, AND INVENTION ASSIGNMENT AGREEMENT
This [Amended and Restated] Executive Employment and Non-Disclosure, Non-Competition, and Invention Assignment Agreement (this “Agreement”) is made as of the ___ day of [____] 20[__] (the “Effective Date”) by and between Cognizant Technology Solutions Corporation, a Delaware corporation (the “Company” (where applicable, the definition of Company shall include the Company’s subsidiaries and affiliates and any successors or assigns)), and [_____] (“Employee”).
[WHEREAS, Employee is currently employed by the Company as its [_____]; [and]]
WHEREAS, the Company desires to [continue to] retain the services of Employee; [and]
[WHEREAS, the Parties desire to amend and restate, in its entirety, the parties’ prior agreements pertaining to Employee’s employment, and set forth the new terms and conditions of Employee’s employment by the Company].
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements hereinafter set forth and intending to be legally bound hereby, the Company and Employee (individually a “Party” and together, the “Parties”) agree as follows:
1.Definitions.
(a)“Annual Base Salary” shall mean Employee’s annualized rate of base salary, as in effect immediately prior to Employee’s Termination Date.
(b)“Board” shall mean the Board of Directors of Cognizant Technology Solutions Corporation.
(c) “Cause” shall mean (i) willful malfeasance or willful misconduct by the Employee in connection with his employment, (ii) continuing failure to perform such duties as are reasonably assigned by Employee’s supervisor, (iii) failure by the Employee to abide by material policies of the Company applicable to the Employee, including without limitation the Code of Ethics (as defined below), (iv) the commission by the Employee of (x) any felony or (y) any misdemeanor involving moral turpitude, (v) Employee engaging in any fraudulent act or act of embezzlement, or (vi) any material breach by Employee of this Agreement or any other written agreement between Employee and the Company.
(d)“Code” means the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder.
(e)“Disability” means Employee’s total and permanent disability as determined in accordance with the Company’s long-term disability policy, whether or not Employee is covered by such policy (or, if the Company has no long-term disability policy, then “Disability” means that Employee has become “disabled” within the meaning of Code Section 409A).
(f)“Good Reason” means, the occurrence of one or more of the following events or actions:
(i)A material diminution by the Company of Employee’s authority, duties or responsibilities (it being understood that a modification of duties in the manner described in Section 3(a) below shall not constitute Good Reason);
(ii)A material diminution in Employee’s overall compensation package, which is not otherwise caused by an overall policy by the Company to reduce senior employee compensation throughout the Company; or
(iii)A change, without Employee’s consent, in the principal place of work of the Employee to a location that is more than 50 miles from his primary work location as of the date of this Agreement, but only if such change occurs on or after a Change in Control.
(g)“Notice of Termination” means a written notice that (i) indicates the specific termination provision in this Agreement relied upon and (ii) briefly summarizes the facts and circumstances deemed to provide a basis for termination of Employee’s employment under the provision so indicated.
(h)“Termination Date” shall mean the last day of Employee’s employment with the Company.
(i)“Termination of Employment” shall mean the termination of Employee’s active employment relationship with the Company.
2.Employment. The Company hereby [employs][continues to employ] Employee, and Employee hereby accepts[continuation of] such employment, upon the terms and conditions set forth herein.
3.Duties.
(a)Position. Employee [shall be][continues to be] employed as [_____] and shall have the duties and responsibilities assigned by [_____] upon initial hire and from time to time thereafter. Employee shall perform faithfully and diligently all duties assigned to Employee. The Company reserves the right to modify Employee’s position and duties at any time in its sole and absolute discretion, provided that the duties assigned are consistent with the position of a senior executive and that Employee continues to report to [_____] or such other position of a similar or more senior level.
(b)Best Efforts/Full-time. To the maximum extent permitted by law, Employee agrees to devote Employee’s best efforts and entire business time and attention to the Company’s business during the term of Employee’s employment with the Company. Employee agrees that, during the term of Employee’s employment, except as otherwise approved in writing by the Company, which approval the Company may in its absolute discretion withhold, Employee will not, either directly or indirectly, or for himself/herself or through, on behalf of, or in conjunction with any person, persons or legal entity, operate, engage in, assist, or be employed by any business activity to or for the benefit of any person or entity other than the Company; provided that the foregoing is not intended to prevent an Employee from pursuing hobbies or participating in any other activity that is not to the detriment of the Company. Employee further acknowledges and agrees that Employee has access to the Company’s Core Values & Code of Ethics (the “Code of Ethics”) located at www.cognizant.com, and Employee has read and understands the Code of Ethics and shall abide by all the terms of said Code of Ethics, as may be amended from time to time, and said Code of Ethics shall be incorporated into this Agreement. Employee will abide by all policies and decisions made by the Company, as well as all applicable federal, state and local laws, regulations or ordinances. Employee will act in the best interest of the Company at all times.
(c)Work Location. Employee’s principal place of work shall initially be located in the [_____] metropolitan area.
4.At-Will Employment. Employee’s employment with the Company will be “at will,” meaning it is for no specified term and may be terminated by Employee or the Company at any time, with or without Cause or advance notice, subject to the provisions of Section 9 below.
5.Compensation.
(a)Annual Base Salary. As compensation for Employee’s performance of Employee’s duties hereunder, the Company shall pay to Employee a base salary as most recently determined by the Compensation Committee of the Board and last communicated to the Employee, as may be modified by the Compensation Committee of the Board, payable in accordance with the normal payroll practices of the Company, less required deductions for state and federal withholding tax, social security and all other employment taxes and payroll deductions. In the event Employee’s employment under this Agreement is terminated by either Party, for any reason, Employee will earn the Annual Base Salary prorated to Employee’s Termination Date.
(b)Incentive Compensation. Employee will be eligible to earn incentive compensation as determined by the Compensation Committee of the Board in accordance with the bonus plan(s) provided to Employee by the Company, in accordance with the terms and conditions of such plan(s).
(c)[Stock Options and Other Equity Awards. Except as set forth herein, this Agreement does not modify or change the existing agreements regarding stock options, stock appreciation rights, restricted stock awards and restricted stock units (each, an “Equity Award” and collectively, “Equity Awards”) previously issued to Employee.]
6.Customary Fringe Benefits. Employee will be eligible for all customary and usual fringe benefits generally available to employees of the Company subject to the terms and conditions of the Company’s benefit plan documents. The Company reserves the right to change or eliminate the fringe benefits on a prospective basis, at any time, effective upon notice to Employee.
7.Business Expenses. Employee will be reimbursed for all reasonable, out-of-pocket business expenses incurred in the performance of Employee’s duties on behalf of the Company. To obtain reimbursement, expenses must be submitted promptly with appropriate supporting documentation in accordance with the Company’s policies.
8.Company Access. Employee agrees and consents that, during the term of Employee’s employment with the Company and thereafter, the Company may review, audit, intercept, access and disclose all messages created, received or sent over the electronic mail and internet access system provided by the Company with or without notice to Employee and that such review, audit, interception, access, or disclosure may occur during or after working hours. Employee further consents and agrees that the Company may, at any time, access and review the contents of all computers, computer disks, other data storage equipment and devices, files, desks, drawers, closets, cabinets and work stations that are either on the Company’s premises or that are owned or provided by the Company.
9.Involuntary Termination of Employment.
(a)Prior to a Change in Control. In the event that Employee’s employment with the Company is involuntarily terminated by the Company for any reason other than Cause, death or Disability or in the event Employee resigns his employment for
Good Reason pursuant to Section 10 and the Company’s right to cure (as set forth in Section 10) has expired (an “Involuntary Termination”), and in either such case Employee’s employment termination becomes effective before any Change in Control (as defined in Section 9(d) below) has occurred following the date of this Agreement, Employee shall be entitled to the payments and benefits described below, provided that Employee timely executes and does not revoke the Release (as defined in Section 13) and the Release first becomes effective:
(i)Employee shall receive a cash payment equal to one (1) times Employee’s Annual Base Salary, such amount to be paid in regular installments in accordance with the Company’s normal payroll practices over a period of twelve (12) months following Employee’s Termination Date, provided, that no such installments shall be paid prior to the later to occur of (A) the first regular Company payroll date occurring on or after the date on which the Release becoming effective and irrevocable and (B) solely if the period during which Employee may consider and revoke the Release spans two calendar years, the first regular Company payroll date occurring in the latter such calendar year (in either case, the “First Payroll Date”), with any installments otherwise payable prior to the First Payroll Date instead paid on the First Payroll Date (without interest thereon).
(ii)Employee shall receive a cash payment equal to one (1) times the amount of the Employee’s target annual bonus for the performance year in which the Employee’s Termination Date occurs, payable in a lump sum payment on the First Payroll Date.
(iii)The Company shall, for a period of eighteen (18) months following the Employee’s Termination Date, pay the Employee each month an amount equal to the monthly COBRA medical insurance cost under the Company’s group medical plan for Employee and, where applicable, Employee’s spouse and eligible dependents; provided that Employee, and, where applicable, Employee’s spouse and dependents, are eligible for and timely elect to receive COBRA healthcare continuation coverage and provided further that the payments specified under this Section 9(a)(iii) shall cease if the Company’s statutory obligation to provide such COBRA healthcare continuation coverage terminates for any reason before the expiration of the eighteen (18)‑month period. All Company payments under this Section 9(a)(iii) to the Employee can be used for any purpose and will be reported as taxable payments.
(iv)The portion of any outstanding Equity Awards that were subject to vesting solely upon continuous service with the Company and would have vested had Employee remained employed by the Company during the twelve (12) month period following Employee’s Termination Date shall automatically become fully vested and exercisable, as applicable, as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such Equity Awards shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(v)With respect to any outstanding Equity Award that was subject to vesting in whole or in part based on achievement of performance objective(s), to the extent that the applicable performance period has expired on or before
Employee’s Termination Date, the performance objective(s) has/have been satisfied and the only condition to vesting that remains is continuous service until one or more future dates, the portion of such Equity Award that would have vested had Employee remained employed by the Company during the twelve (12) month period following Employee’s Termination Date shall become fully vested and exercisable as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such Equity Award shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(vi)Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company. The payment of amounts described in this Section 9(a)(vi) are not conditioned upon the Release becoming effective unless the applicable benefit plan or program provides otherwise.
(b)Coincident with or within One Year After a Change in Control. In the event that Employee suffers an Involuntary Termination that becomes effective coincident with, or within the twelve (12) month period immediately after, the first occurrence of a Change in Control following the date of this Agreement, Employee shall be entitled to the payments and benefits described below in this Section 9(b) in lieu of, and not in addition to, the payments and benefits described in Section 9(a); provided that Employee timely executes and does not revoke the Release (as defined in Section 13) and the Release first becomes effective:
(i)Employee shall receive a cash payment equal to two (2) times Employee’s Annual Base Salary, such amount to be paid in regular installments in accordance with the Company’s normal payroll practices over a period of twenty-four (24) months following Employee’s Termination Date, provided, that no such installments shall be paid prior to the First Payroll Date, with any installments otherwise payable prior to the First Payroll Date instead paid on the First Payroll Date (without interest thereon).
(ii)Employee shall receive a cash payment equal to two (2) times the amount of the Employee’s target annual bonus for the performance year in which the Employee’s Termination Date occurs, payable in a lump sum payment on the First Payroll Date.
(iii)The Company shall, for a period of eighteen (18) months following the date of Employee’s Termination of Employment, pay Employee each month an amount equal to the monthly COBRA medical insurance cost under the Company’s group medical plan for Employee and, where applicable, Employee’s spouse and eligible dependents; provided that Employee, and, where applicable, Employee’s spouse and dependents, are eligible for and timely elect to receive COBRA healthcare continuation coverage and provided further that the payments specified under this Section 9(b)(iii) shall cease if the Company’s statutory obligation to provide such COBRA healthcare continuation coverage terminates for any reason before the expiration of the eighteen (18)‑month period. All Company payments under this Section 9(a)(iii) to the Employee can be used for any purpose and will be reported as taxable payments.
(iv)The portion of any outstanding Equity Awards that were subject to vesting solely upon continuous service with the Company shall automatically become fully vested and exercisable, as applicable, as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such vested Equity Awards shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(v)Outstanding Equity Awards the vesting of which is conditioned, in whole or in part, upon the achievement of performance objectives shall become vested and exercisable as follows:
(A) To the extent that the applicable performance period has expired on or before Employee’s Termination Date, the performance objective(s) has/have been satisfied and the only condition to vesting that remains is continuous service until one or more future dates, such Equity Award shall become fully vested and exercisable as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date).
(B) To the extent that the applicable performance period has not expired on or before Employee’s Termination Date, the Company shall pro-rate the performance objective(s) for the portion of the performance period that has transpired up to the date of closing of the Change in Control, make a good faith determination of the level of achievement of such pro-rated performance objective as of such closing date, and treat as fully vested and exercisable a proportionate amount of such Equity Award that corresponds with the level of achievement of the pro-rated performance objective, disregarding any future service conditions that otherwise would apply to such Equity Award.
(vi)Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company. The payment of amounts described in this Section 9(b)(vi) are not conditioned upon the Release becoming effective unless the applicable benefit plan or program provides otherwise.
(c)Notice of Termination. Any termination on account of this Section 9 shall be communicated by a Notice of Termination to the other Party hereto given in accordance with Section 26 hereof.
(d)Definition of Change in Control. For purposes of this Agreement, the term “Change in Control” shall have the meaning set forth in the Company’s 2017 Incentive Award Plan, as amended from time to time or any successor plan in effect as of Employee’s Termination Date.
10.Resignation for Good Reason. If Employee provides notice of his intent to terminate for Good Reason, then, subject to the expiration of the cure period and Employee’s actual termination as described below, such resignation shall be deemed an Involuntary Termination for purposes of this Agreement and Employee shall be entitled to the payments and benefits described in Section 9 subject to the requirements set forth in this Agreement, including Section 13. Employee must provide written notice to the Company of his intent to terminate his employment for Good Reason within thirty (30) days of the
action or omission giving rise to such claim of Good Reason. Thereafter, the Company shall have a period of thirty (30) days within which it may correct the event or action that constitutes the grounds for Good Reason as set forth in Employee’s notice of termination. If the Company does not correct the event or action prior to the expiration of the foregoing cure period, Employee must terminate his employment for Good Reason within thirty (30) days after the expiration of the cure period, in order for the termination to be considered a Good Reason termination under this Agreement.
11.Termination Due to Death. If Employee’s employment with the Company is terminated due to death, Employee shall be entitled to the payments and benefits described below, provided that Employee’s estate timely executes and does not revoke the Release (as defined in Section 13) and the Release first becomes effective:
(a)Employee shall receive a cash payment equal to (1) times the amount of the Employee’s target annual bonus for the performance year in which the Employee’s Termination Date occurs, pro-rated based on the portion of such year that has elapsed as of Employee’s Termination Date, payable on the First Payroll Date.
(b)The portion of any outstanding Equity Awards that were subject to vesting solely upon continuous service with the Company shall automatically become fully vested and exercisable, as applicable, as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such vested Equity Awards shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(c)Outstanding Equity Awards the vesting of which is conditioned, in whole or in part, upon the achievement of performance objectives shall become vested and exercisable as follows:
(i)To the extent that the applicable performance period has expired on or before Employee’s Termination Date, the performance objective(s) has/have been satisfied and the only condition to vesting that remains is continuous service until one or more future dates, such Equity Award shall become fully vested and exercisable as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date).
(ii)To the extent that the applicable performance period has not expired on or before Employee’s Termination Date, the Company shall pro-rate the performance objective(s) for the portion of the performance period that has transpired up to Employee’s Termination Date, make a good faith determination of the level of achievement of such pro-rated performance objective as of such Termination Date, and treat as fully vested and exercisable a proportionate amount of such Equity Award that corresponds with the level of achievement of the pro-rated performance objective, disregarding any future service conditions that otherwise would apply to such Equity Award.
(d)Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company. The payment of amounts described in this Section 11(d) are not
conditioned upon the Release becoming effective unless the applicable benefit plan or program provides otherwise.
12.Termination Due to Disability or For Cause. If Employee’s employment with the Company is terminated by the Company due to Disability or for Cause, Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company; all other Company obligations to Employee will be extinguished as of the Termination Date.
13.Release. Notwithstanding the foregoing, no payments or benefits shall be provided under Sections 9, 10 and 11, as applicable (except for those payments that are owed pursuant to applicable law and/or are specifically not conditioned upon the execution of a release by Employee or Employee’s estate, as applicable), unless Employee or his estate, if applicable, executes, and does not revoke, the Company’s then standard written general release (the “Release”) of any and all claims against the Company and all related parties with respect to all matters arising out of Employee’s employment by the Company (other than any entitlements under the terms of this Agreement or under any other plans or programs of the Company in which Employee participated and under which Employee has accrued and earned a benefit) or the termination thereof. The Company will provide Employee with the form of release agreement within seven days after Employee’s separation from service. To be entitled to any severance or other benefits (other than payments of accrued compensation that are explicitly excluded from applicable Release requirements), Employee must execute and deliver to the Company the release agreement on or before the last day of the minimum required waiver consideration period provided under the Age Discrimination in Employment Act or other applicable law or such later date specified in the release agreement. If Employee timely delivers an executed release agreement to the Company, and Employee does not revoke the release agreement during the minimum revocation period required under applicable law, if any, the severance or other benefits shall be paid or commence being paid, as specified in this Agreement, subject to any delay required pursuant to Section 32(b) of this Agreement. Consistent with section 409A of the Code, Employee may not, directly or indirectly, designate the calendar year of any payment. Nothing in this Section 13 shall be construed to alter the terms of this Agreement that condition Employee’s entitlement to any severance or other benefits upon Employee’s compliance with the restrictive covenants and any other terms and conditions specified in this Agreement.
14.Other Payments. Any payments and benefits that become due under Sections 9, 10 and 11 hereof shall be in addition to (but not in duplication of) and not in lieu of any payments and benefits due to Employee under any other plan, policy or program of the Company, except that Employee shall not be entitled to any payments or benefits under any other Company severance pay plan or policies (other than severance expressly contemplated by this Agreement).
15.No Mitigation. Employee shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for herein be reduced by any compensation earned by other employment or otherwise; provided, however, that any obligation of the Company to make the payments described in Sections 9(a)(iii) and 9(b)(iii) shall cease upon Employee becoming covered under a healthcare plan of another employer.
16.Non-Exclusivity of Rights. Except as provided in Section 14, nothing in this Agreement shall prevent or limit Employee’s [continuing or] future participation in or rights under any benefit, bonus, incentive or other plan or program provided by the Company or any of its subsidiaries or affiliates and for which Employee may qualify.
17.No Set-Off. Other than with respect to the Recoupment Policy (as hereinafter defined), the Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right that the Company may have against Employee or others.
18.Taxes.
(a)All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. Employee shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due from Employee with respect to any payment received under this Agreement, including, without limitation, any excise tax imposed by Section 4999 of the Code.
(b)If the payments and benefits received or to be received by Employee in connection with a Change in Control or the termination of Employee’s employment (whether payable pursuant to the terms of this Agreement (“Contract Payments”) or any other plan, arrangement or agreement with the Company or any affiliate (collectively with the Contract Payments, the “Total Payments”), would constitute a “parachute payment” under Section 280G of the Code, then the Total Payments shall be reduced, in the manner set forth below, by the minimum amount necessary to result in no portion of the Total Payments being non‑deductible to the Company pursuant to Section 280G of the Code or subject to the excise tax imposed under Section 4999 of the Code.
(c)All determinations required to be made under this Section 18, including whether a reduction in Total Payments is required, the amount of any such reduction and the assumptions to be utilized in arriving at such determination, shall be made by an accounting or law firm of recognized standing reasonably selected by the Company (the “Firm”), which may be, but will not be required to be, the Company’s independent auditors. The Firm shall submit its determination and detailed supporting calculations to both Employee and the Company within fifteen (15) days after receipt of a notice from either the Company or Employee that Employee may receive payments that may be “parachute payments.” If the Firm determines that a reduction is required by this Section 18, the Contract Payments consisting of cash severance shall be reduced to the extent necessary so that no portion of the Total Payments shall be subject to the excise tax imposed by section 4999 of the Code, and the Company shall pay such reduced amount to Employee in accordance with the terms of this Agreement. If additional Contract Payments must be reduced pursuant to this Section 18 after the cash severance has been reduced to zero, the Contract Payments allocable to performance-vested Equity Awards shall next be reduced, followed by the Contract Payments allocable to time-vested Equity Awards, to the extent necessary to satisfy the requirements of this Section 18.
(d)Employee and the Company shall each provide the Firm access to and copies of any books, records, and documents in the possession of Employee or the Company, as the case may be, reasonably requested by the Firm, and otherwise cooperate with the Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Section 18. The fees and expenses of the Firm for its services in connection with the determinations and calculations contemplated by this Section 18 shall be borne by the Company.
19.Confidential Information. Employee agrees that Employee’s services to the Company [have been and will continue to be][will be] of a special, unique and extraordinary character, and that Employee’s position places Employee in a position of confidence and trust with the Company’s customers and employees. Employee also recognizes that Employee’s position with the Company will give Employee substantial access to Confidential Information (as defined below), the disclosure of which to competitors of the Company would cause the Company to suffer substantial and irreparable damage. Employee recognizes, therefore, that it is in the Company’s legitimate business interest to restrict Employee’s use of Confidential Information for any purposes other than the discharge of Employee’s employment duties at the Company, and to limit any potential appropriation of Confidential Information by Employee for the benefit of the Company’s competitors and to the detriment of the Company. Accordingly, Employee agrees as follows:
(a)Employee will not at any time, whether during or after the termination of Employee’s employment, reveal to any person or entity any of the trade secrets or confidential information of the Company or of any third party that the Company is under an obligation to keep confidential (including but not limited to trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects, plans and proposals) (“Confidential Information”), except as may be required in the ordinary course of performing Employee’s duties as an employee of the Company, and Employee shall keep secret all matters entrusted to Employee and shall not use or attempt to use any such information in any manner that may injure or cause loss or may be calculated to injure or cause loss whether directly or indirectly to the Company. By way of example and not limitation, Confidential Information also includes any and all information, whether or not meeting the legal definition of a trade secret, concerning the Company’s actual, planned or contemplated: (i) marketing plans, business plans, strategies, forecasts, budgets, projections and costs; (ii) personnel information; (iii) customer, vendor and supplier lists; (iv) customer, vendor and supplier needs, transaction histories, contacts, volumes, characteristics, agreements and prices; (v) promotions, operations, sales, marketing, and research and development; (vi) business operations, internal structures and financial affairs; (vii) software and operating systems and procedures; (viii) pricing structure of the Company’s services and products; (ix) proposed services and products; (x) contracts with other parties; (xi) performance characteristics of the Company’s products; and (xii) Inventions and Works (each as defined in Section 20). Confidential Information also includes any and all information of Company’s clients and customers that is deemed confidential by such clients and customers (whether past, present or potential), including, but not limited to: marketing tools, inventions, processes, contact lists, materials, software program
code, logic diagrams, flow charts, procedural diagrams, computer programming techniques and know how, maps and any documentation related thereto.
(b)The above restrictions shall not apply to: (i) information that at the time of disclosure is in the public domain through no fault of Employee; (ii) information received from a third party outside of the Company that was publicly disclosed without a breach of any confidentiality obligation; or (iii) information approved for release by written authorization of the Company. In addition, in the event that Employee is requested or required (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) to disclose any of the Confidential Information, it is agreed that Employee will provide the Company with prompt notice of such request(s) so that the Company may seek an appropriate protective order or other appropriate remedy and/or waive compliance with the confidentiality provisions of this Agreement. In the event that such protective order or other remedy is not obtained, or the Company grants a waiver hereunder, Employee may furnish that portion (and only that portion) of the Confidential Information that Employee is legally compelled to disclose and will exercise its reasonable best efforts to obtain reliable assurance that confidential treatment will be accorded any Confidential Information so furnished.
(c)Further, Employee agrees that during Employee’s employment Employee shall not take, use or permit to be used any notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials of any nature relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs otherwise than for the benefit of the Company. Employee further agrees that Employee shall not, after the termination of Employee’s employment, use or permit to be used any such notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials, it being agreed that all of the foregoing shall be and remain the sole and exclusive property of the Company and that, immediately upon the termination of Employee’s employment, Employee shall deliver all of the foregoing plus any other Confidential Information, and all copies thereof, to the Company, at its main office.
(d)Employee agrees that upon the termination of Employee’s employment with the Company, Employee will not take or retain without written authorization any documents, files or other property of the Company, and Employee will return promptly to the Company any such documents, files or property in Employee’s possession or custody, including any copies thereof maintained in any medium or format. Employee recognizes that all documents, files and property that Employee has received and will receive from the Company, including but not limited to scientific research, customer lists, handbooks, memoranda, product specifications, and other materials (with the exception of documents relating to benefits to which Employee might be entitled following the termination of Employee’s employment with the Company), are for the exclusive use of the Company and employees who are discharging their responsibilities on behalf of the Company, and that Employee has no claim or right to the continued use, possession or custody of such documents, files or property following the termination of Employee’s employment with the Company.
(e)Employee acknowledges that the Company has provided Employee with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act of 2016: (i) Employee shall not be held criminally or civilly liable under any U.S. federal or state trade secret law for the disclosure of Confidential Information that is made in confidence to a U.S. federal, state or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) Employee shall not be held criminally or civilly liable under any U.S. federal or state trade secret law for the disclosure of Confidential Information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii) if Employee files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Employee may disclose the Confidential Information to Employee’s attorney and use the Confidential Information in the court proceeding, if Employee files any document containing the Confidential Information under seal, and does not disclose the Confidential Information, except pursuant to court order. However, under no circumstance will Employee be authorized to disclose any information covered by attorney-client privilege or attorney work product of the Company without prior written consent of the Company’s General Counsel or other officer designated by the Company. Notwithstanding anything to the contrary contained herein, no provision of this Agreement shall be interpreted so as to impede Employee (or any other individual) from reporting possible violations of U.S. federal law or regulation to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, and any agency Inspector General of the U.S. government, or making other disclosures under the whistleblower provisions of U.S. federal law or regulation. Employee does not need the prior authorization of the Company to make any such reports or disclosures and Employee shall not be not required to notify the Company that such reports or disclosures have been made.
20.Intellectual Property.
(a)Employee agrees to disclose fully, promptly, and in writing to the Company any and all Inventions and Works (each as defined below) that are conceived, made, reduced to practice, developed, authored, created, drawn or written at any time while Employee is employed by the Company and for a period of six (6) months thereafter. Employee will generate and provide to the Company adequate and current written records of all Inventions and Works in the form of notes, sketches, drawings, reports, flow charts, procedural diagrams, logic diagrams, software program code, procedural diagrams, computer programming techniques or other documents relating thereto or in such other form as will be requested by the Company, which records and any copies thereof will be and will remain the exclusive property of the Company and will be available to the Company at all times, along with all available information relating thereto (with all necessary plans and models) to the Company.
(b)The Company and Employee agree that “Inventions,” is defined in this Agreement to include any and all new or useful ideas, developments, discoveries, improvements, designs, formulas, modifications, trademarks, service marks, trade secrets, and other intellectual property, whether patentable or not (including without limitation any technology, computer programs, software, software
program code, logic diagrams, flow charts, procedural diagrams, computer programming techniques, test, concept, idea, process, method, composition of matter, formula or technique), and all know-how related thereto, that Employee conceives, makes, reduces to practice, or develops, solely or jointly with others (i) that relate to the actual or contemplated business, work or activities of the Company, (ii) that result from or are suggested by any work which Employee [has done or] may do on behalf of the Company, or by any information that Employee may receive by virtue of Employee’s employment by the Company, or (iii) that are developed, tested, improved or investigated either in part or entirely on time for which Employee was paid by the Company, or with the use of premises, equipment or property provided, owned, leased, or contracted for by or on behalf of the Company.
(c)The Company and Employee agree that “Works” is defined in this Agreement to include any and all materials for which copyright protection may be obtained, including without limitation literary works (including books, pamphlets, articles and other writings), mask works, artistic works (including designs, graphs, drawings, blueprints and other graphic works), computer programs, software program code, logic diagrams, flow charts, procedural diagrams, computer programming, compilations, recordings, photographs, motion pictures and other audio-visual works that Employee authors, conceives, creates, draws, makes, or writes, solely or jointly with others (i) that relate to the actual or contemplated business, work or activities of the Company, (ii) that result from or are suggested by any work which Employee has done or may do on behalf of the Company, or by any information that Employee may receive by virtue of Employee’s employment by the Company, or (iii) that are developed, tested, improved or investigated either in part or entirely on time for which Employee was paid by the Company, or with the use of premises, equipment or property provided, owned, leased, or contracted for, by, or on behalf of the Company.
(d)Employee agrees to assign, transfer and convey, and hereby assigns, transfers and conveys to the Company all of the rights, titles and interests in and to any and all such Inventions and Works that Employee [has or] may acquire in such Inventions or Works that are conceived, made, reduced to practice, developed, authored, created, drawn or written at any time while Employee is employed by the Company and for a period of six (6) months thereafter. Employee agrees that the Company will be the sole owner of all patents, copyrights, trademarks and other intellectual property rights in connection therewith, and agrees to take all such actions as may be requested by the Company during Employee’s employment with the Company and at any time thereafter, with respect to any such Inventions or Works to confirm or evidence such assignment, transfer, conveyance or ownership, and to assist in the Company’s maintenance, enforcement, license, assignment, transfer, or conveyance of rights in respect of the Inventions or Works.
(e)By way of example and not limitation, at any time and from time to time, upon the request of the Company, Employee agrees to execute, acknowledge, swear to, seal and deliver to the Company, any and all lawful instruments, documents and papers, give evidence and do any and all other lawful acts that, in the opinion of the Company, are or may be necessary or desirable to document such assignment, transfer and conveyance or to enable the Company to file and prosecute
applications for and to acquire, maintain and enforce any and all patents, trademarks, copyrights and other property rights under United States, local, state or foreign law with respect to any such Inventions or Works or to obtain any extension, validation, reissue, continuance or renewal of any such patent, trademark, copyright, or other intellectual property right. By way of further example and not limitation, Employee agrees to meet with the Company representatives or attorneys for the purpose of initiating, maintaining or defending litigation, administrative or other proceedings; and to participate fully in litigation, administrative or other proceedings as requested by the Company. In the event that the Company may be unable, for any reason whatsoever, after reasonable effort, to secure Employee’s signature on any patent, copyright, trademark or other intellectual property application or other papers, Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents, as Employee’s agent and attorney-in-fact to act for and on behalf of Employee to execute, acknowledge, swear to, seal and deliver to the Company and to file any such application or applications or other papers, and to do all other lawfully permitted acts to further the provisions of this Section 20 of this Agreement.
(f)The Company agrees to reimburse Employee for reasonable expenses incurred by Employee in complying with the provisions of Sections 20(d) and 20(e) of this Agreement. The Company and Employee agree that Employee is not entitled to additional compensation beyond that paid to Employee for the period of time that he is employed by the Company, which compensation, along with the Company’s understandings set forth in this Agreement, is expressly acknowledged to be adequate consideration for all of the Employee promises and obligations set forth in this Agreement.
(g)Employee expressly acknowledges and states that all Works that are made by Employee (solely or jointly with others) are being created at the instance of the Company and are “works made for hire,” as that term is defined in the Copyright Act of 1976, 17 USC § 101. In the event that such laws are inapplicable or in the event that any such Works, or any part thereof, are determined by a court of competent jurisdiction not to be a work made for hire, this Agreement will operate as an irrevocable and unconditional assignment by Employee to the Company of all Employee’s right, title and interest (including, without limitation, all rights in and to the copyrights throughout the world, including the right to prepare derivative works and the rights to all renewals and extensions) in the Works in perpetuity.
(h)Employee represents that Attachment A to this Agreement describes all inventions and works, whether patentable or not, that have been conceived, made, reduced to practice, developed, authored, created, drawn or written prior to Employee’s employment by the Company; provided, however, that, Employee has not disclosed in Attachment A information that is a trade secret belonging to another, or that is the subject of a contract preventing Employee’s disclosure of the information to the Company.
21.Non-Competition and Non-Solicitation. In further consideration of the compensation to be paid to Employee hereunder, Employee acknowledges that during the course of Employee’s employment with the Company, the Company will provide Employee Confidential Information, which Employee promises to not disclose. Further, Employee
will become and/or remain familiar with the Company’s trade secrets and with other Confidential Information concerning the Company and that Employee’s services shall be of special, unique and extraordinary value to the Company, and therefore, the Employee agrees that some restrictions on Employee’s activities during and after Employee’s employment are necessary to protect the goodwill, Confidential Information and other legitimate interests of the Company:
(a)During the period of Employee’s employment by the Company and, if Employee’s employment with the Company terminates for any reason, for a period of one (1) year thereafter (“Covenant Period”), except with the written consent of the Board, Employee shall not directly or indirectly, own, control, finance or participate in the ownership, control or financing of, or be employed by or provide services to, any Competitor. For the purposes of this Agreement, a “Competitor” is defined as a person, business or enterprise (including divisions of persons, businesses and enterprises) that directly or indirectly engages in services of the type conducted, authorized, offered or provided by the Company (the “Restricted Business”) in the Territory. Without limiting the foregoing, for purposes of this Agreement, each entity listed on Attachment B, as shall be modified from time to time by the Company upon written notice to Employee, shall constitute a “Competitor.” For purposes of this Agreement, “Territory” is defined as the territory or territories within which Employee actually worked, or in respect of which Employee was involved in providing services, during the twelve (12) month period prior to Employee’s Termination Date. Notwithstanding the foregoing, nothing herein shall prevent Employee from providing services to, or being employed by, or owning, controlling, financing or participating in the ownership, control or financing of, any diversified entity or other person (other than the entities listed on Attachment B) that is engaged in the Restricted Business, so long as (i) the Restricted Business does not constitute greater than 25% of the aggregate revenue of such diversified entity or other person and (ii) Employee is not employed within and does not have involvement with business development or business strategy with respect to the Restricted Business. In further consideration for the Company’s promises herein, Employee agrees that during the Covenant Period, Employee will not directly or indirectly (i) solicit, entice, induce, cause, encourage or recruit any part-time or full-time employee, representative, consultant, customer, subscriber or supplier of the Company or its subsidiaries or affiliates to work for, provide services to or do business with a third party other than the Company or its subsidiaries or affiliates or engage in any activity that would cause any employee, representative, consultant, customer, subscriber or supplier to violate any agreement with the Company or its subsidiaries or affiliates or otherwise terminate or change its relationship with the Company or its subsidiaries or affiliates or (ii) hire any current or former part-time or full-time employee, representative or consultant of the Company or its Affiliates who was employed or engaged by the Company or its subsidiaries or affiliates at any time during the twelve (12) month period prior to Employee’s Termination Date or who thereafter becomes employed or engaged by the Company or its subsidiaries or affiliates.
(b)The foregoing restrictions shall not be construed to prohibit Employee’s ownership of less than one percent (1%) of any class of securities of any corporation that is engaged in any of the foregoing businesses and has a class of
securities registered pursuant to the Securities Exchange Act of 1934, as amended, provided that such ownership represents a passive investment and that neither Employee nor any group of persons including Employee in any way, either directly or indirectly, manages or exercises control of any such corporation, guarantees any of its financial obligations, otherwise takes any part in its business, other than exercising Employee’s rights as a stockholder, or seeks to do any of the foregoing.
22.Employee Representations.
(a)Employee represents and warrants that this Agreement and his employment by the Company does not conflict with and will not be constrained by any prior business relationship or contract, that Employee does not possess trade secrets or other proprietary information arising out of any prior business relationship or contract that, in Employee’s best judgment would be utilized in connection with Employee’s employment with the Company. Employee further agrees that he will not disclose any such trade secrets or other proprietary information to the Company or others.
(b)Employee represents and warrants that (i) before signing this Agreement, he has read this Agreement and is entering into this Agreement freely and with knowledge of its contents with the intent to be bound by it and the restrictions contained herein; (ii) Employee has been advised by the Company to consult Employee’s own legal counsel in respect of this Agreement, and Employee has had full opportunity, prior to execution of this Agreement, to review thoroughly this Agreement with Employee’s counsel; (iii) the restrictions imposed on Employee by this Agreement are fair, reasonable and proper and required for the protection of the Company’s business interests, particularly its investments in Employee (e.g., Employee’s job knowledge and skills), its Confidential Information, as well as the goodwill developed, and its business relationships, with its clients, customers and prospective clients and customers; (iv) the Company would not have entered into this Agreement in the absence of such restrictions, and that any violation of any provision of Sections 19, 20 or 21 hereof will result in irreparable injury to the Company; and (v) the restrictions imposed on Employee by this Agreement, particularly, the post-termination restrictions, shall not preclude Employee from earning a living or engaging in Employee’s profession or trade, or pursuing a career or a business, in each case at the same general level of economic benefit as is currently the case.
23.Consequences of Breach of Covenants; Equitable Relief.
(a)Employee agrees that the Company shall be entitled to preliminary and permanent injunctive relief, without the necessity of proving actual damages, as well as an equitable accounting of all earnings, profits and other benefits arising from any violation of Sections 19, 20, and 21 hereof, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled. The period of the injunction shall be measured from the date of a court order granting the injunctive relief. In the event that any of the provisions of Sections 19, 20, and 21 hereof should ever be adjudicated to exceed the time, geographic, service, or other limitations permitted by applicable law in any jurisdiction, then such provisions shall be deemed reformed in such jurisdiction to the maximum time, geographic, service, or other limitations permitted by applicable law.
(b)Notwithstanding anything to the contrary herein, Employee acknowledges and agrees that the severance payments and benefits provided herein are being provided by the Company to Employee, among other things, as additional consideration and solely for Employee’s agreement with and adherence to the post-employment restrictive covenants in Section 21 (a)-(c) and Employee’s other promises, covenants, commitments and obligations in this Agreement (including the releases granted in Section 13), the adequacy and sufficiency of which Employee expressly acknowledges. Employee agrees that should the Company, in its sole discretion, deem Employee to be in violation of any provision(s) in said Section 21 (a)-(c), the Company may immediately cease payment of all or any portion of the severance payments and benefits provided hereunder. Employee acknowledges that the severance payments and benefits provided for herein are in addition to anything of value to which Employee was already entitled.
(c)Employee irrevocably and unconditionally (i) agrees that any suit, action or other legal proceeding arising out of Section 19, 20, and 21 hereof, including without limitation, any action commenced by the Company for preliminary and permanent injunctive relief or other equitable relief, may be brought in the United States District Court for the District of New Jersey, or if such court does not have jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in New Jersey, (ii) consents to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding, and (iii) waives any objection that Employee may have to the laying of venue of any such suit, action or proceeding in any such court. Employee also irrevocably and unconditionally consents to the service of any process, pleadings, notices or other papers in a manner permitted by the notice provisions of Section 26 hereof.
24.Term of Agreement. This Agreement shall continue in full force and effect for the duration of Employee’s employment with the Company; provided, however, that after the termination of Employee’s employment during the term of this Agreement, this Agreement shall remain in effect until all of the obligations of the Parties hereunder are satisfied or have expired.
25.Successor Company. The Company shall require any successor or successors (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, by agreement in form and substance satisfactory to Employee, to acknowledge expressly that this Agreement is binding upon and enforceable against the Company in accordance with the terms hereof, and to become jointly and severally obligated with the Company to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession or successions had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Agreement. As used in this Agreement, the Company shall mean the Company as hereinbefore defined and any such successor or successors to its business and/or assets, jointly and severally.
26.Notice. All notices and other communications required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be delivered personally or mailed by registered or certified mail, return receipt requested, or by overnight express courier service, as follows:
| | | | | |
If to the Company, to: |
|
| Cognizant Technology Solutions Corporation 300 Frank W. Burr Blvd. Suite 36, 6th Floor Teaneck, NJ 07666 Attn: General Counsel
|
If to Employee, to: |
| |
| [__________]
|
or to such other names or addresses as the Company or Employee, as the case may be, shall designate by notice to the other Parties hereto in the manner specified in this Section; provided, however, that if no such notice is given by the Company following a change in control, notice at the last address of the Company or to any successor pursuant to this Section 26 shall be deemed sufficient for the purposes hereof. Any such notice shall be deemed delivered and effective when received in the case of personal delivery, five days after deposit, postage prepaid, with the U.S. Postal Service in the case of registered or certified mail, or on the next business day in the case of overnight express courier service.
27.Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of New Jersey without giving effect to any conflict of laws provisions.
28.Contents of Agreement, Amendment and Assignment.
(a)This Agreement, including the Code of Ethics, supersedes all prior agreements with respect to the subject matter hereof, sets forth the entire understanding between the Parties hereto with respect to the subject matter hereof and cannot be changed, modified, extended or terminated except upon written amendment executed by Employee and executed on the Company’s behalf by a duly authorized officer, except for revisions or additions to Attachment B, which may be unilaterally modified by the Company upon written notice to Employee[; provided, however, that this Agreement, except as expressly set forth in Section 9, does not supersede, modify or change any existing written award agreements regarding stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, performance units or other stock-based awards issued to Employee prior to the effective date of this Agreement]. The provisions of this Agreement may provide for payments to Employee under certain compensation or bonus plans under circumstances where such plans would not provide for payment thereof. It is the specific intention of the Parties that the provisions of this Agreement shall supersede any provisions to the contrary in such plans, and such plans shall be deemed to have been amended to correspond with this Agreement without further action by the Company, the Company’s Board of Directors or the Board unless such amendment would contravene the provisions of section 409A of the Code and result in the imposition of additional taxes under section 409A of the Code upon Employee.
(b)Nothing in this Agreement shall be construed as giving Employee any right to be retained in the employ of the Company, or as changing or modifying the “at will” nature of Employee’s employment status.
(c)All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, representatives, successors and assigns of the Parties hereto, except that the duties and responsibilities of Employee and the Company hereunder shall not be assignable in whole or in part by the Company. If Employee should die after Employee’s Termination Date and while any amount payable hereunder would still be payable to Employee hereunder if Employee had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Employee’s devises, legates or other designees or, if there is no such designee, to Employee’s estate.
29.Severability. If any provision of this Agreement is declared illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid, and enforceable, or otherwise deleted, and the remainder of the terms of this Agreement shall not be affected except to the extent necessary to reform or delete such illegal, invalid, or unenforceable provision.
30.Remedies Cumulative; No Waiver. No right conferred upon the Parties by this Agreement is intended to be exclusive of any other right or remedy, and each and every such right or remedy shall be cumulative and shall be in addition to any other right or remedy given hereunder or now or hereafter existing at law or in equity. No delay or omission by a Party in exercising any right, remedy or power hereunder or existing at law or in equity shall be construed as a waiver thereof.
31.Miscellaneous. All section headings are for convenience only. This Agreement may be executed in several counterparts, each of which is an original. It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or account for any of the other counterparts.
32.Section 409A.
(a)Interpretation. This Agreement is intended to comply with the requirements of Section 409A of the Code and/or one or more available exemptions therefrom, and shall in all respects be administered and construed in accordance with Section 409A of the Code or such available exemption(s). If any payment or benefit hereunder cannot be provided or made at the time specified herein without incurring taxes on Employee under or by operation of Section 409A of the Code, then such payment or benefit shall be provided in full at the earliest time thereafter when such taxes will not be imposed. For purposes of Section 409A of the Code, all payments to be made upon a Termination of Employment under this Agreement may only be made upon a “separation from service” (within the meaning of such term under Section 409A of the Code), each payment made under this Agreement shall be treated as a separate payment, the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments, and if a payment is not made by the designated payment date under this Agreement, the payment shall be made by December 31 of the calendar year in which the designated date occurs. To the extent that any payment provided for hereunder would be subject to additional tax under Section 409A of the Code, or would cause the administration of this Agreement to fail to satisfy the requirements of Section 409A of the Code, such provision shall be deemed null and void to the extent permitted by applicable law, and, to the extent applicable, any such amount shall be payable in accordance with Section 32(b). In no event shall the Employee, directly or indirectly, designate the calendar year
of payment. Nothing herein shall be construed as having modified the time and form of payment of any amounts or payments of “deferred compensation” (as defined under Treas. Reg. Section 1.409A-1(b)(1), after giving effect to the exemptions in Treas. Reg. Sections 1.409A-1(b)(3) through (b)(12)) that were otherwise payable pursuant to the terms of any agreement between the Company and Employee in effect on or after January 1, 2005 and prior to the date of this Agreement.
(b)Payment Delay. Notwithstanding anything herein to the contrary, if it is necessary to postpone the commencement of any payments or benefits otherwise payable under this Agreement as a result of Employee’s “separation from service” with the Company to prevent the imposition of any accelerated or additional tax under Section 409A of the Code, then the Company will postpone the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Employee) that are not otherwise paid within the “short-term deferral exception” under Treas. Reg. Section 1.409A-1(b)(4) and the “separation pay exception” under Treas. Reg. Section 1.409A-1(b)(9)(iii), until the first payroll date that occurs after the date that is six months following Employee’s “separation of service” with the Company. If any payments are postponed due to such requirements, such postponed amounts will be paid to Employee in a lump sum on the first payroll date that occurs after the date that is six months following Employee’s “separation of service” with the Company. If Employee dies during the postponement period prior to the payment of the postponed amount, the amounts withheld on account of Section 409A of the Code shall be paid to the personal representative of Employee’s estate within sixty (60) days after the date of the Employee’s death.
(c)Reimbursements. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Employee’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the taxable year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit.
33.Recoupment Policy. Employee acknowledges that Employee shall be subject to and hereby agrees to abide by the terms of any clawback or recoupment policy that the Company has adopted or may hereafter adopt, as may be amended from time to time, with or without notice (the “Recoupment Policy”) to further the Company’s interests in enhancing its corporate governance practices and/or to comply with applicable law, rules or regulations promulgated by the Securities and Exchange Commission or the rules of the national securities exchange on which shares of the common stock of the Company are listed for trade. Employee understands that pursuant to the Recoupment Policy, the Company may seek to recoup all or part of any severance payments, bonus or other incentive compensation paid to certain officers and former officers, including Equity Awards, in the event that the Company is required to restate its financial statements. In consideration of the [continued] benefits to be received from the Company (or a
subsidiary) and the right to participate in, and receive future awards under, the Company’s cash and equity-based incentive programs, Employee hereby acknowledges, understands and agrees that:
(a)The Recoupment Policy applies to severance, cash bonuses and other incentive compensation, including Equity Awards, paid or awarded to Employee prior to or after the date on which the Recoupment Policy is adopted, and Employee agrees that, to the extent provided in the Recoupment Policy, the Recoupment Policy shall apply to equity and other award agreements outstanding as of the date of this Agreement or hereafter executed, and such agreements shall be deemed amended by, and to incorporate, the terms of the Recoupment Policy even if the Recoupment Policy is not explicitly referenced therein;
(b)The Company shall be fully entitled to enforce the Recoupment Policy against Employee in accordance with its terms, and Employee promptly shall comply with any demand authorized by the Board of Directors of the Company pursuant to the terms of the Recoupment Policy for repayment, return or rescission of, severance payments, a cash bonus or other incentive compensation, including Equity Awards, subject to the Recoupment Policy; and
(c)Nothing in this acknowledgement shall be construed to expand the scope or terms of the Recoupment Policy, and Employee is not waiving any defenses Employee may have in the event of an action for recoupment of compensation under the Recoupment Policy, other than (i) waiving any defense regarding the retroactive application of the Recoupment Policy to prior or existing payments or awards and (ii) waiving any claim that the integration clause of any agreement excludes the application of the Recoupment Policy.
[Signature Page Follows]
IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have executed this Agreement as of the date first above written. | | | | | |
| COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION |
|
Name: Title:
[NAME OF EXECUTIVE]
|
| |
ATTACHMENT A
1. The following is a complete list of all inventions and works that have been conceived, made, reduced to practice, developed, authored, created, drawn or written by me alone or jointly with others prior to my engagement by the Company.
None.
______________________________________________________________________________________________________________________________________________________________________________________________________
Due to a preexisting contract with another party, I cannot disclose certain Inventions or Works that would otherwise be included on the above-described list.
Additional sheets are attached.
(number)
EMPLOYEE:
Signature: ___________________
Name: ______________________
(Print)
Title: ______________________
Date: ______________________
ATTACHMENT B – List of Direct Competitors
1.International Business Machines Corporation
2.Accenture LTD
3.Cap Gemini S.A.
4.Tata Consultancy Services
5.Infosys Limited
6.Wipro Limited
7.HCL Technologies Limited
8.DXC Technology Company
[UK] [AMENDED AND RESTATED] EXECUTIVE EMPLOYMENT AND NON-DISCLOSURE, NON-COMPETITION, AND INVENTION ASSIGNMENT AGREEMENT
This [Amended and Restated] Executive Employment and Non-Disclosure, Non-Competition, and Invention Assignment Agreement (this “Agreement”) is made as of the ___ day of [____] 20[___] (the “Effective Date”) by and between Cognizant Worldwide Limited 1 Kingdom Street, Paddington Central, London, W2 6BD (the “Company” (where applicable, the definition of Company shall include the Company’s subsidiaries and affiliates and any successors or assigns)), and [_____] (“Employee”, or “You”).
[WHEREAS, Employee is currently employed by the Company as its [_____];]
[and]
WHEREAS, the Company desires to [continue to] retain the services of Employee; [and]
[WHEREAS, the Parties desire to amend and restate, in its entirety, the parties’ prior agreements pertaining to Employee’s employment, and set forth the new terms and conditions of Employee’s employment by the Company].
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements hereinafter set forth and intending to be legally bound hereby, the Company and Employee (individually a “Party” and together, the “Parties”) agree as follows:
1.Definitions.
(a)“Annual Base Salary” shall mean Employee’s annualized rate of base salary, as in effect immediately prior to Employee’s Termination Date.
(b)“Board” shall mean the Board of Directors of Cognizant.
(c) “Cause” shall mean (i) willful malfeasance or willful misconduct by the Employee in connection with his employment, (ii) continuing failure to perform such duties as are reasonably assigned by Employee’s supervisor, (iii) failure by the Employee to abide by material policies of the Company applicable to the Employee, including without limitation the Code of Ethics (as defined below), (iv) the commission by the Employee of a criminal offence (other than minor traffic violations) (v) Employee engaging in any fraudulent act or act of embezzlement, or (vi) any material breach by Employee of this Agreement or any other written agreement between Employee and the Company.
(d)“Code” means the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder.
(e)“Cognizant” means Cognizant Technology Solutions Corporation, a Delaware Corporation
(f) “Disability” means Employee’s total and permanent disability as determined in accordance with the Company’s long-term disability policy, whether or not Employee is covered by such policy (or, if the Company has no long-term disability policy, then “Disability” means that Employee has become “disabled” within the meaning of Code Section 409A).
(g)“Good Reason” means, the occurrence of one or more of the following events or actions:
(i)A material diminution by the Company of Employee’s authority, duties or responsibilities (it being understood that a modification of duties in the manner described in Section 3(a) below shall not constitute Good Reason);
(ii)A material diminution in Employee’s overall compensation package, which is not otherwise caused by an overall policy by the Company to reduce senior employee compensation throughout the Company; or
(iii)A change, without Employee’s consent, in the principal place of work of the Employee to a location that is more than 50 miles from his primary work location as of the date of this Agreement, but only if such change occurs on or after a Change in Control.
(h)“Group” means together or separately Cognizant, the Company and any holding company or undertaking of the Company and any subsidiaries and subsidiary undertakings of the Company or such holding company or undertaking from time to time (and the words “subsidiary” and “holding company” shall have the meanings given to them in section 1159 in the UK Companies Act 2006, and the term “Group Company” shall be construed accordingly).
(i)“Notice of Termination” means a written notice that (i) indicates the specific termination provision in this Agreement relied upon and (ii) briefly summarizes the facts and circumstances deemed to provide a basis for termination of Employee’s employment under the provision so indicated.
(j)“Termination Date” shall mean the last day of Employee’s employment with the Company.
(k)“Termination of Employment” shall mean the termination of Employee’s active employment relationship with the Company.
2.Employment. The Company hereby continues to employ Employee, and Employee hereby accepts continuation of such employment, upon the terms and conditions set forth herein with effect from [INSERT]. The Employee’s period of continuous employment commenced on [INSERT].
3.Duties.
(a)Position. Employee shall be employed as [_____] and shall have the duties and responsibilities assigned by [_____] upon commencement of employment under this Agreement, and from time to time thereafter. Employee shall perform faithfully and diligently all duties assigned to Employee. The Company reserves the right to modify Employee’s position and duties at any time in its sole and absolute discretion, provided that the duties assigned are consistent with the position of a senior executive and that Employee continues to report to [_____] or such other position of a similar or more senior level. No probationary period shall apply to the Employee’s employment.
(b)Best Efforts/Full-time. To the maximum extent permitted by law, Employee agrees to devote Employee’s best efforts and entire business time and attention to the Company’s business during the term of Employee’s employment with the Company. Employee agrees that, during the term of Employee’s employment, except as otherwise approved in writing by the Company, which approval the Company may in its absolute discretion withhold, Employee will not, either directly or indirectly, or for himself/herself or through, on behalf of, or in conjunction with any person, persons or legal entity, operate, engage in, assist, or be employed by any business activity to or for the benefit of any person or entity other than the Company; provided that the foregoing is not intended to prevent an Employee from pursuing hobbies or participating in any other activity that is not to the detriment of the Company. Employee further acknowledges and agrees that Employee has access to Cognizant’s Core Values & Code of Ethics (the “Code of
Ethics”) located at www.cognizant.com, and Employee has read and understands the Code of Ethics and shall abide by all the terms of said Code of Ethics, as may be amended from time to time, and said Code of Ethics shall be incorporated into this Agreement. Employee will abide by all policies and decisions made by the Company, as well as all applicable federal, state and local laws, regulations or ordinances. Employee will act in the best interest of the Company at all times.
(c)Disciplinary and Grievance Procedures, Collective Agreements, Training and Suspension. Company policies and procedures including our disciplinary and grievance procedure are available on Be.Cognizant and maybe amended from time to time. The disciplinary and grievance procedures do not form part of this Agreement. The Company does not recognize a trade union and there are no collective agreements that apply to Employee’s employment with the Company. The Company may suspend Employee from any or all of his duties for no longer than is necessary to investigate any disciplinary matter involving Employee or so long as is otherwise reasonable with any disciplinary procedure against Employee is outstanding. As at the date of this Agreement, the Employee is not required to undertake any particular training. If any particular training is required or offered, details will be provided.
(d)Hours of work. Employee agrees that he shall work normal business hours together with such additional hours as are necessary for the proper performance of his duties. Employee shall work a minimum of 40 hours per week from 9.00 am to 6.00 pm Monday to Friday, with a break of one hour for lunch each day.
(e)Working Time Regulations Employee has autonomous decision making powers. The duration of his working time is not measured or predetermined.
(f)Work Location. Employee’s principal place of work shall be located in 1 Kingdom, Street, Paddington Central, London, W2 6BD, or such other location as the parties may, agree upon from time to time. The Employee may be required to be absent from the United Kingdom for periods exceeding one month at any one time, however there are currently no particulars in this regard.
4.Termination of Employment.
(a)Employee’s employment with the Company may be terminated by either Party providing the other with not less than six months’ prior written notice.
(b)The Company shall be entitled, at its sole discretion, to terminate the Employee’s employment immediately at any time by giving the Employee notice in writing. In these circumstances the Company will make a payment to the Employee in lieu of notice (the payment being referred to as a “Notice Payment”). For the avoidance of doubt, there is no obligation to make a Notice Payment. If the Company shall decide not to pay a Notice Payment, the Employee shall not be entitled to enforce that payment as a contractual debt nor as liquidated damages. The Notice Payment will be paid less all deductions that are required or permitted by law to be made including in respect of income tax, national insurance contributions and any sums due to the Company. The Notice Payment will consist of a sum equivalent to the Annual Base Salary which the Employee would have received in respect of any notice period outstanding on the Termination Date but will exclude any bonus, commission and share of profit and any other benefits which he would have received or would have accrued to him during that period.
(c)During any notice period or for the purpose of investigating any matter in which the Employee is implicated or involved, the Company reserves the right in its
absolute discretion to suspend all or any of the Employee’s duties and powers on terms it considers expedient or to require him to perform only such duties, specific projects or tasks as are assigned to him expressly by the Company in any case for such period or periods and at such place or places (including, without limitation, the Employee’s home) as the Company in its absolute discretion deems necessary and Employee will not contact or deal with (or attempt to contact or deal with) any customer, client, supplier, agent, distributor, shareholder, employee, officer or other business contact of the Company except as authorized by the Company (the “Garden Leave”). During any period of Garden Leave the terms and conditions set out in this Agreement shall continue to apply to the Employee. For the avoidance of doubt, during Garden Leave, the Employee will continue to receive his Annual Base Salary and benefits.
(d)Notwithstanding the provisions of Sections 4(b) to 4(c) above the Company shall be entitled, but not bound, to terminate the employment with immediate effect by giving to the Employee a Notice of Termination at any time for Cause. In such case, the Employee shall not be entitled to receive any Notice Payment nor make any claim against the Company for damages for loss of office or termination of the employment. Regardless of this, the termination shall be without prejudice to the continuing obligations of the Employee under this Agreement.
5.Compensation.
(a)Annual Base Salary. As compensation for Employee’s performance of Employee’s duties hereunder, the Company shall pay to Employee of £[INSERT] per annum (less required deductions for withholding tax, social security and all other employment taxes and payroll deductions) which will accrue from day to day, and as may be modified by the compensation committee of the Board, one month in arrears in 12 equal installments on the last working day of the month payable in accordance with the normal payroll practices of the Company.
(b)Incentive Compensation. Employee will be eligible to earn incentive compensation as determined by the compensation committee of the Board in accordance with the bonus plan(s) provided to Employee by the Company, in accordance with the terms and conditions of such plan(s).
(c)[Stock Options and Other Equity Awards. Except as set forth herein, this Agreement does not modify or change the existing agreements regarding stock options, stock appreciation rights, restricted stock awards and restricted stock units (each, an “Equity Award” and collectively, “Equity Awards”) previously issued to Employee.
(d)By signing this Agreement, Employee agrees that Company shall be entitled to deduct any money owed by Employee by Company or any Group Company from any salary or other payments due to Employee whether during employment or at its termination.
6.Customary Fringe Benefits. Employee will be eligible for certain fringe benefits generally available to UK-based employees of the Company subject to the terms and conditions of the Company’s benefit plan documents and any policies relating thereto. The Company reserves the right to change or eliminate the fringe benefits on a prospective basis, at any time, effective upon notice to Employee. The benefits applicable to Employee as at the date of this Agreement while his primary place of work is in the United Kingdom are set out in the Schedule to this Agreement.
7.Business Expenses. Employee will be reimbursed for all reasonable, out-of-pocket business expenses incurred in the performance of Employee’s duties on behalf of the Company. To obtain reimbursement, expenses must be submitted promptly with appropriate supporting documentation in accordance with the Company’s policies.
8.Company Access. Employee agrees and consents that, during the term of Employee’s employment with the Company and thereafter, the Company may review, audit, intercept, access and disclose all messages created, received or sent over the electronic mail and internet access system provided by the Company with or without notice to Employee and that such review, audit, interception, access, or disclosure may occur during or after working hours. Employee further consents and agrees that the Company may, at any time, access and review the contents of all computers, computer disks, other data storage equipment and devices, files, desks, drawers, closets, cabinets and work stations that are either on the Company’s premises or that are owned or provided by the Company. Employee agrees that he has read the Company’s Associate Privacy Notice (available at https://www.cognizant.com/about-cognizant-resources/global-associate-privacy-notice.pdf ) and that he will comply with the terms of the Company’s Acceptable Use Policy (available in the Corporate Security section of Be.Cognizant)
9.Involuntary Termination of Employment.
(a)Prior to a Change in Control. In the event that Employee’s employment with the Company is involuntarily terminated by the Company for any reason other than Cause, death or Disability or in the event Employee resigns his employment for Good Reason pursuant to Section 10 and the Company’s right to cure (as set forth in Section 10) has expired (an “Involuntary Termination”), and in either such case Employee’s employment termination becomes effective before any Change in Control (as defined in Section 9(d) below) has occurred following the date of this Agreement, Employee shall be entitled to the payments and benefits described below, provided that Employee timely executes and does not revoke the Release (as defined in Section 13) and the Release first becomes effective:
(i)Employee shall receive a cash payment equal to one (1) times Employee’s Annual Base Salary, such amount to be paid in regular installments in accordance with the Company’s normal payroll practices over a period of twelve (12) months following Employee’s Termination Date, provided, that no such installments shall be paid prior to the later to occur of (A) the first regular Company payroll date occurring on or after the date on which the Release becoming effective and irrevocable and (B) solely if the period during which Employee may consider and revoke the Release spans two calendar years, the first regular Company payroll date occurring in the latter such calendar year (in either case, the “First Payroll Date”), with any installments otherwise payable prior to the First Payroll Date instead paid on the First Payroll Date (without interest thereon).
(ii)Employee shall receive a cash payment equal to one (1) times the amount of the Employee’s target annual bonus for the performance year in which the Employee’s Termination Date occurs, payable in a lump sum payment on the First Payroll Date.
(iii)The Company shall, for a period of eighteen (18) months following the Employee’s Termination Date, pay the Employee each month an amount equal to the monthly COBRA medical insurance cost under the Company’s group medical plan for Employee and, where applicable,
Employee’s spouse and eligible dependents; provided that Employee, and, where applicable, Employee’s spouse and dependents, are eligible for and timely elect to receive COBRA healthcare continuation coverage and provided further that the payments specified under this Section 9(a)(iii) shall cease if the Company’s statutory obligation to provide such COBRA healthcare continuation coverage terminates for any reason before the expiration of the eighteen (18)‑month period. All Company payments under this Section 9(a)(iii) to the Employee can be used for any purpose and will be reported as taxable payments.
(iv)The portion of any outstanding Equity Awards that were subject to vesting solely upon continuous service with the Company and would have vested had Employee remained employed by the Company during the twelve (12) month period following Employee’s Termination Date shall automatically become fully vested and exercisable, as applicable, as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such Equity Awards shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(v)With respect to any outstanding Equity Award that was subject to vesting in whole or in part based on achievement of performance objective(s), to the extent that the applicable performance period has expired on or before Employee’s Termination Date, the performance objective(s) has/have been satisfied and the only condition to vesting that remains is continuous service until one or more future dates, the portion of such Equity Award that would have vested had Employee remained employed by the Company during the twelve (12) month period following Employee’s Termination Date shall become fully vested and exercisable as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such Equity Award shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(vi)Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company. The payment of amounts described in this Section 9(a)(vi) are not conditioned upon the Release becoming effective unless the applicable benefit plan or program provides otherwise.
(b)Coincident with or within One Year After a Change in Control. In the event that Employee suffers an Involuntary Termination that becomes effective coincident with, or within the twelve (12) month period immediately after, the first occurrence of a Change in Control following the date of this Agreement, Employee shall be entitled to the payments and benefits described below in this Section 9(b) in lieu of, and not in addition to, the payments and benefits described in Section 9(a); provided that Employee timely executes and does not revoke the Release (as defined in Section 13) and the Release first becomes effective:
(i)Employee shall receive a cash payment equal to two (2) times Employee’s Annual Base Salary, such amount to be paid in regular installments in accordance with the Company’s normal payroll practices over a period of
twenty-four (24) months following Employee’s Termination Date, provided, that no such installments shall be paid prior to the First Payroll Date, with any installments otherwise payable prior to the First Payroll Date instead paid on the First Payroll Date (without interest thereon).
(ii)Employee shall receive a cash payment equal to two (2) times the amount of the Employee’s target annual bonus for the performance year in which the Employee’s Termination Date occurs, payable in a lump sum payment on the First Payroll Date.
(iii)The Company shall, for a period of eighteen (18) months following the date of Employee’s Termination of Employment, pay Employee each month an amount equal to the monthly COBRA medical insurance cost under the Company’s group medical plan for Employee and, where applicable, Employee’s spouse and eligible dependents; provided that Employee, and, where applicable, Employee’s spouse and dependents, are eligible for and timely elect to receive COBRA healthcare continuation coverage and provided further that the payments specified under this Section 9(b)(iii) shall cease if the Company’s statutory obligation to provide such COBRA healthcare continuation coverage terminates for any reason before the expiration of the eighteen (18)‑month period. All Company payments under this Section 9(a)(iii) to the Employee can be used for any purpose and will be reported as taxable payments.
(iv)The portion of any outstanding Equity Awards that were subject to vesting solely upon continuous service with the Company shall automatically become fully vested and exercisable, as applicable, as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such vested Equity Awards shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(v)Outstanding Equity Awards the vesting of which is conditioned, in whole or in part, upon the achievement of performance objectives shall become vested and exercisable as follows:
(A) To the extent that the applicable performance period has expired on or before Employee’s Termination Date, the performance objective(s) has/have been satisfied and the only condition to vesting that remains is continuous service until one or more future dates, such Equity Award shall become fully vested and exercisable as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date).
(B) To the extent that the applicable performance period has not expired on or before Employee’s Termination Date, the Company shall pro-rate the performance objective(s) for the portion of the performance period that has transpired up to the date of closing of the Change in Control, make a good faith determination of the level of achievement of such pro-rated performance objective as of such closing date, and treat as fully vested and exercisable a proportionate amount of such Equity Award that corresponds with the level of achievement of the pro-rated performance objective, disregarding any future service conditions that otherwise would apply to such Equity Award.
(vi)Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company. The payment of amounts described in this Section 9(b)(vi) are not conditioned upon the Release becoming effective unless the applicable benefit plan or program provides otherwise.
(c)Notice of Termination. Any termination on account of this Section 9 shall be communicated by a Notice of Termination to the other Party hereto given in accordance with Section 26 hereof.
(d)Definition of Change in Control. For purposes of this Agreement, the term “Change in Control” shall have the meaning set forth in the Company’s 2017 Incentive Award Plan, as amended from time to time or any successor plan in effect as of Employee’s Termination Date.
10.Resignation for Good Reason. If Employee provides notice of his intent to terminate for Good Reason, then, subject to the expiration of the cure period and Employee’s actual termination as described below, such resignation shall be deemed an Involuntary Termination for purposes of this Agreement and Employee shall be entitled to the payments and benefits described in Section 9 subject to the requirements set forth in this Agreement, including Section 13. Employee must provide written notice to the Company of his intent to terminate his employment for Good Reason within thirty (30) days of the action or omission giving rise to such claim of Good Reason. Thereafter, the Company shall have a period of thirty (30) days within which it may correct the event or action that constitutes the grounds for Good Reason as set forth in Employee’s notice of termination. If the Company does not correct the event or action prior to the expiration of the foregoing cure period, Employee must terminate his employment for Good Reason within thirty (30) days after the expiration of the cure period, in order for the termination to be considered a Good Reason termination under this Agreement.
11.Termination Due to Death. If Employee’s employment with the Company is terminated due to death, Employee shall be entitled to the payments and benefits described below, provided that Employee’s estate timely executes and does not revoke the Release (as defined in Section 13) and the Release first becomes effective:
(a)Employee shall receive a cash payment equal to (1) times the amount of the Employee’s target annual bonus for the performance year in which the Employee’s Termination Date occurs, pro-rated based on the portion of such year that has elapsed as of Employee’s Termination Date, payable on the First Payroll Date.
(b)The portion of any outstanding Equity Awards that were subject to vesting solely upon continuous service with the Company shall automatically become fully vested and exercisable, as applicable, as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date). Such vested Equity Awards shall continue to be governed by and exercised, settled or paid in accordance with the terms of the applicable award agreement.
(c)Outstanding Equity Awards the vesting of which is conditioned, in whole or in part, upon the achievement of performance objectives shall become vested and exercisable as follows:
(i)To the extent that the applicable performance period has expired on or before Employee’s Termination Date, the performance objective(s) has/have been satisfied and the only condition to vesting that remains is continuous service until one or more future dates, such Equity Award shall become fully vested and exercisable as of the date on which the Release becomes effective and irrevocable (and for clarity, shall remain outstanding and eligible to vest on such date).
(ii)To the extent that the applicable performance period has not expired on or before Employee’s Termination Date, the Company shall pro-rate the performance objective(s) for the portion of the performance period that has transpired up to Employee’s Termination Date, make a good faith determination of the level of achievement of such pro-rated performance objective as of such Termination Date, and treat as fully vested and exercisable a proportionate amount of such Equity Award that corresponds with the level of achievement of the pro-rated performance objective, disregarding any future service conditions that otherwise would apply to such Equity Award.
(d)Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company. The payment of amounts described in this Section 11(d) are not conditioned upon the Release becoming effective unless the applicable benefit plan or program provides otherwise.
12.Termination Due to Disability or For Cause. If Employee’s employment with the Company is terminated by the Company due to Disability or for Cause, Employee shall receive any amounts earned, accrued and owing but not yet paid to Employee as of Employee’s Termination Date and any benefits accrued and earned in accordance with the terms of any applicable benefit plans and programs of the Company; all other Company obligations to Employee will be extinguished as of the Termination Date.
13.Release. Notwithstanding the foregoing, no payments or benefits shall be provided under Sections 9, 10 and 11, as applicable (except for those payments that are owed pursuant to applicable law and/or are specifically not conditioned upon the execution of a release by Employee or Employee’s estate, as applicable), unless Employee or his estate, if applicable, executes, and does not revoke, the Company’s then standard written general release (the “Release”) of any and all claims against the Company and all related parties with respect to all matters arising out of Employee’s employment by the Company (other than any entitlements under the terms of this Agreement or under any other plans or programs of the Company in which Employee participated and under which Employee has accrued and earned a benefit) or the termination thereof. The Company will provide Employee with the form of release agreement within seven days after Employee’s separation from service. To be entitled to any severance or other benefits (other than payments of accrued compensation that are explicitly excluded from applicable Release requirements), Employee must execute and deliver to the Company the release agreement on or before the last day of the minimum required waiver consideration period provided under the Age Discrimination in Employment Act or other applicable law or such later date specified in the release agreement. If Employee timely delivers an executed release agreement to the Company, and Employee does not revoke the release agreement during the minimum revocation period required under applicable law, if any, the severance or
other benefits shall be paid or commence being paid, as specified in this Agreement, subject to any delay required pursuant to Section 32(b) of this Agreement. Consistent with section 409A of the Code, Employee may not, directly or indirectly, designate the calendar year of any payment. Nothing in this Section 13 shall be construed to alter the terms of this Agreement that condition Employee’s entitlement to any severance or other benefits upon Employee’s compliance with the restrictive covenants and any other terms and conditions specified in this Agreement.
14.Other Payments. Any payments and benefits that become due under Sections 9, 10 and 11, hereof shall be in addition to (but not in duplication of) and not in lieu of any payments and benefits due to Employee under any other plan, policy or program of the Company, except that Employee shall not be entitled to any payments and benefits under the Company’s then current severance pay policies. For the avoidance of doubt, the aggregate amount of any payments that become due to Employee under Sections 9 or 10 shall be reduced by the amount of any Notice Payment.
15.No Mitigation. Employee shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for herein be reduced by any compensation earned by other employment or otherwise; provided, however, that any obligation of the Company to make the payments described in Sections 9(a)(iii) and 9(b)(iii) shall cease upon Employee becoming covered under a healthcare plan of another employer.
16.Non-Exclusivity of Rights. Except as provided in Section 14, nothing in this Agreement shall prevent or limit Employee’s future participation in or rights under any benefit, bonus, incentive or other plan or program provided by the Company and for which Employee may qualify.
17.No Set-Off. Other than with respect to the Recoupment Policy (as hereinafter defined), the Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right that the Company may have against Employee or others.
18.Taxes.
(a)All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. Except as may be otherwise specified under applicable law, Employee shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect to any payment received under this Agreement, including, without limitation, any excise tax imposed by Section 4999 of the Code.
(b)If the payments and benefits received or to be received by Employee in connection with a Change in Control or the termination of Employee’s employment (whether payable pursuant to the terms of this Agreement (“Contract Payments”) or any other plan, arrangement or agreement with the Company (collectively with the Contract Payments, the “Total Payments”), would constitute a “parachute payment” under Section 280G of the Code, then the Total Payments shall be reduced, in the manner set forth below, by the minimum amount necessary to result in no portion of the Total Payments being non‑deductible to
the Company pursuant to Section 280G of the Code or subject to the excise tax imposed under Section 4999 of the Code.
(c)All determinations required to be made under this Section 18, including whether a reduction in Total Payments is required, the amount of any such reduction and the assumptions to be utilized in arriving at such determination, shall be made by an accounting or law firm of recognized standing reasonably selected by the Company (the “Firm”), which may be, but will not be required to be, the Company’s independent auditors. The Firm shall submit its determination and detailed supporting calculations to both Employee and the Company within fifteen (15) days after receipt of a notice from either the Company or Employee that Employee may receive payments that may be “parachute payments.” If the Firm determines that a reduction is required by this Section 18, the Contract Payments consisting of cash severance shall be reduced to the extent necessary so that no portion of the Total Payments shall be subject to the excise tax imposed by section 4999 of the Code, and the Company shall pay such reduced amount to Employee in accordance with the terms of this Agreement. If additional Contract Payments must be reduced pursuant to this Section 18 after the cash severance has been reduced to zero, the Contract Payments allocable to performance-vested Equity Awards shall next be reduced, followed by the Contract Payments allocable to time-vested Equity Awards, to the extent necessary to satisfy the requirements of this Section 18.
(d)Employee and the Company shall each provide the Firm access to and copies of any books, records, and documents in the possession of Employee or the Company, as the case may be, reasonably requested by the Firm, and otherwise cooperate with the Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Section 18. The fees and expenses of the Firm for its services in connection with the determinations and calculations contemplated by this Section 18 shall be borne by the Company.
19.Confidential Information. Employee agrees that Employee’s services to the Company have been and will continue to be of a special, unique and extraordinary character, and that Employee’s position places Employee in a position of confidence and trust with the Company’s customers and employees. Employee also recognizes that Employee’s position with the Company will give Employee substantial access to Confidential Information (as defined below), the disclosure of which to competitors of the Company would cause the Company to suffer substantial and irreparable damage. Employee recognizes, therefore, that it is in the Company’s legitimate business interest to restrict Employee’s use of Confidential Information for any purposes other than the discharge of Employee’s employment duties at the Company, and to limit any potential appropriation of Confidential Information by Employee for the benefit of the Company’s competitors and to the detriment of the Company. Accordingly, Employee agrees as follows:
(a)Employee will not at any time, whether during or after the termination of Employee’s employment, reveal, or allow to be revealed to any person or entity any of the trade secrets or confidential information of the Company or of any third party that the Company is under an obligation to keep confidential (including but not limited to trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects, plans and proposals) (“Confidential Information”), except as may be required in the ordinary course of
performing Employee’s duties as an employee of the Company, and Employee shall keep secret all matters entrusted to Employee and shall not use or attempt to use any such information in any manner that may injure or cause loss or may be calculated to injure or cause loss whether directly or indirectly to the Company. By way of example and not limitation, Confidential Information also includes any and all information, whether or not meeting the legal definition of a trade secret, concerning the Company’s actual, planned or contemplated: (i) marketing plans, business plans, strategies, forecasts, budgets, projections and costs; (ii) personnel information; (iii) customer, vendor and supplier lists; (iv) customer, vendor and supplier needs, transaction histories, contacts, volumes, characteristics, agreements and prices; (v) promotions, operations, sales, marketing, and research and development; (vi) business operations, internal structures and financial affairs; (vii) software and operating systems and procedures; (viii) pricing structure of the Company’s services and products; (ix) proposed services and products; (x) contracts with other parties; (xi) performance characteristics of the Company’s products; and (xii) Inventions and Works (each as defined in Section 20). Confidential Information also includes any and all information of Company’s employees ,clients and customers that is deemed confidential by such clients and customers (whether past, present or potential), including, but not limited to: marketing tools, inventions, processes, contact lists, materials, software program code, logic diagrams, flow charts, procedural diagrams, computer programming techniques and know how, maps and any documentation related thereto.
(b)The above restrictions shall not apply to: (i) information that at the time of disclosure is in the public domain through no fault of Employee; (ii) information received from a third party outside of the Company that was publicly disclosed without a breach of any confidentiality obligation; or (iii) information approved for release by written authorization of the Company. In addition, in the event that Employee is requested or required (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) to disclose any of the Confidential Information, it is agreed that Employee will provide the Company with prompt notice of such request(s) so that the Company may seek an appropriate protective order or other appropriate remedy and/or waive compliance with the confidentiality provisions of this Agreement. In the event that such protective order or other remedy is not obtained, or the Company grants a waiver hereunder, Employee may furnish that portion (and only that portion) of the Confidential Information that Employee is legally compelled to disclose and will exercise its reasonable best efforts to obtain reliable assurance that confidential treatment will be accorded any Confidential Information so furnished.
(c)Further, Employee agrees that during Employee’s employment Employee shall not take, use or permit to be used any notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials of any nature relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs otherwise than for the benefit of the Company. Employee further agrees that Employee shall not, after the termination of Employee’s employment, use or permit to be used any such notes, memoranda, reports, lists, records, drawings, sketches,
specifications, software programs, data, documentation or other materials, it being agreed that all of the foregoing shall be and remain the sole and exclusive property of the Company and that, immediately upon the termination of Employee’s employment, Employee shall deliver all of the foregoing plus any other Confidential Information, and all copies thereof, to the Company, at its main office.
(d)Employee agrees that upon the termination of Employee’s employment with the Company, Employee will not take or retain without written authorization any documents, files or other property of the Company, and Employee will return promptly to the Company any such documents, files or property in Employee’s possession or custody, including any copies thereof maintained in any medium or format. Employee recognizes that all documents, files and property that Employee has received and will receive from the Company, including but not limited to scientific research, customer lists, handbooks, memoranda, product specifications, and other materials (with the exception of documents relating to benefits to which Employee might be entitled following the termination of Employee’s employment with the Company), are for the exclusive use of the Company and employees who are discharging their responsibilities on behalf of the Company, and that Employee has no claim or right to the continued use, possession or custody of such documents, files or property following the termination of Employee’s employment with the Company.
(e)These restrictions shall not apply to any use or disclosure authorised by the Board or required by law, or any protected disclosure within the meaning of section 43A of the Employment Rights Act 1996.
(f)Employee acknowledges that, where applicable, the Company has provided Employee with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act of 2016: (i) Employee shall not be held criminally or civilly liable under any U.S. federal or state trade secret law for the disclosure of Confidential Information that is made in confidence to a U.S. federal, state or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) Employee shall not be held criminally or civilly liable under any U.S. federal or state trade secret law for the disclosure of Confidential Information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii) if Employee files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Employee may disclose the Confidential Information to Employee’s attorney and use the Confidential Information in the court proceeding, if Employee files any document containing the Confidential Information under seal, and does not disclose the Confidential Information, except pursuant to court order. However, under no circumstance will Employee be authorized to disclose any information covered by attorney-client privilege or attorney work product of the Company without prior written consent of the Company’s General Counsel or other officer designated by the Company. Notwithstanding anything to the contrary contained herein, no provision of this Agreement shall be interpreted so as to impede Employee (or any other individual) from reporting possible violations of U.S. federal law or regulation to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S.
Congress, and any agency Inspector General of the U.S. government, or making other disclosures under the whistleblower provisions of U.S. federal law or regulation. Employee does not need the prior authorization of the Company to make any such reports or disclosures and Employee shall not be not required to notify the Company that such reports or disclosures have been made.
20.Intellectual Property.
(a)Employee agrees to disclose fully, promptly, and in writing to the Company any and all Inventions and Works (each as defined below) that are conceived, made, reduced to practice, developed, authored, created, drawn or written at any time while Employee is employed by the Company and for a period of six (6) months thereafter. Employee will generate and provide to the Company adequate and current written records of all Inventions and Works in the form of notes, sketches, drawings, reports, flow charts, procedural diagrams, logic diagrams, software program code, procedural diagrams, computer programming techniques or other documents relating thereto or in such other form as will be requested by the Company, which records and any copies thereof will be and will remain the exclusive property of the Company and will be available to the Company at all times, along with all available information relating thereto (with all necessary plans and models) to the Company.
(b)The Company and Employee agree that “Inventions,” is defined in this Agreement to include any and all new or useful ideas, developments, discoveries, improvements, designs, formulas, modifications, rights in utility models, trademarks, rights in marks, logos and names, service marks, database rights, domain names, trade secrets, and rights in confidential information, goodwill and the right to sue for passing off, copyrights, rights in designs and other intellectual property, whether patentable or capable of registration or not (including without limitation any technology, computer programs, software, software program code, logic diagrams, flow charts, procedural diagrams, computer programming techniques, test, concept, idea, process, method, composition of matter, formula or technique), whether registered or unregistered and including all applications (or rights to apply), renewals or extensions of, and rights to claim priority, and any similar or equivalent rights in any jurisdictions, and all know-how related thereto, that Employee conceives, makes, reduces to practice, or develops, solely or jointly with others (i) that relate to the actual or contemplated business, work or activities of the Company, (ii) that result from or are suggested by any work which Employee has done or may do on behalf of the Company, or by any information that Employee may receive by virtue of Employee’s employment by the Company, or (iii) that are developed, tested, improved or investigated either in part or entirely on time for which Employee was paid by the Company, or with the use of premises, equipment or property provided, owned, leased, or contracted for by or on behalf of the Company.
(c)The Company and Employee agree that “Works” is defined in this Agreement to include any and all materials, including without limitation literary works (including books, pamphlets, articles and other writings), mask works, artistic works (including designs, graphs, drawings, blueprints and other graphic works), computer programs, software program source or object code, logic diagrams, flow charts, procedural diagrams, computer programming, compilations, databases, recordings, photographs, motion pictures and other audio-visual works whether
registered or unregistered, whether capable of registration or not, that Employee authors, conceives, creates, draws, makes, or writes, solely or jointly with others (i) that relate to the actual or contemplated business, work or activities of the Company, (ii) that result from or are suggested by any work which Employee has done or may do on behalf of the Company, or by any information that Employee may receive by virtue of Employee’s employment by the Company, or (iii) that are developed, tested, improved or investigated either in part or entirely on time for which Employee was paid by the Company, or with the use of premises, equipment or property provided, owned, leased, or contracted for, by, or on behalf of the Company.
(d)Employee acknowledges that all of the rights, titles and interests in and to any and all such Inventions and Works that Employee may acquire in such Inventions or Works that are conceived, made, reduced to practice, developed, authored, created, drawn or written at any time while Employee is employed by the Company shall automatically vest in the Company to the fullest extent permitted by law.
(e)Employee acknowledges that, because of the nature of Employee’s duties and the particular responsibilities arising from the nature of those duties, Employee has, and shall have at all times while employed by the Company, a special obligation to further the interests of the Company.
(f)Without prejudice to Section 20(d) and to the extent that the rights, titles and interests referred to therein do not vest in the Company automatically, Employee agrees to assign, transfer and convey, and hereby assigns, transfers and conveys to the Company all of the rights, titles and interests in and to any and all such Inventions and Works that Employee has or may acquire in such Inventions or Works that are conceived, made, reduced to practice, developed, authored, created, drawn or written at any time while Employee is employed by the Company and for a period of six (6) months thereafter. Employee agrees that the Company will be the sole owner of all patents, copyrights, trademarks and other intellectual property rights in connection therewith, and agrees to take all such actions as may be requested by the Company during Employee’s employment with the Company and at any time thereafter, with respect to any such Inventions or Works to confirm or evidence such assignment, transfer, conveyance or ownership, and to assist in the Company’s maintenance, enforcement, license, assignment, transfer, or conveyance of rights in respect of the Inventions or Works.
(g)By way of example and not limitation, at any time and from time to time, upon the request of the Company, Employee agrees to execute, acknowledge, swear to, seal and deliver to the Company, any and all lawful instruments, documents and papers, give evidence and do any and all other lawful acts that, in the opinion of the Company, are or may be necessary or desirable to document such assignment, transfer and conveyance or to enable the Company to file and prosecute applications for and to acquire, maintain and enforce any and all patents, trademarks, copyrights and other property rights under United States, local, state or foreign law (including English law) with respect to any such Inventions or Works or to obtain any extension, validation, reissue, continuance or renewal of any such patent, trademark, copyright, or other intellectual property right. By way of further example and not limitation, Employee agrees to meet with the
Company representatives or attorneys for the purpose of initiating, maintaining or defending litigation, administrative or other proceedings; and to participate fully in litigation, administrative or other proceedings as requested by the Company. In the event that the Company may be unable, for any reason whatsoever, after reasonable effort, to secure Employee’s signature on any patent, copyright, trademark or other intellectual property application or other papers, Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents, as Employee’s agent and attorney-in-fact to act for and on behalf of Employee to execute, acknowledge, swear to, seal and deliver to the Company and to file any such application or applications or other papers, and to do all other lawfully permitted acts to further the provisions of this Section 20 of this Agreement.
(h)The Company agrees to reimburse Employee for reasonable expenses incurred by Employee in complying with the provisions of Sections 20(d) and 20(e) of this Agreement. The Company and Employee agree that Employee is not entitled to additional compensation beyond that paid to Employee for the period of time that he is employed by the Company, which compensation, along with the Company’s understandings set forth in this Agreement, is expressly acknowledged to be adequate consideration for all of the Employee promises and obligations set forth in this Agreement.
(i)Employee expressly acknowledges and states that all Works that are made by Employee (solely or jointly with others) are being created at the instance of the Company and are “works made for hire,” as that term is defined in the Copyright Act of 1976, 17 USC § 101. In the event that such laws are inapplicable or in the event that any such Works, or any part thereof, are determined by a court of competent jurisdiction not to be a work made for hire, this Agreement will operate as an irrevocable and unconditional assignment by Employee to the Company of all Employee’s right, title and interest (including, without limitation, all rights in and to the copyrights throughout the world, including the right to prepare derivative works and the rights to all renewals and extensions) in the Works in perpetuity.
(j)If, for any reason, any rights, titles and interests in and to any of the Inventions and Works cannot be lawfully assigned, transferred or conveyed to the Company pursuant to Section 20 Employee grants the Company an exclusive, worldwide, royalty-free, perpetual, unconditional, irrevocable license to use such Inventions or Works for any purpose whatsoever
(k)To the fullest extent permitted under applicable law, Employee hereby absolutely and irrevocably waives, in respect of the Inventions and Works (and any updates or revisions thereto), all moral rights and other rights to be identified as the author of any Inventions or Works and all rights to object to derogatory treatment of the Inventions or Works to which the Employee may now or at any future time be entitled, including under the (UK) Copyright, Designs and Patents Act 1988 as amended from time to time and under all similar or equivalent legislation from time to time in force anywhere in the world, and Employee agrees not to support, maintain or permit any claim for infringement of such moral rights.
(l)Employee represents that Attachment A to this Agreement describes all inventions and works, whether patentable or not, that have been conceived, made, reduced to practice, developed, authored, created, drawn or written prior to
Employee’s employment by the Company; provided, however, that, Employee has not disclosed in Attachment A information that is a trade secret belonging to another, or that is the subject of a contract preventing Employee’s disclosure of the information to the Company.
21.Non-Competition and Non-Solicitation. In further consideration of the compensation to be paid to Employee hereunder, Employee acknowledges that during the course of Employee’s employment with the Company, the Company will provide Employee Confidential Information, which Employee promises to not disclose. Further, Employee will become and/or remain familiar with the Company’s trade secrets and with other Confidential Information concerning the Company and that Employee’s services shall be of special, unique and extraordinary value to the Company, and therefore, the Employee agrees that some restrictions on Employee’s activities during and after Employee’s employment are necessary to protect the goodwill, Confidential Information and other legitimate interests of the Company:
(a)During the period of Employee’s employment by the Company and, if Employee’s employment with the Company terminates for any reason, for a period of one (1) year thereafter (less any time spent on Garden Leave) (“Covenant Period”), except with the written consent of the Board, Employee shall not directly or indirectly, own, control, finance or participate in the ownership, control or financing of, or be employed by or provide services to, any Competitor. Notwithstanding the foregoing, nothing herein shall prevent Employee from providing services to, or being employed by, or owning, controlling, financing or participating in the ownership, control or financing of, any diversified entity or other person (other than the entities listed on Attachment B) that is engaged in the Restricted Business, so long as (i) the Restricted Business does not constitute greater than 25% of the aggregate revenue of such diversified entity or other person and (ii) Employee is not employed within and does not have involvement with business development or business strategy with respect to the Restricted Business. In further consideration for the Company’s promises herein, Employee agrees that during the Covenant Period, Employee will not so as to compete with the Company directly or indirectly (i) solicit, entice, induce, cause, encourage or recruit any Restricted Employee, Customer or Supplier of the Company or its subsidiaries or affiliates to work for, provide services to or do business with a third party other than the Company or its subsidiaries or affiliates or engage in any activity that would cause any employee, representative, consultant, customer, subscriber or supplier to violate any agreement with the Company or its subsidiaries or affiliates or otherwise terminate or change its relationship with the Company or its subsidiaries or affiliates or (ii) hire Restricted Employee.
(b)The foregoing restrictions shall not be construed to prohibit Employee’s ownership of less than one percent (1%) of any class of securities of any corporation that is engaged in any of the foregoing businesses and has a class of securities registered pursuant to the Securities Exchange Act of 1934 (or such similar local legislation), as amended, provided that such ownership represents a passive investment and that neither Employee nor any group of persons including Employee in any way, either directly or indirectly, manages or exercises control of any such corporation, guarantees any of its financial obligations, otherwise
takes any part in its business, other than exercising Employee’s rights as a stockholder, or seeks to do any of the foregoing.
(c)In this Section 21, unless the context otherwise requires:
(i) “Competitor” means a person, business or enterprise (including divisions of persons, businesses and enterprises) that directly or indirectly engages or seeks to engage in the Restricted Business in the Restricted Territory, if the person, business or enterprise is or seeks to be in competition with the Company. Without limiting the foregoing, for purposes of this Agreement, each entity listed on Attachment B, as shall be modified from time to time by the Company upon written notice to Employee, shall constitute a Competitor.
(ii) “Customer” means any person to which the Company distributed, sold or supplied services as part of the Restricted Business during the Relevant Period and with which, during that period either the Employee, or any employee under the direct or indirect supervision of the Employee, had material dealings in the course of the employment, but always excluding therefrom, any division, branch or office of such person with which the Employee and/or any such employee had no dealings during that period;
(iii) “Relevant Period” means: (A) where the employment is continuing, the period of the employment; and (B) where the employment has terminated, the period of twelve months immediately preceding the Termination Date;
(iv) “Restricted Business” means a business in respect of services of the type conducted, authorized, offered or provided by the Company and for which the duties of the Employee were materially concerned or for which he was responsible during the Relevant Period;
(v) “Restricted Employee” means any person who was a director, employee or consultant of the Company at any time within the Relevant Period who by reason of that position and in particular his or his seniority and expertise or knowledge of Confidential Information or knowledge of or influence over the clients, customers or contacts of the Company is likely to cause damage to the Company if he or she were to leave the employment of the Company and become employed by a competitor of the Company;
(vi) “Restricted Territory” means the territory or territories within which the Employee actually worked, or in respect of which the Employee was materially involved in providing services, during the twelve (12) month period prior to the Employee’s Termination Date.
(vii) “Supplier” means any supplier, agent, distributor or other person who, during the Relevant Period was in the habit of dealing with the Company and with which, during that period, the Employee, or any employee under the direct or indirect supervision of the Employee, had material dealings in the course of the employment.
(d)This Section 21 shall also apply as though references to the “Company” in Section 21 include references to each Group Company in relation to which the Employee has in the course of the employment or by reason of rendering services to or holding office in such Group Company:
(i) acquired knowledge of its products, services, trade secrets or Confidential Information; or
(ii) had personal dealings with its customers or prospective customers; or
(iii) supervised directly or indirectly employees having personal dealings with its customers or prospective customers.
(e)the obligations undertaken by the Employee pursuant to this Section 21 shall, with respect to each Group Company, constitute a separate and distinct covenant in favour of and for the benefit of each Group Company and which shall be enforceable either by the particular Group Company or by the Company on behalf of the Group Company and the invalidity or unenforceability of any such covenant shall not affect the validity or enforceability of the covenants in favour of any other Group Company.
22.Employee Representations.
(a)Employee represents and warrants that this Agreement and his employment by the Company does not conflict with and will not be constrained by any prior business relationship or contract, that Employee does not possess trade secrets or other proprietary information arising out of any prior business relationship or contract that, in Employee’s best judgment would be utilized in connection with Employee’s employment with the Company. Employee further agrees that he will not disclose any such trade secrets or other proprietary information to the Company or others.
(b)Employee represents and warrants that (i) before signing this Agreement, he has read this Agreement and is entering into this Agreement freely and with knowledge of its contents with the intent to be bound by it and the restrictions contained herein; (ii) Employee has been advised by the Company to consult Employee’s own legal counsel in respect of this Agreement, and Employee has had full opportunity, prior to execution of this Agreement, to review thoroughly this Agreement with Employee’s counsel; (iii) the restrictions imposed on Employee by this Agreement are fair, reasonable and proper and required for the protection of the Company’s business interests, particularly its investments in Employee (e.g., Employee’s job knowledge and skills), its Confidential Information, as well as the goodwill developed, and its business relationships, with its clients, customers and prospective clients and customers; (iv) the Company would not have entered into this Agreement in the absence of such restrictions, and that any violation of any provision of Sections 19, 20 or 21 hereof will result in irreparable injury to the Company; and (v) the restrictions imposed on Employee by this Agreement, particularly, the post-termination restrictions, shall not preclude Employee from earning a living or engaging in Employee’s profession or trade, or pursuing a career or a business, in each case at the same general level of economic benefit as is currently the case.
(c)Employee’s employment is subject to the Employee being legally entitled to work in the United Kingdom.
23.Consequences of Breach of Covenants; Equitable Relief.
(a)Employee agrees that the Company shall be entitled to preliminary and permanent injunctive relief, without the necessity of proving actual damages, as well as an equitable accounting of all earnings, profits and other benefits arising from any violation of Sections 19, 20, or 21 hereof, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled.
The period of the injunction shall be measured from the date of a court order granting the injunctive relief. In the event that any of the provisions of Sections 19, 20, or 21 hereof should ever be adjudicated to exceed the time, geographic, service, or other limitations permitted by applicable law in any jurisdiction, then such provisions shall be deemed reformed in such jurisdiction to the maximum time, geographic, service, or other limitations permitted by applicable law.
(b)Notwithstanding anything to the contrary herein, Employee acknowledges and agrees that the severance payments and benefits provided herein are being provided by the Company to Employee, among other things, as additional consideration and solely for Employee’s agreement with and adherence to the post-employment restrictive covenants in Section 21 and Employee’s other promises, covenants, commitments and obligations in this Agreement (including the releases granted in Section 13), the adequacy and sufficiency of which Employee expressly acknowledges. Employee agrees that should the Company, in its sole discretion, deem Employee to be in violation of any provision(s) in said Section 21 the Company may immediately cease payment of all or any portion of the severance payments and benefits provided hereunder. Employee acknowledges that the severance payments and benefits provided for herein are in addition to anything of value to which Employee was already entitled.
(c)Employee irrevocably and unconditionally (i) agrees that any suit, action or other legal proceeding arising out of Section 19, 20, or 21 hereof, including without limitation, any action commenced by the Company for preliminary and permanent injunctive relief or other equitable relief, may be brought in the United States District Court for the District of New Jersey, or if such court does not have jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in New Jersey, (ii) consents to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding, and (iii) waives any objection that Employee may have to the laying of venue of any such suit, action or proceeding in any such court. Employee also irrevocably and unconditionally consents to the service of any process, pleadings, notices or other papers in a manner permitted by the notice provisions of Section 26 hereof.
24.Term of Agreement. This Agreement shall continue in full force and effect for the duration of Employee’s employment with the Company; provided, however, that after the termination of Employee’s employment during the term of this Agreement, this Agreement shall remain in effect until all of the obligations of the Parties hereunder are satisfied or have expired.
25.Successor Company. The Company shall require any successor or successors (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, by agreement in form and substance satisfactory to Employee, to acknowledge expressly that this Agreement is binding upon and enforceable against the Company in accordance with the terms hereof, and to become jointly and severally obligated with the Company to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession or successions had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Agreement. As used in this Agreement, the Company shall mean the Company as hereinbefore defined and any such successor or successors to its business and/or assets, jointly and severally.
26.Notice. All notices and other communications required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be delivered via Cognizant email accounts, personally or mailed by registered or certified mail, return receipt requested, or by overnight express courier service, as follows:
| | | | | |
If to the Company, to: |
|
| Cognizant Worldwide Limited 1 Kingdom Street, Paddington Central, London, W2 6BD Attn: General Counsel
and
Cognizant Technology Solutions Corporation 300 Frank W. Burr Blvd. Suite 36, 6th Floor Teaneck, NJ 07666 Attn: General Counsel
|
If to Employee, to: |
| |
| [__________]
|
or to such other names or addresses as the Company or Employee, as the case may be, shall designate by notice to the other Parties hereto in the manner specified in this Section; provided, however, that if no such notice is given by the Company following a change in control, notice at the last address of the Company or to any successor pursuant to this Section 26 shall be deemed sufficient for the purposes hereof. Any such notice shall be deemed delivered and effective when received in the case of personal delivery, five days after deposit, postage prepaid, with the U.S. Postal Service in the case of registered or certified mail, or on the next business day in the case of overnight express courier service.
27.Governing Law. This Agreement is governed and to be construed in accordance with English law and any dispute is subject to the exclusive jurisdiction of the English courts.
28.Contents of Agreement, Amendment and Assignment.
(a)This Agreement, including the Code of Ethics, supersedes all prior agreements with respect to the subject matter hereof, sets forth the entire understanding between the Parties hereto with respect to the subject matter hereof and cannot be changed, modified, extended or terminated except upon written amendment executed by Employee and executed on the Company’s behalf by a duly authorized officer, except for revisions or additions to Attachment B, which may be unilaterally modified by the Company upon written notice to Employee; provided, however, that this Agreement, except as expressly set forth in Section 9, does not supersede, modify or change any existing written award agreements
regarding stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, performance units or other stock-based awards issued to Employee prior to the effective date of this Agreement. The provisions of this Agreement may provide for payments to Employee under certain compensation or bonus plans under circumstances where such plans would not provide for payment thereof. It is the specific intention of the Parties that the provisions of this Agreement shall supersede any provisions to the contrary in such plans, and such plans shall be deemed to have been amended to correspond with this Agreement without further action by the Company, the Company’s Board of Directors or the Board unless such amendment would contravene the provisions of section 409A of the Code and result in the imposition of additional taxes under section 409A of the Code upon Employee.
(b)All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, representatives, successors and assigns of the Parties hereto, except that the duties and responsibilities of Employee and the Company hereunder shall not be assignable in whole or in part by the Company. If Employee should die after Employee’s Termination Date and while any amount payable hereunder would still be payable to Employee hereunder if Employee had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Employee’s devises, legates or other designees or, if there is no such designee, to Employee’s estate.
29.Severability. If any provision of this Agreement is declared illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid, and enforceable, or otherwise deleted, and the remainder of the terms of this Agreement shall not be affected except to the extent necessary to reform or delete such illegal, invalid, or unenforceable provision.
30.Remedies Cumulative; No Waiver. No right conferred upon the Parties by this Agreement is intended to be exclusive of any other right or remedy, and each and every such right or remedy shall be cumulative and shall be in addition to any other right or remedy given hereunder or now or hereafter existing at law or in equity. No delay or omission by a Party in exercising any right, remedy or power hereunder or existing at law or in equity shall be construed as a waiver thereof.
31.Miscellaneous. All section headings are for convenience only. This Agreement may be executed in several counterparts, each of which is an original. It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or account for any of the other counterparts.
32.Section 409A.
(a)Interpretation. This Agreement is intended to comply with the requirements of Section 409A of the Code and/or one or more available exemptions therefrom, and shall in all respects be administered and construed in accordance with Section 409A of the Code or such available exemption(s). If any payment or benefit hereunder cannot be provided or made at the time specified herein without incurring taxes on Employee under or by operation of Section 409A of the Code, then such payment or benefit shall be provided in full at the earliest time thereafter when such taxes will not be imposed. For purposes of Section 409A of the Code, all payments to be made upon a Termination of Employment under this Agreement may only be made upon a “separation from service” (within the
meaning of such term under Section 409A of the Code), each payment made under this Agreement shall be treated as a separate payment, the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments, and if a payment is not made by the designated payment date under this Agreement, the payment shall be made by December 31 of the calendar year in which the designated date occurs. To the extent that any payment provided for hereunder would be subject to additional tax under Section 409A of the Code, or would cause the administration of this Agreement to fail to satisfy the requirements of Section 409A of the Code, such provision shall be deemed null and void to the extent permitted by applicable law, and, to the extent applicable, any such amount shall be payable in accordance with Section 32(b). In no event shall the Employee, directly or indirectly, designate the calendar year of payment. Nothing herein shall be construed as having modified the time and form of payment of any amounts or payments of “deferred compensation” (as defined under Treas. Reg. Section 1.409A-1(b)(1), after giving effect to the exemptions in Treas. Reg. Sections 1.409A-1(b)(3) through (b)(12)) that were otherwise payable pursuant to the terms of any agreement between the Company and Employee in effect on or after January 1, 2005 and prior to the date of this Agreement.
(b)Payment Delay. Notwithstanding anything herein to the contrary, if it is necessary to postpone the commencement of any payments or benefits otherwise payable under this Agreement as a result of Employee’s “separation from service” with the Company to prevent the imposition of any accelerated or additional tax under Section 409A of the Code, then the Company will postpone the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Employee) that are not otherwise paid within the “short-term deferral exception” under Treas. Reg. Section 1.409A-1(b)(4) and the “separation pay exception” under Treas. Reg. Section 1.409A-1(b)(9)(iii), until the first payroll date that occurs after the date that is six months following Employee’s “separation of service” with the Company. If any payments are postponed due to such requirements, such postponed amounts will be paid to Employee in a lump sum on the first payroll date that occurs after the date that is six months following Employee’s “separation of service” with the Company. If Employee dies during the postponement period prior to the payment of the postponed amount, the amounts withheld on account of Section 409A of the Code shall be paid to the personal representative of Employee’s estate within sixty (60) days after the date of the Employee’s death.
(c)Reimbursements. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Employee’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the taxable year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit.
33.Recoupment Policy. Employee acknowledges that Employee shall be subject to and hereby agrees to abide by the terms of any clawback or recoupment policy that the Company has adopted or may hereafter adopt, as may be amended from time to time, with or without notice (the “Recoupment Policy”) to further the Company’s interests in enhancing its corporate governance practices and/or to comply with applicable law, rules or regulations promulgated by the Securities and Exchange Commission or the rules of the national securities exchange on which shares of the common stock of the Company are listed for trade. Employee understands that pursuant to the Recoupment Policy, the Company may seek to recoup all or part of any severance payments, bonus or other incentive compensation paid to certain officers and former officers, including Equity Awards, in the event that the Company is required to restate its financial statements. In consideration of the continued benefits to be received from the Company (or a Group Company) and the right to participate in, and receive future awards under, the Company’s cash and equity-based incentive programs, Employee hereby acknowledges, understands and agrees that:
(a)The Recoupment Policy applies to severance, cash bonuses and other incentive compensation, including Equity Awards, paid or awarded to Employee prior to or after the date on which the Recoupment Policy is adopted, and Employee agrees that, to the extent provided in the Recoupment Policy, the Recoupment Policy shall apply to equity and other award agreements outstanding as of the date of this Agreement or hereafter executed, and such agreements shall be deemed amended by, and to incorporate, the terms of the Recoupment Policy even if the Recoupment Policy is not explicitly referenced therein;
(b)The Company shall be fully entitled to enforce the Recoupment Policy against Employee in accordance with its terms, and Employee promptly shall comply with any demand authorized by the Board of Directors of the Company pursuant to the terms of the Recoupment Policy for repayment, return or rescission of, severance payments, a cash bonus or other incentive compensation, including Equity Awards, subject to the Recoupment Policy; and
(c)Nothing in this acknowledgement shall be construed to expand the scope or terms of the Recoupment Policy, and Employee is not waiving any defenses Employee may have in the event of an action for recoupment of compensation under the Recoupment Policy, other than (i) waiving any defense regarding the retroactive application of the Recoupment Policy to prior or existing payments or awards and (ii) waiving any claim that the integration clause of any agreement excludes the application of the Recoupment Policy.
[Signature Page Follows]
IN WITNESS WHEREOF, this Agreement has been executed and delivered as a deed on the first date written above.
EXECUTED AS A DEED BY COGNIZANT WORLDWIDE LIMITED
--------------------------
Name:
Title:
In the presence of:
Witness’s signature:
--------------------------
Full name:
Title:
Address:
EXECUTED AS A DEED BY [INSERT NAME OF EMPLOYEE]
--------------------------
Name:
Title:
In the presence of:
Witness’s signature:
--------------------------
Full name:
Title:
Address:
SCHEDULE
DETAILS OF UK TERMS AND BENEFITS
All benefits will be subject to the terms and conditions, policies and rules applicable to those benefits from time to time (whether issued by the Company or the relevant provider, and which may change from time to time) in addition and subject to any rules, variations or limits imposed by HM Revenue & Customs or any other government authority (including, without limitation, any requirements regarding the administration and deduction of tax in respect of such benefits).
Provision of cover is subject to acceptance of Employee by Company’s insurers or other providers at normal rates of premium and they may also be subject to Employee passing a medical examination, if required. Subject to statutory requirements, the Company reserves the right to vary or discontinue any benefit. All insurance cover and benefits cease on the termination of Employee’s employment.
Further information on the policies and rules that apply to these benefits, is available on the Company’s One The Company portal (https://cas/the Company.com) and is also available on request. The Company administers its benefits via an online benefits platform (The HUB).
Annual leave:
You will be entitled to 25 days’ paid holiday during each holiday year. The holiday year runs from 1 January to 31 December and holidays will be pro-rated accordingly in your first and last year of employment.
You may carry over 5 days of untaken leave which must be taken by 31 March of the following year. If you do not take carried over leave by 31 March, that entitlement will lapse and no payment in lieu thereof will be made.
If your employment terminates, you will be paid in lieu of accrued but untaken holiday up to the termination date. If you have taken more than your accrued allowance as at the date of termination, the value of such excess holiday will be deducted from your final payment of salary. Such payments or deductions will be calculated at a rate of 1/260th of your annual basic salary per day of holiday.
You are also entitled to bank holidays, of which there are typically 8 per year. You will be notified of the dates of the bank holidays prior to the start of each holiday year and they can be found on the UK HR page on Be.The Company - https://be.the Company.com/sites/global-human-resources/united-kingdom-human-resources/SitePage/604548/annual-leave”
Sick pay: Details of the Company sick pay scheme (as amended from time to time) are available on the Be.The Company UK HR home page and are also available on request from your HR Manager.
Pension:
You are eligible to participate in the Company’s group pension scheme (“the Scheme”). Please note the Company is required to re-enroll you into the Scheme at least every three years, unless you opt out again. The Company reserves the right to change the pension scheme provider or
change the contribution rates from time to time. You will be enrolled in the GPP at 5% employee contribution and 5% employer contribution. As you have been appointed at Executive Vice President level, The Company offers a matched contribution of up to 10% of your pensionable salary into the scheme (inclusive of the statutory minimum contribution). To take advantage of this matched contribution of up to 10%, you must change your employee contribution in the HUB. You are free to contribute more than 10%, up to the statutory maximum laid down by HM Revenue & Customs, as varied from time to time (although such excess contributions will not be matched by the Company). If you reduce your employee contribution, the employer contribution will also decrease to match the employee contribution.
The Company will deduct pension contributions payable to the Scheme from your salary. The Company operates a default Pension Salary Sacrifice (PSS) option which means that unless you opt out, you consent to PSS. Your employee contribution to the Scheme will be deducted from your gross salary at the agreed level and will be paid to the Scheme together with any employer contributions.
You must advise the Company if you have any form of Pensions Protection or have reached your Lifetime Allowance.
The Company, working in conjunction with our pensions advisors Aon, will provide you with pension information in relation to the Scheme, including information on how to choose your investments. Pension information will be available via a variety of methods, including presentations, one to ones, a telephone helpdesk and additional media. Please also refer to the guidance and information provided on The HUB.
Please note that it is up to you to make sure that you have informed yourself sufficiently about the options available to you in the light of your own circumstances. Neither the Company nor Aon are responsible for providing you with financial, tax or legal advice regarding your pension or other financial affairs, and the Company makes no warranty or guarantee about the accuracy or competence of any advice given to you by it or by Aon (or any other pension advisor it may use from time to time).
ATTACHMENT A
1. The following is a complete list of all inventions and works that have been conceived, made, reduced to practice, developed, authored, created, drawn or written by me alone or jointly with others prior to my engagement by the Company.
None.
______________________________________________________________________________________________________________________________________________________________________________________________________
Due to a preexisting contract with another party, I cannot disclose certain Inventions or Works that would otherwise be included on the above-described list.
Additional sheets are attached.
(number)
EMPLOYEE:
Signature: ___________________
Name: ______________________
(Print)
Title: ______________________
Date: ______________________
ATTACHMENT B – List of Direct Competitors
1.International Business Machines Corporation
2.Accenture LTD
3.Cap Gemini S.A.
4.Tata Consultancy Services
5.Infosys Limited
6.Wipro Limited
7.HCL Technologies Limited
8.DXC Technology Company
GENERAL RELEASE
This General Release of Claims, including its Schedules and Appendices (this “Release”) is made by and between Greg Hyttenrauch (“Employee”), of Cognizant Technology Solutions Corporation (the “Company”) and the “Releasees” (as defined below), as of the date of Employee’s execution of this Release.
1.Termination of Employment. Employee acknowledges that his employment has terminated and his employment relationship with the Company was severed effective 28 June 2022 (“Termination Date”), and that Employee has no right to return to that employment. Employee has been paid through the Termination Date. The Company is providing Employee with an information sheet concerning unemployment benefits that may be available to Employee. New York State makes all final decisions on Employee’s eligibility for unemployment benefits.
(a)Employee agrees that the Company has paid him all compensation and wages, accrued vacation/paid time off, and other benefits that were or could have been due to him through the Termination Date, when his employment ended. Employee further agrees that he has received all amounts that he is entitled to receive by virtue of his employment with the Company and that he has no right to any additional compensation, wages, bonuses, severance, vacation, paid time off or other paid leave, insurance or any other type of compensation or benefits of any kind from the Company and/or in connection with his employment.
(b)Employee acknowledges and agrees that his right to participate as an employee in any benefits plans of the Company terminated on the Termination Date, when his employment with the Company ended. This Release does not affect Employee’s right, if any, to continue group health insurance benefits under federal law.
2.Release by Employee. In exchange for the payments and benefits set forth in the UK settlement agreement between the Employee and Cognizant Worldwide Limited (“CWW”) set out in Schedule One of this Release and for other good and valuable consideration (the “Severance”), the receipt and adequacy of which are hereby acknowledged, in executing this general release and the UK settlement agreement set out in Schedule One of this Release, Employee, individually and for Employee’s heirs, successors, administrators and assigns, agrees to release and discharge CWW, the Company and the Company’s affiliated, related, parent and subsidiary corporations, as well as their respective past and present parents, subsidiaries, affiliates, associates, members, stockholders, employee benefit plans, attorneys, agents, representatives, partners, joint venturers, predecessors, successors, assigns, insurers, owners, employees, officers, directors and all persons acting by, through, under, or in concert with them, or any of them (hereinafter the “Releasees”) from any and all manner of claims, actions, causes of action, in law or in equity, demands, rights, or damages of any kind or nature which he may now have, or ever have, whether known or unknown, fixed or contingent, including any claims, causes of action or demands of any nature (hereinafter called “Claims”), that Employee now has or may hereafter have against the Releasees by reason of any and all acts, omissions, events or facts occurring or existing prior to Employee’s execution of this Release which arise in connection with or relate to Employee’s employment with CWW or termination therefrom. The Claims released hereunder specifically include, but are not limited to, any claims for fraud; breach of contract; breach of implied covenant of good faith and fair dealing; inducement of breach; interference with contract; wrongful or unlawful discharge or demotion; violation of public policy; sexual or any other type of assault and battery; invasion of privacy; intentional or negligent infliction of emotional distress; intentional or negligent misrepresentation; conspiracy; failure to pay wages, benefits, vacation pay, severance pay, commissions, equity, attorneys’ fees, or other compensation of any sort; failure to accommodate disability, including pregnancy; discrimination or harassment on the basis of pregnancy, race, color, sex, gender, national origin, ancestry, religion, disability, handicap, medical condition, marital status, sexual orientation or any other protected category; any claim under the Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621 et seq. (“ADEA”); the Older Workers’ Protection Benefit Act of 1990; Title VII of the Civil Rights Act of 1964, as amended, by the Civil Rights Act of 1991, 42 U.S.C. § 2000 et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601 et seq.; the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq.; the False Claims Act, 31 U.S.C. § 3729 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C. § 2101 et seq.; the Fair Labor Standards Act, 29 U.S.C. § 215 et seq.; the New York State Human Rights Act, the New York City Human Rights Act, the New York State Labor Law, the discrimination or retaliation provisions of the
New York State Workers’ Compensation Law; and any federal, state or local laws of similar effect. This Release shall not apply to: the Company’s or CWW’s obligations to provide the Severance (as set out in Clause 4 of Schedule One of this Release); Employee’s right to indemnification under any applicable indemnification agreement with the Company, the Company’s governing documents or applicable law and under any applicable directors’ and officers’ or other third party liability insurance policy(ies); Employee’s right to assert claims for workers’ compensation or unemployment benefits; Employee’s right to bring to the attention of the Equal Employment Opportunity Commission (“EEOC”) claims of discrimination (provided, however, that Employee releases his right to secure any damages for alleged discriminatory treatment); any right to communicate directly with, cooperate with, or provide information to, any federal, state or local government regulator; any right to file an unfair labor practice charge under the National Labor Relations Act (“NLRA”); Employee’s vested rights under any retirement or welfare benefit plan of the Company; Employee’s rights in his capacity as an equity holder of the Company; or any other rights that may not be waived by an employee under applicable law.
3.Older Worker’s Benefit Protection Act. In accordance with the Older Worker’s Benefit Protection Act, Employee is hereby advised as follows:
(a)Employee has read this Release and understands its terms and effect, including the fact that Employee is agreeing to release and forever discharge the Company and each of the Releasees from any Claims released in this Release. Specifically, Employee understands and agrees that age discrimination claims are specifically intended to be included as part of the released claims described in this Release and Employee is waiving and releasing any and all rights or claims that he may have under the Age Discrimination in Employment Act (“ADEA”) and the Older Workers Benefit Protection Act (“OWBPA”) which may have arisen on or before the date of execution of this Release.
(b)Employee understands that, by entering into this Release, Employee does not waive any Claims that may arise after the date of Employee’s execution of this Release, including without limitation any rights or claims that Employee may have to secure enforcement of the terms and conditions of this Release including payment of the Severance (as defined in Clause 4 of Schedule One).
(c)Employee has signed this Release voluntarily and knowingly in exchange for the consideration described in this Release, which Employee acknowledges is adequate and satisfactory to Employee and in addition to any other benefits to which Employee is otherwise entitled.
(d)The Company advises Employee to consult with an attorney prior to executing this
Release.
(e)Employee has twenty-one (21) days to review and decide whether or not to sign this Release. If Employee signs this Release prior to the expiration of such period, Employee acknowledges that Employee has done so voluntarily, had sufficient time to consider the Release, to consult with counsel and that Employee does not desire additional time and hereby waives the remainder of the twenty-one (21) period. In the event of any changes to this Release, whether or not material, Employee waives the restarting of the twenty-one (21) day period.
(f)Employee has seven (7) days after signing this Release to revoke this Release and this Release will become effective upon the expiration of that revocation period. If Employee revokes this Release during such seven (7)-day period, this Release will be null and void and of no force or effect on either the Company or Employee and Employee will not be entitled to any of the payments or benefits which are expressly conditioned upon the execution and non-revocation of this Release.
If Employee wishes to revoke this Release, Employee shall deliver written notice stating his intent to revoke this Release to John Kim, Executive Vice President, General Counsel and Chief Corporate Affairs Officer of the Company (or such other individual as the Company may nominate) on or before 5:00 p.m. on the seventh (7th) day after the date on which Employee signs this Release.
4.Representations. Employee represents and warrants that there has been no assignment or other transfer of any interest in any Claim which he may have against Releasees, or any of them, and Employee agrees to indemnify and hold Releasees, and each of them, harmless from any liability, Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as the result of any such assignment or transfer or any rights or Claims under any such assignment
or transfer. It is the intention of the parties that this indemnity does not require payment as a condition precedent to recovery by the Releasees against Employee under this indemnity. Employee agrees that if he hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder or in any manner asserts against Releasees, or any of them, any of the Claims released hereunder, then Employee agrees to pay to Releasees, and each of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred by Releasees in defending or otherwise responding to said suit or Claim.
5.No Actions. Employee represents and warrants to the Company that Employee has no pending actions, Claims or charges of any kind provided, however, that Employee shall not be obligated to pay the Releasees’ attorneys’ fees to the extent such fees are attributable to: (i) claims under the ADEA or a challenge to the validity of the release of claims under the ADEA; or (ii) Employee’s right to file a charge with the EEOC; however, Employee hereby waives any right to any damages or individual relief resulting from any such charge.
6.Non-Competition and Solicitation. Employee acknowledges and agrees that he remains subject to Paragraph 21, as amended by this paragraph, of his Executive Employment and Non-Disclosure, Non-Competition, and Invention Assignment Agreement (“Employment Agreement
“). The parties hereby agree to amend Section 21 of the Employment Agreement in the following manner:
(a) Deleting the term “Restricted Employee” from the 3rd sentence of Paragraph 21(a);
(b) Deleting sub-section (ii) from the 3rd sentence of Paragraph 21(a);
(c) Deleting the definition of “Restricted Employee” from Paragraph 21(c)(v); and
(d) Adding the following sentence at the end of Paragraph 21(a):
In further consideration for the Company’s promises herein, Employee agrees that during the Covenant Period, Employee will not directly or indirectly (i) solicit, entice, induce, cause, encourage or recruit any part-time or full-time employee, representative, or consultant of the Company or its subsidiaries or affiliates to work for, provide services to or do business with a third party other than the Company or its subsidiaries or affiliates or engage in any activity that would cause any employee, representative, or consultant to violate any agreement with the Company or its subsidiaries or affiliates or otherwise terminate or change its relationship with the Company or its subsidiaries or affiliates or (ii) hire any current or former part-time or full-time employee, representative or consultant of the Company or its Affiliates who was employed or engaged by the Company or its subsidiaries or affiliates at any time during the twelve (12) month period prior to Employee’s Termination Date or who thereafter becomes employed or engaged by the Company or its subsidiaries or affiliates.
7.Exceptions. Notwithstanding anything in this Release to the contrary, nothing contained in this Release shall prohibit Employee (or Employee’s attorney) from (i) filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or cooperating with the U.S. Securities and Exchange Commission (“SEC”), the Financial Industry Regulatory Authority, the EEOC, the NLRB, the Occupational Safety and Health Administration, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory agency, self-regulatory authority or federal, state or local regulatory authority (collectively, “Government Agencies”), or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation, (ii) communicating directly with, cooperating with, or providing information (including trade secrets) in confidence to any Government Agencies for the purpose of reporting or investigating a suspected violation of law, or from providing such information to Employee’s attorney or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding, and/or (iii) receiving an award for information provided to any Government Agency. Pursuant to 18 USC Section 1833(b), Employee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Release is intended to or shall preclude Employee from providing truthful testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law. If Employee is required to provide testimony, then unless otherwise directed or requested
by a Governmental Agency or law enforcement, Employee shall notify the Company in writing as promptly as practicable after receiving any such request of the anticipated testimony and at least ten (10) days prior to providing such testimony (or, if such notice is not possible under the circumstances, with as much prior notice as is possible) to afford the Company a reasonable opportunity to challenge the subpoena, court order or similar legal process.
8.Miscellaneous.
(a)No Admission. Employee understands and agrees that neither the payment of money nor the execution of this Release shall constitute or be construed as an admission of any liability whatsoever by the Releasees.
(b)Severability. If any sentence, phrase, section, subsection or portion of this Release is found to be illegal or unenforceable, such action shall not affect the validity or enforceability of the remaining sentences, phrases, sections, subsections or portions of this Release, which shall remain fully valid and enforceable.
(c)Construction of Agreement. Employee has been represented by, or had the opportunity to be represented by, counsel in connection with the negotiation and execution of this Release.
Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Release.
(d)Entire Agreement/Integration. This Release together with the Settlement Agreement in Schedule One and Appendices, and the terms of the Executive Agreement (as defined in the Settlement Agreement in Schedule One) that continue to apply after the termination of the employment, constitutes the entire agreement between Employee and the Company concerning the subject matter hereof. No covenants, agreements, representations, or warranties of any kind, other than those set forth herein, have been made to any party hereto with respect to this Release. All prior discussions and negotiations have been and are merged and integrated into, and are superseded by, this Release. No amendments to this Release will be valid unless written and signed by Employee and an authorized representative of the Company.
(e)Counterparts. This Release may be executed in any number of counterparts and such counterparts may be obtained by PDF, e-mail, or facsimile transmission, each of which taken together will constitute one and the same instrument.
| | | | | |
|
| |
| Greg Hyttenrauch |
| /s/ Greg Hyttenrauch |
Date: | July 26, 2022 |
SCHEDULE ONE
This agreement is dated July 21, 2022
Parties
(1)COGNIZANT WORLDWIDE LIMITED incorporated and registered in England and Wales with company number 07195160 whose registered office is at One Kingdom Street London W2 6BD (CWW / we / us)
(2)COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION incorporated in the United States of America of 300 Frank W. Burr Blvd. Suite 36, 6th Floor, Teaneck NJ 07666, USA (the “Company”)
(3)GREG HYTTENRAUCH of Greenwood, Heathway, Camberley, Surrey GU15 2EL (Employee / you)
BACKGROUND
(A)Your employment with us terminated on 28 June 2022.
(B)The parties have entered into this agreement to record and implement the terms on which they have agreed to settle all outstanding claims which you have or may have against all Group Companies or their respective officers or employees arising out of or in connection with or as a consequence of your employment and/or its termination and your office as a director and/or its cessation. The terms set out in this Agreement constitute the entire Agreement between the parties and are without admission of liability on the part of CWW, the Company or any Group Company.
(C)We enter into this agreement for ourselves and as agent and trustee for all Group Companies and we are authorised to do so. The parties intend that each Group Company should be able to enforce in its own right the terms of this Agreement which expressly or impliedly confer a benefit on that company subject to and in accordance with the provisions of the Contracts (Rights of Third Parties) Act 1999.
Agreed terms
1.Interpretation
The following definitions and rules of interpretation apply in this agreement.
1.1Definitions:
Adviser: Gill Brown of Phillips Solicitors Limited of Town Gate, 38 London Street, Basingstoke, Hampshire RG21 7NY.
Executive Agreement: the Executive Employment, Non-Disclosure, Non-Competition and Invention Assignment Agreement between you and CWW.
Group Company: CWW, its subsidiaries or holding companies from time to time and any subsidiary of any holding company from time to time.
Holding company: has the meaning given in clause 1.6.
Subsidiary: has the meaning in clause 1.6.
1.2The headings in this Schedule are inserted for convenience only and shall not affect its construction.
1.3A reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension, or re-enactment and includes any subordinate legislation for the time being in force made under it.
1.4Unless the context otherwise requires, words in the singular shall include the plural and in the plural shall include the singular.
1.5The Appendices shall form part of this Schedule One and shall have effect as if set out in full in the body of this Schedule One. Any reference to this agreement or this Schedule one includes the Appendices.
1.6A reference to a holding company or a subsidiary means a holding company or a subsidiary (as the case may be) as defined in section 1159 of the Companies Act 2006 and a company shall be treated, for the purposes only of the membership requirement contained in sections 1159(1)(b) and (c), as a member of another company even if its shares in that other company are registered in the name of (a) another person (or its nominee), whether by way of security or in connection with the taking of security, or (b) as a nominee.
2.Permitted Disclosures
2.1Nothing in this agreement prevents the parties from making a disclosure:
(a)which amounts to a protected disclosure within the meaning of section 43A of the Employment Rights Act 1996;
(b)in order to report an offence to a law enforcement agency or to co-operate with a criminal investigation or prosecution;
(c)for the purposes of reporting misconduct, or a serious breach of regulatory requirements, to any body responsible for supervising or regulating the matters in question;
(d)if and to the extent required by law.
2.1All other terms of this agreement are to be read subject to this Clause.
3.Arrangements on termination
3.1Your employment with us terminated on 28 June 2022 (Termination Date).
3.2We shall pay you your salary and benefits up to the Termination Date as specified in the Executive Agreement.
3.3We shall make a payment to you in respect of 7.2 days' accrued but untaken holiday up to and including the Termination Date.
3.4The payments and benefits in this Clause 3 and as specified in the Executive Agreement shall be subject to the income tax, withholding tax and National Insurance or social security contributions that we are obliged by law to pay or deduct in any jurisdiction.
3.5You confirm that you have submitted all outstanding expenses claims totalling £7432.10 in the usual way and we shall reimburse your corporate credit card for these expenses properly incurred before the Termination Date in the usual way. You will not be reimbursed for any expenses incurred after the Termination Date.
3.6Notwithstanding the exit arrangements and full and final settlement of all liabilities between you and us, the tax equalization arrangements with respect to your assignment earnings remain in force and the Company will continue to provide tax return assistance for UK and US tax years where your formal assignment terms were in force (i.e. 2021 and 2022 US, and y/e 5 April 2022 and 2023 UK) and also Canadian tax return for 2021 tax year only, and any tax equalization balances owed to you and notified to the Company by its accountants will be reimbursed to you, and any tax equalization balances owed to the Company and notified to you by the Company’s accountants should be repaid by you. For any avoidance of doubt, during your assignment the Company has funded all of your payroll taxes payable to the United States (Federal/State/Local) resulting in double payment of payroll taxes in the United States and the United Kingdom (“UK”). The tax return filings will include claims to reconcile this double payment resulting in refunds of some of the payroll taxes and these refunds will belong to the Company and should be returned to the Company in accordance with the notification by the Company’s accountants.
3.7Subject to any legal and regulatory obligations, should any third party ask us to give a reference in relation to you following the Termination Date, any written reference given in response to such a request will be a standard reference confirming your dates of employment and roles undertaken with us and any reference given orally will be consistent with that approach, provided that in either case, the third party’s request is made directly to Fiona Woods, Vice President of Human Resources. Subject to and conditional on you complying with the terms of this agreement, (including, without limitation, the provision by you of a letter from the Adviser dated on or after the date of this
agreement in the form set out in Appendix 2), the Executive Agreement and the terms of the Release (as defined in Section 13 of the Executive Agreement),
4.Termination Payment
4.1CWW shall pay (or shall procure payment by the Company or other relevant Group Company of) you the sum of £824,000 in lieu of your notice period under the Executive Agreement (the “Termination Payment”). We will pay (or procure the payment of) the Termination Payment less all required deductions by a Group Company for withholding tax and National Insurance contributions or other social security payments in any jurisdiction in which they are due within 60 days of the Termination Date.
4.2You shall be responsible for any further withholding tax and employee's National Insurance or other social security contributions due in respect of the Termination Payment and shall indemnify us or the relevant Group Company in respect of such liability in accordance with clause 7.1 of this Schedule One.
4.3For the avoidance of doubt you acknowledge and agree that you have no rights to the payments under Section 9(a) of the Executive Agreement and any rights you may have under Section 9(a) of the Executive Agreement are irrevocably waived.
4.4The provision of all benefits will cease from the Termination Date with the exception of private health care for yourself and family which shall continue for a period of 12 months from the Termination Date.
4.5Your active membership of any pension scheme will cease with effect from the Termination Date.
4.6You agree that any shares held by you will be treated in accordance with the rules of the relevant scheme.
5.Legal fees
5.1Subject to and conditional upon your compliance with the terms of this agreement and subject to receipt of an invoice from the your Adviser and provided the Adviser is a qualified lawyer (as defined in the Employment Rights Act 1996), we agree to pay to the Adviser up to a maximum of £1,500 plus VAT as a contribution towards your legal fees incurred exclusively in connection with the termination of your employment. Any invoice should be addressed to you but expressed to be payable by us and sent under private and confidential cover to the General Counsel at the Company.
6.Waiver of claims
6.1You agree that the terms of this agreement are offered by us and the Company without any admission of liability on our or the Company’s part and are in full and final settlement of all and any claims or rights of action that you have or may have against us, the Company or any other Group Company or its or their officers, employees or workers arising out of your employment with us (or any other Group Company) or its termination, whether under common law, contract, statute or otherwise, whether such claims are, or could be, known to the parties or in their contemplation at the date of this agreement in any jurisdiction and including, but not limited to any claim for breach of contract or wrongful dismissal, unfair dismissal or any of the claims specified in Appendix 1 of this Schedule One (each of which is waived by this clause).
6.2The waiver in clause 6.1 shall not apply to the following:
(a)claims in respect of personal injury of which you are not aware and could not reasonably be expected to be aware at the date of this agreement (other than claims under discrimination legislation);
(b)any claims in relation to accrued entitlements under any pension scheme; and
(c)enforcing the terms of this agreement.
6.3You warrant that:
(a)before entering into this agreement you received independent advice from the Adviser as to the terms and effect of this agreement and, in particular, on its effect on your ability to pursue the claims specified in clause 6.1 above and Appendix 1 to this Schedule One;
(b)the Adviser has confirmed to you that they are a solicitor holding a current practising certificate and that there is in force a policy of insurance covering the risk of a claim by you in respect of any loss arising in consequence of their advice;
(c)the Adviser shall sign and deliver to us a letter in the form attached as Appendix 2 to this agreement;
(d)before receiving the advice you disclosed to the Adviser all facts and circumstances that may give rise to a claim by you against any Group Company or its officers, employees or workers;
(e)the only claims that you have or may have against any Group Company or its officers, employees or workers (whether at the time of entering into this agreement or in the future) relating to your employment with us or any other Group Company or its termination are specified in clause 6.1; and
(f)You are not aware of any facts or circumstances that may give rise to any claim against any Group Company or its officers, employees or workers other than those claims specified in clause 6.1.
You acknowledge that we acted in reliance on these warranties when entering into this agreement.
6.1You acknowledge that the conditions relating to settlement agreements under section 147(3) of the Equality Act 2010, section 288(2B) of the Trade Union and Labour Relations (Consolidation) Act 1992, section 203(3) of the Employment Rights Act 1996, regulation 35(3) of the Working Time Regulations 1998, section 49(4) of the National Minimum Wage Act 1998, regulation 41(4) of the Transnational Information and Consultation etc. Regulations 1999, regulation 9 of the Part-Time Workers (Prevention of Less Favourable Treatment) Regulations 2000, regulation 10 of the Fixed-Term Employees (Prevention of Less Favourable Treatment) Regulations 2002, regulation 40(4) of the Information and Consultation of Employees Regulations 2004, paragraph 13 of the Schedule to the Occupational and Personal Pension Schemes (Consultation by Employers and Miscellaneous Amendment) Regulations 2006, regulation 62 of the Companies (Cross Border Mergers) Regulations 2007 and section 58 of the Pensions Act 2008 have been satisfied.
6.2The waiver in clause 6.1 shall have effect irrespective of whether or not, at the date of this agreement, you are or could be aware of such claims or have such claims in your express contemplation (including such claims of which you become aware after the date of this agreement in whole or in part as a result of new legislation or the development of common law or equity).
6.3You agree that, except for the payments and benefits provided for in this agreement and subject to the waiver in clause 6.1, you shall not be eligible for any further payment from any Group Company relating to your employment or its termination and you expressly waive any right or claim that you have or may have to payment of bonuses, any benefit or award programme, under any share plan operated by any Group Company (save for shares already vested prior to the Termination Date) or any stand-alone share incentive arrangement, or to any other benefit, payment or award you may have received had your employment not terminated.
7.Employee indemnities
7.1You shall indemnify us on a continuing basis in respect of any income tax, withholding taxes or National Insurance or social security contributions (save for employers' National Insurance contributions) due in respect of the payments and benefits in clauses 3 and 4 of this agreement (and any related interest, penalties, costs and expenses) due in any jurisdiction but excluding tax which is deducted at source by the Company. We shall give you reasonable notice of any demand for tax which may lead to liabilities on you under this indemnity and shall provide you with reasonable access to any documentation you may reasonably require to dispute such a claim (provided that
nothing in this clause shall prevent us from complying with our legal obligations with regard to HM Revenue and Customs or other competent body).
7.2In the event of you commencing any action or issuing or pursuing any proceedings or being granted any judgment against us, the Company or any Group Company arising out of your employment or its termination you shall indemnify us or the relevant Group Company in respect of:
(a)its legal costs of defending such action or proceedings (including reasonable legal and professional fees and disbursements together with VAT thereon); and
(b)any award or judgment,
7.3and such part of the Termination Payment equivalent to the amount of such costs, award or judgment shall become immediately repayable to us or the relevant Group Company as a debt.
8.Return of property
8.1On or within 21 days after the Termination Date you will return to us all credit cards, keys, your security pass, any identity badge, all computer disks, memory cards, software and computer programs, any mobile telephone, laptop computer, printer, and other electronic equipment, all documents and copies (including electronic or recorded versions and copies in whatever medium held) together with all other property belonging to us or any Group Company or relating to our or their business in your possession or control except for such property as the parties agree in writing that you may retain.
8.2On or within fourteen days after the Termination Date, you amend your profiles on any social media accounts to show that you are no longer employed by us.
8.3You shall, if requested, provide us with a signed statement confirming that you have complied fully with your obligations under Clause 8.2 and Clause 8.3 and shall provide such reasonable evidence of compliance as may be requested.
9.Warranties and representations
9.1You warrant as a strict condition of this agreement and represent to us that up to and as at the Termination Date:
(a)except as already disclosed by you following the investigation conducted in June of 2022, you have not committed any breach of any duty owed to us or any Group Company;
(b)you have not retained any software or computer programs, documents or copies (electronically or otherwise) which belong to us or any Group Company or to which we or any Group Company is entitled;
(c)you have not done or failed to do anything, which act or omission amounts to a repudiatory breach of the express or implied terms of your employment with us or which, if it were to be done or omitted after the date of this Agreement, would be in breach of any of its terms;
(d)you are not employed or self-employed in any capacity by a party other than us nor are you in discussions which are likely to lead to nor have you received such an offer of employment or self-employment;
(e)you have not commenced any action or issued any proceedings against us or any Group Company or any of their officers or employees.
9.2We are under no obligation to make the payments or provide the benefits specified in Clause 4 and Clause 5 if:
(a)you are in breach of any of the warranties referred to in this Clause 9; or
(b)on or before the Termination Date you do or fail to do, or have done or failed to do, anything which act or omission amounts to a repudiatory breach of the express or implied terms of your employment with us.
10.Confidentiality and other restrictions
10.1You accept and agree that your express and implied duties relating to confidential information and restrictive covenants continue after the Termination Date. In particular, you affirm the duties and restrictions in clauses 19 and 21 of the Executive Agreement. For the purposes of interpretation and enforcement of this agreement in the United Kingdom only, the definition of “Restricted Employee” as set out in Clause 21(c)(v) of the Executive Agreement shall be replaced with the following definition:
any employee, agent, director, consultant or independent contractor employed, appointed or engaged by the Company or any Group Company in a senior, executive, professional, technical, marketing, distribution, sales or managerial capacity and with whom the Employee had material contact in the course of that person’s employment, appointment or engagement during the Relevant Period.
10.2The parties consider that confidentiality is mutually beneficial in all the circumstances and agree and undertake (in consideration of their mutual promises to that effect) that neither will :
(a)make or publish any statement to a third party concerning the fact, negotiations or terms of this Agreement, the dispute settled by it or the circumstances surrounding the termination of your employment;
(b)make or publish any derogatory or disparaging statement or do anything in relation to the other and in your case in relation to any Group Company or any past, current or future
officers or employees of any Group Company which is intended to or which might be expected to damage or lower their respective reputations,
provided that the parties will not be prevented from making a disclosure:
(a)in accordance with clause 2;
(b)for the purposes of seeking legal or tax advice in relation to this agreement, provided the professional adviser is bound by a duty of confidence, or to HMRC for tax purposes;
(c)in your case:
(i)to your spouse, civil partner or partner, provided such person agrees to maintain confidentiality; or
(ii)to a medical practitioner or counsellor for the purpose of seeking or obtaining treatment;
(a)in our case, where in its reasonable opinion it is in the interests of good corporate governance to do so and/or in order to defend any litigation brought (or intimated may be brought) by you or resist or process any actual or intimated claim of insurance, for which latter purpose you hereby provide express consent on the basis that the insurer has agreed to keep any disclosed information confidential.
10.3You warrant that you have not done or failed to do anything including without limitation published any statement or authorised or permitted anyone else to do so prior to the date of this agreement which would constitute a breach of Clauses 10.1 or 10.2 if it had occurred after the date of this agreement.
10.4We will not be liable for any breach of our undertakings at Clause 10.2 caused by the actions of any of its past, current or future officers or employees if we have taken such steps as are reasonable to prevent that breach or breaches of that kind.
10.5You are advised that pursuant to the Defend Trade Secrets Act an individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, you understand that in the event that disclosure of any Group Company’s trade secrets was not done in good faith pursuant to the above, you will be subject to substantial damages, including punitive damages and attorney's fees.
11.Resignation from offices
You undertake that you will immediately resign from any and all directorships that you hold of any Group Companies and from any other offices, trusteeships or positions that you hold in or on any Group Company's behalf. The Company and any applicable Group Company will maintain for so long as it maintains a policy in respect of its directors generally, directors’ and officers’ liability insurance in respect of the period during which you were a director of the Company and/or any Group Company, at no less than the level of cover for other individuals who were directors of the Company at the Termination Date.
12.Third party rights
Except as expressly provided elsewhere in this Schedule One, no person other than you and any Group Company shall have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement.
13.Governing law
This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.
14.Jurisdiction
Each party irrevocably agrees that the courts of England and Wales shall have non-exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).
15.Counterparts
This agreement may be executed and delivered in any number of counterparts, each of which, when executed, shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement.
This agreement has been entered into on the date stated at the beginning of it. In the event of any conflicts between the terms of this Agreement and the Release, the terms of the Release will take precedence.
Appendix 1
Claims
1.1in relation to the right to a written statement of reasons for dismissal, under section 93 of the Employment Rights Act 1996;
1.2for a statutory redundancy payment, under section 163 of the Employment Rights Act 1996;
1.3in relation to an unlawful deduction from wages or unlawful payment, under section 23 of the Employment Rights Act 1996;
1.4for unlawful detriment, under section 48 of the Employment Rights Act 1996 or section 56 of the Pensions Act 2008
1.5in relation to written employment particulars and itemised pay statements, under section 11 of the Employment Rights Act 1996;
1.6in relation to guarantee payments, under section 34 of the Employment Rights Act 1996;
1.7in relation to suspension from work, under section 70 of the Employment Rights Act 1996;
1.8in relation to parental leave, under section 80 of the Employment Rights Act 1996;
1.9in relation to a request for flexible working, under section 80H of the Employment Rights Act 1996;
1.10in relation to time off work, under sections 51, 54, 57, 57B, 57ZC, 57ZF, 57ZH, 57ZM, 57ZQ, 60, 63 and 63C of the Employment Rights Act 1996;
1.11in relation to working time or holiday pay, under regulation 30 of the Working Time Regulations 1998;
1.12in relation to the national minimum wage, under sections 11, 18, 19D and 24 of the National Minimum Wage Act 1998;
1.13for equal pay or equality of terms under sections 120 and 127 of the Equality Act 2010 and/or section 2 of the Equal Pay Act 1970;
1.14for pregnancy or maternity discrimination, direct or indirect discrimination, harassment or victimisation related to sex, marital or civil partnership status, pregnancy or maternity or gender reassignment under section 120 of the Equality Act 2010 and/or direct or indirect discrimination,
harassment or victimisation related to sex, marital or civil partnership status, gender reassignment, pregnancy or maternity under section 63 of the Sex Discrimination Act 1975;
1.15for direct or indirect discrimination, harassment or victimisation related to race under section 120 of the Equality Act 2010 and/or direct or indirect discrimination, harassment or victimisation related to race, colour, nationality or ethnic or national origin, under section 54 of the Race Relations Act 1976;
1.16for direct or indirect discrimination, harassment or victimisation related to disability, discrimination arising from disability, or failure to make adjustments under section 120 of the Equality Act 2010 and/or direct discrimination, harassment or victimisation related to disability, disability-related discrimination or failure to make adjustments under section 17A of the Disability Discrimination Act 1995;
1.17for direct or indirect discrimination, harassment or victimisation related to religion or belief under section 120 of the Equality Act 2010 and/or under regulation 28 of the Employment Equality (Religion or Belief) Regulations 2003;
1.18for direct or indirect discrimination, harassment or victimisation related to sexual orientation, under section 120 of the Equality Act 2010 and/or under regulation 28 of the Employment Equality (Sexual Orientation) Regulations 2003;
1.19for direct or indirect discrimination, harassment or victimisation related to age, under section 120 of the Equality Act 2010 and/or under regulation 36 of the Employment Equality (Age) Regulations 2006;
1.20for less favourable treatment on the grounds of part-time status, under regulation 8 of the Part-Time Workers (Prevention of Less Favourable Treatment) Regulations 2000;
1.21for less favourable treatment on the grounds of fixed-term status, under regulation 7 of the Fixed-Term Employees (Prevention of Less Favourable Treatment) Regulations 2002;
1.22under regulations 27 and 32 of the Transnational Information and Consultation of Employees Regulations 1999;
1.23under regulations 29 and 33 of the Information and Consultation of Employees Regulations 2004;
1.24under regulations 45 and 51 of the Companies (Cross-Border Mergers) Regulations 2007;
1.25under paragraphs 4 and 8 of the Schedule to the Occupational and Personal Pension Schemes (Consultation by Employers and Miscellaneous Amendment) Regulations 2006;
1.26under sections 68A, 87, 137, 145A, 145B, 146, 168, 168A, 169, 170, 174 and 192 of the Trade Union and Labour Relations (Consolidation) Act 1992;
1.27in relation to the obligations to elect appropriate representatives or any entitlement to compensation, under the Transfer of Undertakings (Protection of Employment) Regulations 2006;
1.28in relation to the right to be accompanied under section 11 of the Employment Relations Act 1999;
1.29in relation to refusal of employment, refusal of employment agency services and detriment under regulations 5, 6 and 9 of the Employment Relations Act 1999 (Blacklists) Regulations 2010;
1.30in relation to the right to request time off for study or training under section 63I of the Employment Rights Act 1996;
1.31in relation to the right to equal treatment, access to collective facilities and amenities, access to employment vacancies and the right not to be subjected to a detriment under regulations 5, 12, 13 and 17(2) of the Agency Workers Regulations 2010;
1.32in relation to the right to a written statement and the right not to be unfairly dismissed or subjected to detriment under regulations 4 and 5 of the Agency Workers (Amendment) Regulations 2019;
1.33in relation to personal injury, of which you are or ought reasonably to be aware at the date of this agreement;
1.34for harassment under the Protection from Harassment Act 1997;
1.35for failure to comply with obligations under the Human Rights Act 1998;
1.36for failure to comply with obligations under the Data Protection Act 1998, the Data Protection Act 2018 or the General Data Protection Regulation ((EU) 2016/679);
1.37arising as a consequence of the United Kingdom's membership of the European Union; and
1.38in relation to the right not to be subjected to a detriment under regulation 3 of the Exclusivity Terms in Zero Hours Contracts (Redress) Regulations 2015.
Appendix 2: Form of Adviser's certificate
[ON HEADED NOTEPAPER OF ADVISER]
For the attention of [NAME]
[DATE]
To whom it may concern,
I am writing in connection with the agreement between my client, Greg Hyttenrauch, Cognizant Worldwide Limited and Cognizant Technology Solutions Corporation (Company) [of today's date OR dated [DATE]] (Agreement) to confirm that:
1. I, [NAME] of [FIRM], whose address is [ADDRESS], am a Solicitor of the Senior Courts of England and Wales who holds a current practising certificate.
2. I have given Greg Hyttenrauch legal advice on the terms and effect of the agreement and, in particular, its effect on my client's ability to pursue the claims specified in clause 6 and Appendix 1 of the agreement.
3. I gave the advice to Greg Hyttenrauch as a relevant independent adviser within the meaning of the above acts and regulations referred to at clause 6.4 of the agreement.
4. There is now in force (and was in force at the time I gave the advice referred to above) a policy of insurance or an indemnity provided for members of a profession or professional body covering the risk of claim by my client in respect of loss arising in consequence of the advice I have given them.
Yours faithfully,
[NAME]
[DATE]
| | | | | |
Signed by Jan Siegmund, for and on behalf of COGNIZANT WORLDWIDE LIMITED | /s/ Jan Siegmund
Director |
| |
Signed by Jan Siegmund, for and on behalf of COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION | /s/ Jan Siegmund
Chief Financial Officer |
| |
| |
Signed by Greg Hyttenrauch | /s/ Greg Hyttenrauch |
EXHIBIT 31.1
CERTIFICATION
I, Brian Humphries, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Cognizant Technology Solutions Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| | | | | | | | | | | | | | |
| | | | |
Dated: | July 27, 2022 | | /s/ Brian Humphries | |
| | | Brian Humphries, | |
| | | Chief Executive Officer (Principal Executive Officer) | |
EXHIBIT 31.2
CERTIFICATION
I, Jan Siegmund, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Cognizant Technology Solutions Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| | | | | | | | | | | | | | |
Dated: | July 27, 2022 | | /s/ Jan Siegmund | |
| | | Jan Siegmund, | |
| | | Chief Financial Officer (Principal Financial Officer) |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*
In connection with the Quarterly Report on Form 10-Q of Cognizant Technology Solutions Corporation (the “Company”) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Brian Humphries, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | | | | | | | | | | | | | |
Dated: | July 27, 2022 | | /s/ Brian Humphries | |
| | | Brian Humphries, | |
| | | Chief Executive Officer (Principal Executive Officer) | |
___________________
* A signed original of this written statement required by Section 906 has been provided to Cognizant Technology Solutions Corporation and will be retained by Cognizant Technology Solutions Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*
In connection with the Quarterly Report on Form 10-Q of Cognizant Technology Solutions Corporation (the “Company”) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jan Siegmund, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | | | | | | | | | | | | | |
Dated: | July 27, 2022 | | /s/ Jan Siegmund | |
| | | Jan Siegmund, | |
| | | Chief Financial Officer (Principal Financial Officer) |
___________________
* A signed original of this written statement required by Section 906 has been provided to Cognizant Technology Solutions Corporation and will be retained by Cognizant Technology Solutions Corporation and furnished to the Securities and Exchange Commission or its staff upon request.